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Abstract 
 
 
 
Abstract 
 
Glycosidases are involved in a range of important biological processes. The possibility of 
blocking or modifying these processes using glycosidase-inhibiting sugar mimics for 
therapeutic or biotechnological applications has attracted much interest. This may have 
significance in the treatment of cancer, viral infections, diabetes and obesity.  
 
Iminosugars are analogues of mono- or disaccharides where the ring oxygen is replaced by a 
nitrogen atom. These compounds include polyhydroxylated derivatives of monocyclic 
structures such as piperidines and pyrrolizidines, and also of bicyclic structures such as 
indolizidines and pyrrolizidines. 
 
Routes to nitrone 190 from L-xylose and D-arabinose were explored and the application of 
nitrone 190 towards the synthesis to hyacinthacine A1 and hyacinthacine B2 were 
investigated. The differential protection of the C-3 position of nitrone 190 meant that this 
position would be selectively deprotected after cycloaddition, liberating the C-1 hydroxyl 
group (hyacinthacine numbering) as a site for inversion. Inversion of the hydroxyl group 
would then provide the required stereochemical outcome for hyacinthacines A1 and B2, 
where the stereochemistry at C-1 and C-2 is cis.  
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Ac  acetyl 
AIBN  Azobisisobutyronitrile 
AIDS  Acquired Immune Deficiency Syndrome 
Bn  benzyl 
Bu  butyl 
Boc  tert-Butyloxycarbonyl 
Cbz  Carboxybenzyl 
COSY  correlated spectroscopy 
d  doublet 
DCM  dichloromethane 
dd  double doublet 
ddd  double double doublet 
DEAD  diethyl azodicarboxylate 
DIBAL diisobutylaluminium hydride 
DMJ  deoxymannojirimycin 
DMSO  dimethyl sulfoxide 
DNJ  deoxynojirimycin 
dt  doublet of triplets 
ES  electrospray 
Et  ethyl 
EtOAc  ethyl acetate 
EtOH  ethanol 
h  hour 
HIV  Human Immunodeficiency Virus 
HOMO highest occupied molecular orbital 
iPr  iso-propyl 
IR  infrared 
LUMO lowest occupied molecular orbital 
m  multiplet 
Me  methyl 
MeOH  methanol 
min  minute(s) 
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mmol  milimole 
MOM  methoxymethayl 
m.p.  melting point 
Ms  methanesulfonyl 
MS  mass spectrometry 
NMR  nuclear magnetic resonance 
PCC  pyridinium chlorochromate 
Ph  phenyl 
Py  pyridine 
q  quartet 
RCM  ring closing metathesis 
Rf  retention factor 
rt  room temperature 
s  singlet 
t  triplet 
TBAF  tetrabutylammonium fluoride 
TBAP  Tetrabutylammonium perchlorate 
TBDMS tert-butyldimethylsilyl 
TBDPS tert-butlydiphenylsilyl 
THF  tetrahydrofuran 
TMS  trimethyl silyl 
t.l.c  thin layer chromatography 
TPAP  Tetrapropylammonium perruthenate 
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1.1 Iminosugars 
Iminosugars have the potential to block or modifiy glycosidase enzymes which are 
involved in a wide range of biological processes, and they have therefore attracted a great 
deal of interest since they were first discovered. This interest has focused on the isolation 
of new iminosugars, their biological activity and indeed their synthesis. This thesis 
describes synthetic routes towards some of the recently isolated polyhydroxylated 
pyrrolizidines of the hyacinthacine family via a common nitrone precursor.  
 
1.2 Structure of iminosugars 
Iminosugars are potential glycosidase inhibitors and are analogues of mono- or 
disaccharides in which the ring oxygen has been replaced by nitrogen. The first 
iminosugar, nojirimycin (1, NJ) [figure 2], was discovered in 19661 and numerous 
iminosugars have since been isolated from plants and microorganisms.2 Naturally 
occurring sugar mimics with a nitrogen in the ring are classified into five structural 
classes: polyhydroxylated piperidines, pyrrolidines, indolizidines, pyrrolizidines and 
nortropanes, and these can therefore be grouped as monocyclic or bicyclic structures as 
shown in Figure 1. 
 
 
 
Figure 1.  General structure and numbering of iminosugar core structures; the numbering 
applied to the piperidine and pyrrolidine compounds is adapted from carbohydrate 
nomenclature. 
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1.2.1 Monocyclic structures 
 
There are two classes of monocyclic iminosugars, piperidines and pyrrolidines, with the 
general structures general structures shown in Figure 1. Nojirimycin (or 5-amino-5-
deoxy-D-glucopyranose) (NJ, 1) [figure 2] is the main representative of the piperidine 
class of monocyclic iminosugars. It is a polyhydroxylated piperidine corresponding to 
glucose in the pyranose form and was first described as an antibiotic produced in bacterial 
cultures of Streptomyces roseochromogenes R-468 and Streptomyces nojiriensis SF-426.3 
As a hemiacetal, NJ is an inherently unstable structure and therefore its corresponding 1-
deoxy analogue, 1-deoxynojirimycin (DNJ; 2) [figure2], was synthesised by reduction 
with NaBH4 by Paulsen and coworkers.4 DNJ was later isolated from the roots of 
mulberry leaves and was called moranoline.5 DNJ is also produced by many strains of the 
Bacillus and Streptomyces genera. DNJ is related to another natural product, 1-
deoxymannojirimycin (DMJ, 3) [figure 2], where the hydroxyl group at C-2 has the 
opposite stereochemistry, mimicking the pyranose form of D-mannose. DMJ was found to 
be produced by Streptomyces lavendulae SF-425 and has recently been extracted from 
Adenophora triphylla.5 A number of other piperidine iminosugars have since been 
isolated from a range of plants and bacterial cultures and these are shown in Figure 2.2 
Iminosugars with a hydroxyl group at C-1, nojirimycin B (manno-NJ, 4) and galactostatin 
(galaco-NJ, 5), were also isolated from species of Streptomyces. Fagomine, 1,2-
dideoxynojirimycin (6) has been isolated from the seeds of Japanese buckwheat 
(Fagopyrum esculentum)6 as well as the Moreton Bay Chestnut and Castanospermum 
australe.7 The search for iminosugars continued and 3-epi-fagomine (7) and 3,4-di-epi-
fagomine (8) were isolated from the leaves and roots of X. zambesiaca.8 Fagomine (6) 
and 6-deoxyfagomine (9) have been isolated from the roots of Lycium Chinese 
(Solanaceae)9 and 2S-carboxy-3R,4R,5S-trihydroxypiperidine (10) was isolated from the 
seeds of the legume Baphhia racemosa.10 The first naturally occurring DNJ derivative 
with a carbon substituent at C-1, α-homonojirimycin (α-HNJ, 11), was isolated from O. 
diandra
11 and more recently has been isolated from the bulbs of Hyacinthus orientalis 
(Hyacinthaceae).12 The isomers and glycosides of α-HNJ such as β-homonojirimycin (β-
HNJ, 12), α-homomannojirimycin (13), β-homomannojirimycin (14), α-
homoallonojirimycin (15) and β-homoaltronojirimycin (16) are also produced by these 
plants. More recently, in 2002, piperidine iminosugars were isolated from the bulbs of 
Scilla sibirica
13 including two new compounds, α-7-deoxyhomonojiromycin (17) and α-
7-deoxyhomomannojiromycin (18). 
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Figure 2. Naturally occurring piperidines  
 
Polyhydroxylated pyrrolidines resemble sugars in the furanose form and can be potent 
inhibitors of the corresponding glycosidases specific for carbohydrates with a matching 
pattern of hydroxyl substitution and stereochemistry. Some of the naturally occurring 
pyrrolidines are shown in Figure 3.   
 
In 1976, 2,5-dihydroxymethyl-3,4-dihydroxypyrrolidine (DMDP, 19), a naturally 
occurring analogue of β-D-fructofuranose was found in the leaves of the legume, Derris 
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elliptica.14, 15 This compound is a very common metabolite as it has since been isolated 
from various other plants and microorganisms.16 A second example of a pyrrolidine 
analogue is 1,4-dideoxy-1,4-imino-D-arabinitol (D-AB1, 20), which resembles 19 but has 
only one hydroxymethyl group. D-AB1 was initially isolated from the fruits of 
Angylocalyx boutiqueanus but, like DMDP, has since been isolated from different species 
of plants.17, 18 
 
β
β
 
Figure 3. Naturally occurring pyrrolidine iminosugars 
 
The 6-deoxy derivative of DMDP (6-deoxy-DMDP, 2,5,-imino-1,2,3-trideoxy-D-
mannitol, 21) was isolated from the seeds of Anglocalyx pynaertii.19 The roots of Morus 
spp have been found to produce the 2-epimer of D-AB1, 1,4-dideoxy-1,4-imino-D-ribitol 
(22) and polyhydroxypyrrolidine nectrisine (23) was isolated from a broth culture of the 
fungus Nectria Ludica.2 The first naturally occurring 2,5-dideoxy-2,5-iminoheptitol, 2,5-
dideoxy-2,5-imino-DL-glycero-D-manno-heptitol (homoDMDP, 24) was found in the 
leaves of bluebell (Hyacinthoides non-scripta).20 More recently, homoDMDP has been 
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found in the bulbs of hyacinths (Hyacinthus orientalis) along with 2,5-imino-2,5,6-
trideoxy-D-manno-heptitol (6-deoxy-homoDMDP, 25) and 2,5-imino-2,5,6-trideoxy-D-
gulo-heptitol (26).12 In 2002, homo-DMDP (24), 6-deoxy-homo-DMDP (25) and 2,5-
imino-2,5,6-trideoxy-D-gulo-heptitol (26) were isolated from Scilla sibirica13 along with 
four new pyrrolidines (27-30). These new pyrrolidines were determined to be 7-deoxy-
homoDMDP (2,5-imino-2,5,7-trideox-glycero-D-manno-heptitol 27), 2,5-dideoxy-2,5-
imino-glycero-D-galacto-heptitol (28), 4-O-β-D-mannopyranosyl-6-deoxy-homoDMDP 
(29), and 4-O-[β-D-mannopyranosyl-(1→4)-β-D-mannopyranosyl]-6-deoxy-homoDMDP 
(30). Three further pyrrolidines (31-33) with longer side chains were isolated from the 
bulbs of Scilla peruviana.21 These D-AB1 derivatives were found to possess, respectively, 
2-hydroxypropyl, 1,2-dihydroxypropyl and 1,5,7,12,13-pentahydroxytridecyl side chains 
at the C-1α position and were therefore identified as α-1-C-(1,5,7,12,13-
pentahydroxytridecyl)-D-AB1 (31), α-1-C-(1,2-dihydroxypropyl)-D-AB1 (32) and α-1-C-
(2-hydroxypropyl)-D-AB1 (33). 
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1.2.2 Bicyclic structures 
 
There are three classes of natural bicyclic iminosugars: indolizidines, pyrrolizidines and 
nortropanes, which have the general structures as shown in Figure 1. The first bicyclic 
iminosugar, an indolizidine, was isolated from a legume called Swainsona canscens in 
1979 and was named swainsonine (34) [figure 4].22 It has since been isolated from 
locoweeds (Astragalus and Oxytropis species) which cause the disorder ‘locoism’ in 
animals. Another similar alkaloid, castanospermine (35) [figure 4], was later isolated 
from the seeds of the tree Castanospermum australe.23 It was found to share the same 
core indolizidine structure as 34 but differs in the substitution pattern of the hydroxyl 
groups. The seeds of Castanospermum australe were also found to produce 6-epi-
canstanospermine (36), 7-deoxy-6-epi-castanospermine (37) and 6,7-di-epi-
castanospermine (38) the structures of which are shown in Figure 4.23 The leaves of 
Astragalus Lentiginous produce lentiginosine (39) and 2-epi-lentiginosine (40).24  
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Figure 4.  Naturally occurring indolizidine iminosugars 
 
The first polyhydroxylated pyrrolizidines, alexine (41) [Figure 5] and australine (or 7a-
epi-alexine, 42) [Figure 5] were isolated in 1988 from the legumes, Alexa leipetala and 
Castanospermum australe.25 These structures differ from the long known necine bases, 
pyrrolizidine alkaloids, with a hydroxymethyl side chain at the C-1 position. 
Castanospermum australe was subsequently found to be a valuable source of other 
pyrrolizidines bearing a carbon branch at the C-3 position, with 3,7-epi-alexine (43), 
1,7a-di-epi-alexine (44), and 7,7a-di-epi-alexine (45), the structures of which are shown 
in Figure 5, all being isolated from this source.2 The pentahydroxylated indolizidine, 
casuarine (46) [Figure 5], which has been used for the treatment of cancer in Western 
Samoa, has been isolated from the bark of Casuarina equistifolia (Casuarinaceae) and 
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from the leaves of Euginia jambolana (Myrtaceae).26  The first naturally occurring 
polyhydroxylated pyrrolizidinecarboxylic acid, 7a-epi-alexaflorine (47) [Figure 5], which 
carries a carboxyl group at C-3, was found in the leaves of Alexa grandiflora.27 
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Figure 5. Examples of polyhydroxylated pyrrolizidine alkaloids isolated from 
Castanospermum australe and other sources and structural comparison with necine 
 
A large family of hydroxylated pyrrolizidine alkaloids, that have a carbon branch at C-3 
or both C-3 and C-5 have been isolated from plants belonging to the hyacinthaceae family 
(Figure 6); these are collectively known as hyacinthacines. Hyacinthacine B1 (48), 
hyacinthacine B2 (49) and hyacinthacine C1 (50) were the first compounds to be 
discovered in this group and were isolated from Hyacinthoides non-scripta and Scilla 
campanulata.
28
  Four further hyacinthacines, A1 (51), A2 (52), A3 (53), and B3 (54), were 
subsequently isolated from the bulbs of Muscari armeniacum in 2000 along with the 
known hyacinthacine C1 (50).29  In 2002, seven more hyacinthacines were isolated from 
the bulbs of Scilla sibirica––hyacinthacines A4 (55), A5 (56), A6 (57), A7 (58), B4 (59), B5 
(60) and B6 (61).13 Four new pyrrolizidines, with longer side chains at the C-5 position, 
were isolated from Scillia peruviana in 2004.21 These were, α-5-C-(3-hydroxbutyl)-7-epi-
australine (62), α-5-C-(3-hydroxybutyl)hyacinthacine A1 (63), α-5-C-(1,3-
dihydroxybutyl)hyacinthacine A1 (64), and α-5-C-(1,3,4-trihydroxybutyl)hyacinthacine 
A1 (65). Finally, in 2007, an examination of the bulbs of Scillia solcialis resulted in the 
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isolation of eleven hyacinthacines, including six new compounds, hyacinthacine B7 (66), 
C2 (67), C3 (68), C4 (69), C5 (70), and α-5-C-(3-hydroxybutyl)hyacinthacine A2 (71).30 
The known hyacinthacines A3 (53), A5 (56), B3 (54), and B4 (59) were also found in 
Scillia solcialis. 
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Figure 6. Hyacinthacine family of polyhydroxylated pyrrolizidines arranged according to 
hyacinthacine letter grouping; A, B or C. 
 
The name hyacinthacine is given to polyhydroxylated pyrrolizidines bearing a 
hydroxymethyl group at the C-3 and/or C-5 positions. These are assigned a letter and a 
number; the letter corresponds to the number of hydroxyl groups present and is related to 
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the mass of the compound. The hyacinthacine A group have 3 hydroxyl groups, the B 
class have 4 hydroxyl groups and the C have 5 hydroxyl groups. Numbers are then used 
to distinguish between compounds within the same class and are assigned in order of 
discovery.  
 
Polyhydroxylated nortropanes were the final class of naturally occurring bicyclic 
iminosugars to be discovered when calystegines were found to be secondary metabolites 
in plants and were implicated in the maintenance of plant-bacterium relationships.31 A 
shown in Figure 7, Calystegines have a nortropane ring system, two to four hydroxyl 
functions of varying stereochemistrics and position and a tertiary alcohol group at the 
bridgehead carbon C-1 of the bicyclic ring. The first calystegines, A3 (72), B1 (73) and B2 
(74), were extracted from root cultures of C. sepium and were classified into two groups, 
calystegines A and B, on the basis of their relative mobilities on paper electrophoresis.31, 
32 Examination of M. bombycis and M. alba both of the Moraceae family resulted in the 
discovery of calystegines B2 and C1 (75).33,34 Later, calystegines A3, A5 (76), B1, B2, and 
B3 (77) were isolated from the roots of Physalis alkekengi var. francheti.35 Calystegines 
A3, B1, and B2 have now been found in the Solanaceae plant family genera Atropa, 
Datura, Duboisia, Hyoscyamus and Scopolia.36 Low amounts of calystegines were 
detected in Datura wrightii leaves37 and D. stramonium roots and leaves.38 Calystegines 
A5, A6 (78), B1, B2, B3, and N1 (79) were subsequently isolated from Hyoscyamus niger.39 
Calystegines A3, A5, B1, B2, B3, B4 (80), C1 and calystegines B1, B2, B4, C1, and C2 (81) 
were found in Scopolia japonica40 and in Duboisia leichhardtii respectively.41  More 
recently, new calystegines, A8 (82) and B6 (83), were isolated from H. niger and S. 
Japonica and it was discovered that Lycium chinense produced N-methyl-calystegines B2 
(84) and C1 (85), and calystegines A7 (86) and B5 (87).42 Edible fruits and vegetables 
have also been found to be a source of calystegines; they have been detected in plants of 
the Convolvulaceae, Solanaceae and Moraceae families that include sweet peppers, chilli 
peppers, potatoes, eggplants, tomatoes, physalis fruits, sweet potatoes and mulberries.43  
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Figure 7: Structures of polyhydroxylated nortropanes. 
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1.3 Biological activity of iminosugars 
Iminosugars possess inhibitory activity against many of the glycosyltransferases and 
glycosidases that mediate, respectively, the biosynthesis and degredation of carbohydrate 
polysaccharides and glycoconujugates (glycoproteins, glycolipids, proteoglycans) in 
nearly all life forms.44 The first example involved the first isolated iminosugar NJ (1) 
which was reported to inhibit both α-glucosidases and β-glucosidases.3 The reduced form 
of NJ, DNJ (2), exhibited activity against glycosidases I and II, whereas DMJ (3) and its 
bicyclic counterpart Swainsonine (34) were reported to inhibit lysosomal α-
mannosidases.2, 15 Castanospermine (35) has been shown to be a powerful inhibitor of the 
α- and β-glucosidases in the mammalian gut.23 Australine was found to be a good 
inhibitor of the α-glucosidases, amylglucosidase and subsequently the glycoprotein 
enzyme glucosidase I.45 
 
Unsurprisingly, the inhibition of glycosidase and glycosyltransferase enzmes can affect 
the digestion and metabolism of polysaccharides as well as the maturation, transportation, 
and secretion of glycoconjugates. Glycocongugates expressed at the cell surface – often 
possessing complex, branched extracellular carbohydrate structures – are involved in 
several fundamental biological functions such as cell-cell recognition, cell adhesion and 
signalling. The role of these biomacromolecules in cell differentiation, immune response, 
oncogenesis, tumor metastasis and viral infections has prompted considerable interest in 
iminosugars as a class of compounds for therapeutic intervention, with the emphasis of on 
their potential applications in the treatment of diabetes, cancer and viral disease. 
 
1.3.1 Inhibition of digestive glycosidases 
 
Digestive glycosidases, located in the small intestine, are enzymes that hydrolyze dietary 
carbohydrates to monosaccharides, which are then absorbed through the intestine wall. It 
was thought that treatment of non insulin dependent diabetes (type II diabetes) could be 
achieved by means of blocking these enzymes, thus regulating the absorption of 
carbohydrates through the intestine wall.  
 
The original discovery of DNJ (2) resulted from investigations prompted by the 
knowledge that extracts of mulberry were able to suppress the rise in blood glucose that 
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follows eating, suggesting that this activity could be beneficial for diabetes treatment.15 
DNJ (2) was subsequently found to have a good inhibitory effect on mammalian α-
glucosidase in vitro and was thus considered to be a promising agent for treatment of 
diabetes.46 Unfortunately, the compound lacked efficacy in vivo for this clinical indication 
but these studies stimulated the synthesis and evaluation of many derivatives of DNJ and 
N-alkylated analogues, such Migitol (88) (BAY m109), were subsequently found to be 
potent inhibitors of the glycogenolysis induced by glucagen in studies with hepatocytes.47 
Migitol (GLYSETTM) is now used in the treatment of type II diabetes and is available in 
the USA and Canada. 
 
In type II diabetes, an increase in hepatic glucose production and blood glucose levels is 
observed. Inhibiting hepatic glycogen phosphorylase could prevent this from occurring. 
Isofagomine (89) [Figure 8] was recently found to be a good inhibitor of liver glycogen 
phosphorylase, blocking glycogen degradation in hepatocytes.48 The specificity of 
iminosugars is well illustrated by the fact that some N-alkylated derivatives of 
isofagomine (89) are active inhibitors at micromolar concentrations, whereas fagomine 
(6) and DNJ (2) lack activity (Figure 8).49 
 
 
 
Figure 8: Structure showing specificity of inhibitory action on digestive glucosidase. 
 
1.3.2 Inhibition of lysosomal glycosidases 
 
Disorders in the biosynthesis or catabolism of glycolipids in the cell have an impact on so 
called lysosomal storage diseases like type I Gaucher disease or Fabry disease.50 In 
normal cells there is a balance between the degradation of glycosphingolipids (GSLs) in 
the lysosome and their biosynthesis in the endoplasmic reticulum (ER)/Golgi system. The 
rates of influx of GSLs and efflux of metabolites are in equilibrium. In a lysosomal 
storage cell, enzyme activity in the lysosome is so low that GSLs accumulate. However, 
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although the catalytic activity of enzymes is reduced, it is not totally eliminated. Thus, 
drugs that could regulate the biosynthesis of GSLs to a concentration that fits well in the 
residual enzymic activity could prevent storage. Studies have thus been carried out with 
N-alkylated DNJs, which are inhibitors of ceramide-specific glycosyltransferases,51 and 
N-butyl DNJ (90) [Figure 9], marketed as Zavesca®, is now used in the treatment of type 
1 Gaucher’s disease.  
 
Figure 9: N-butyl DNJ 
 
The discovery that swainsonine (34) can induce a reversible phenocopy of the genetic 
lysosomal storage disease, mannosidosis, in animals has led to the use of chemically 
induced deficiencies of lysosomal hydrolyses as models for studying the pathogenesis of 
lysosomal storage disease.52,53 Mannosidosis is characterised by the accumulation in cells, 
and excretion in urine, of mannose rich oligosaccharides resulting from a deficiency of 
lysosomal α-mannosidase. Treatment with swainsonine (34) is particularly effective in 
mimicking lysosomal storage disease because of the compound’s potent inhibitory 
activity against lysosomal α-mannosidase and its lysosomotropic behaviour. It is a weak 
base with a pKa of 7.4, which ensures that it is taken up rapidly into cells by permeation 
and, once inside the lysosomes, becomes protonated and becomes concentrated. 
Swainsonine (34) has since been granted orfan drug status for the treatment of Gaucher 
disease. 
 
Seeds containing castanospermine (35) have been reported to be toxic to animals and 
cause various symptoms, including gastrointestinal upset. Castanospermine (35) also 
disturbs lysosomal catabolism in animals, in this case glycogen and glucolipids by 
inhibition of lysosomal α-glucosidases or β-glucosidases. Its physiological effects 
therefore result in symptoms that resemble the genetic disorders of Pompe’s and 
Gaucher’s disease.23,54 The N-hydroxyethyl derivative of DNJ also induces the 
accumulation of glycogen, as demonstrated in normal human fibroplasts and the polarized 
HepG2 cells.2 It also delays the processing of the ER α-glucosidases I and II. Thus, 
lysosomal storage diseases can be induced and exacerbated by the effects of the inhibitory 
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action of iminosugar inhibitors on processing glycosidases. For this reason, attempts to 
harness iminosugar glycosidase inhibitors therapeutically to alter the glycosylation of 
proteins, or inhibit intestinal carbohydrate digestion carry the risk of inducing lysosomal 
storage as a chronic complication. There is some evidence, however, that the doses of 
inhibitor used effectively in experimental therapies may be too low to induce lysosomal 
storage.55 
 
1.3.3 Processing glycosidases 
 
The α-D-glucosidases and α-D-mannosidases involved in the post-translational processing 
of asparagine-linked glycans of glycoproteins can be selectively inhibited by various 
iminosugars.56 Using these inhibitors, the consequences of altering the glycosylation of a 
particular glycoprotein or the glycotype of cells can in a defined way be studied. Indeed, 
castanospermine (35), DMJ (3) and swainsonine (34), the structures of which are shown 
in Figure 10 have become the standard commercially available reagents used in 
biochemical studies for inhibition of α-glucosidases I, α-mannosidases I and α-
mannosidases II. These compounds are not completely specific, however, and they do not 
inhibit processing unless they are present in relatively high concentrations, which in itself 
increases lack of specificity. Consequently, there is current interest in the discovery of 
more specific glycosidase inhibitors and this has prompted structure activity relationship 
studies. For example,  N-methyl-DNJ (91) [Figure 10] has been found to be a poorer 
inhibitor of α-glucosidases I than DNJ (2) [Figure 10] and conversely for α-glucosidases 
II. Castanospermine also exhibited a similar inhibition of α-glucosidases I to N-methyl-
DNJ (91) [Figure 10] suggesting that substitution of the piperidine nitrogen favours 
inhibition of α-glucosidases I. 
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Figure 10  
 
DMJ (3) was found to inhibit α-mannosidase I, which is particularly susceptible to 
iminosugar pyranose analogues. Although swainsonine (34) has been shown to be a 
potent inhibitor of α-mannosidase II, it does not inhibit other processing α-mannosidases 
in human cell cultures.15 The specificity of synthetic iminosugars for the various 
processing glycosidases has not yet been exhaustively evaluated, but the available 
information suggests that many are more specific in vitro than their parent compounds. 
The effect of the common glycoprotein processing inhibitors on the biosynthesis, 
intracelluar transport and function of most well characterised glycoproteins has been 
thoroughly evaluated however. Indeed, their effects on many cellular processes have been 
evaluated, but perhaps the two areas of most excitement and interest relate to anti-cancer 
and antiviral applications. 
1.3.4 Anti-cancer activity and anti-viral activity 
 
Both catabolic and processing glycosidases are involved in oncogenic transformation of 
cells as well as tumour cell invasion and migration behaviour that underpins metathesis. It 
has also been known for some time that levels of glycosidases are elevated in patients 
with various types of tumours. Significantly, castanospermine (35) and swainsonine (34) 
have been reported to inhibit metastasis, and this activity was attributed to their 
glycosidase-inhibitory activity.2 
 
Host cell infection by the Human Immunodeficiency Virus (HIV) is initiated by 
interaction between gp-120, a glycoprotein peplomer on the HIV virion, and CD-4 on 
human lymphocytes.57 Gp-120 is generated in the Golgi apparatus together with a 
transmembrane glycoprotein, gp-41, by endoproteolytic cleavage of a precursor protein, 
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gp-160.58 Both gp-41 and gp-120 are highly N-glycosylated, with most of the glycans 
belonging to high mannose complex types. Indeed, gp-120 has 20 to 25 N-glycan linkable 
sites, and the total carbohydrate content comprises around 50% of the total molecular 
weight for the complete glycoprotein.59 Perturbation of viral glycoprotein processing 
could be an attractive target for chemotherapy to treat HIV, and some inhibitors of 
processing glycosidases I and II, such as castanospermine (35) and DNJ (3), are known to 
decrease the efficiency of HIV infection. Castanospermine (35),60 DMDP (19)61 and 
swainsonine (34)62 have also been reported to prevent the processing of the influenza 
viral glycoprotein (hemagglutinin) that is responsible for adsorption of the inflenza virion 
to host cells. One of the most the most promising compounds in this class to date is N-
butyl DNJ (Zavesca®, 90) which has shown good antiviral activity and low cell toxicity.63 
 
1.4 Enzyme mechanisms and structure activity relationships 
Iminosugars are known to inhibit glycosidase enzymes and other carbohydrate-
recognising proteins. It is generally accepted that pyranose hydrolysis catalysed by such 
carbohydrate processing enzymes (glycosidases and glycosyl transferases) proceeds 
through a half chair transition state with a substantial sp2 character at the anomeric 
carbon. This reaction can occur with one of two stereochemical outcomes, inversion or 
retention of configuration, leading to two different mechanisms for the hydrolysis of a 
glycosidic bond (Figure 11).64. Both of these enzymic mechanisms involve a key 
oxonium intermediate or transition state (TS) with carbocation character that is generated 
by the action of acidic residues in the enzyme’s catalytic pocket.65 In the hydrolysis 
catalyzed by inverting glycosidases, one acidic residue acts as a general acid, facilitating 
the oxocarbenium-like intermediate formation, while a second (in the carboxylate state) 
acts as a general base and assists nucleophilic delivery of a water molecule to the 
anomeric carbon thus producing the glycose with inversion of anomeric configuration 
(Fig. 11A). Retaining glycosidases convert the glycoside to glycose with retention of the 
anomeric configuration. Instead of suffering direct nucleophilic attack by water, the 
oxocarbenium-like intermediate is stabilized by the carboxylate prior to its displacement 
from the anomeric centre by water (Fig. 11B). This double inversion at the anomeric 
centre leads to the retention of anomeric configuration. 
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Figure 11: Inverting (A) and retaining (B) glycosidase mechanisms. 
 
The basic nitrogen atom of iminosugars may be protonated making these compounds 
analogues of the transition state oxonium ion.66 This is the key factor that underpins the 
capacity of iminosugars to bind to and to inhibit glycosidase and other carbohydrate 
processing enzymes. 
 
Perhaps surprisingly the importance of shape, pattern of hydroxyl substitution and 
stereochemistry to an iminosugar’s selectivity is not always easily predictable.67 It was 
initially thought that inhibitors of glucosidases and mannosidases should have structures 
closely resembling glucose and mannose respectively. For example DNJ (2) has a 
structure similar to that of glucose and DMJ (3) has a structure similar to mannose, and 
indeed these compounds are known to inhibit α-glucosidase and α-mannosidase 
respectively, demonstrating that the differing stereochemical arrangement of the hydroxyl 
groups plays a key role in controlling inhibitory selectivity. This argument often holds for 
glucosidase inhibitors, which typically do have structures with hydroxyl substitution 
patterns similar to glucose.68 However, close mimicry between the structure of an 
inhibitory iminosugar and the enzyme’s substrate is not always seen. For example, 6-epi-
castanospermine (36) has a structure closely resembling the D-mannosyl cation (92), but 
was found to inhibit α-glucosidases and not the expected α-mannosidase.64 With the 
exception of DMJ (3), α-D-mannosidase inhibitors in reality generally do not have 
structures that closely resemble mannose. For example, swainsonine (34) exhibits potent 
inhibition of α-mannosidases although its structural resemblance to α-D-mannose is not 
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obvious. Winkler and Holan were able to offer an explanation for these inconsistencies 
based on the results of molecular orbital calculations and structure-activity relationship 
studies with α-D-mannose analogues and mannosidase inhibitors.69 These calculations 
and studies showed that there are two optimized half chair geometries of the mannosyl 
cation, a “flap up” form (93) and the “flap down” form (94), the former being the lower in 
energy [Figure 12]. This study showed that the best inhibitors resembled the “flap up” 
half chair geometry of the mannosyl cation. This model was also able to rationalize why 
6-epi-castanospermine (36), which superficially resembles mannose, is actually a poor 
mannosidase inhibitor, it has the incorrect ring configuration for good superimposition 
onto the mannosyl cation in the “flap up” half chair configuration.70  
 
 
Figure 12: Structural resemblance between selected iminosugars and carbohydrate 
cations 
 
Nevertheless, in many cases, further exploration is required to establish a proper 
understanding of structure activity relationships for carbohydrate processing enzymes. 
Thus, for example, the basis for selective mannosidase-inhibitory activity of protonated 
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DNJ (95) remains unclear since this compound does not appear to closely mimic the 
structure of the “flap up” mannosyl cation (93). A possible explanation might be that 
binding in the mannosidase catalytic pocket is in this case dominated by ionic interactions 
between the protonated DNJ structure and the catalytic acidic residues lining the pocket.71 
 
Given the promising enzyme inhibitory activity of iminosugars in general, considerable 
effort has been made over the last three decades to develop efficient synthetic routes to 
these compounds. This work has been prompted both by the need to provide material for 
biological assessment and clarification of structure activity relationships and also in the 
hope that synthesis of new structures might provide compounds wth improved activity 
and selectivity. 
1.5 Synthetic routes to hyacinthancines  
There are many different methods for the synthesis of bicyclic polyhydroxylated alkaloids 
and indeed there are many examples to be found in the literature.  General methods for 
building polyhydroxylated pyrrolizidines, indolizidines, quinolizidines and nortropanes 
have been reviewed by Lopez et al.72 This review classifies the general routes into three 
categories of cyclisation based on the key step in forming the bicyclic ring; these are: 1) 
standard cyclisation, 2) cycloaddition and 3) ring closing metathesis. In a review by 
Michael, the synthetic methods for producing polyhydroxylated indolizidines and 
quinolizidines have been discussed.73 El Nemr has also reviewed synthetic routes to 
polyhydroxylated indolizidines, with comprehensive coverage of synthetic approaches to 
swainsonine and its analogues.74 Given the vast number of reports concerning the 
synthesis of bicyclic iminosugars, only synthetic approaches to the more relevant 
pyrrolizidines will be discussed here. 
 
A number of synthetic strategies have been devised by several groups for the preparation 
of hyacinthacines and these can be classified by the cyclisation method used. Routes 
using reductive cyclisation, ring closing metathesis (RCM), nucleophilic substitution, 
nitrone umpolung and nitrone 1,3-dipolar cycloaddition as the key reactions have all been 
applied (Figure 13), with starting materials derived from a carbohydrate-based chiral 
pool.  
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Figure 13 Synthetic strategies for synthesis of hyacinthacines 
 
1.5.1 Reductive cyclisation 
 
A series of hyacinthacines prepared by reductive cyclisation of pyrrolidine precursors 
have been reported by Izquierdo et al.  In their first report, the Izquierdo group described 
the application of pyrrolidine derivative 96 for the synthesis of 7a-epi-hyacinthacine A2 
(97, Scheme 1) and 5,7a-diepi-hyacinthacine A3 (98, Scheme 2).75 
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Scheme 1: (a) TPAP,NMO, CH2Cl2, 4 Å MS, (95%); (b) Ph3P=CHCHO, CH2Cl2, (44%); 
(c) H2, 10% Pd/C, (45%); (d) TBAF, (59%); (e) H2, 10% Pd/C, MeOH, HCl, (93%); (f) 
MeOH, Amberlite IRA-400 (OH– form), (76%).  
 
The pyrrolizidine precursor (96) was prepared from D-fructose in 11 steps.76 Oxidation of 
the primary alcohol group catalysed by TPAP produced aldehyde 99. Wittig olefination 
of the aldehyde with (triphenylphosphoranylidine)acetaldehyde produced the 
homologated E-α,β-unsaturated aldehyde (100), which after hydrogenation gave saturated 
aldehyde 101. Intramolecular condensation to the bicyclic enamine (102), and further 
hydrogenation produced the pyrrolizidine (103). Removal of the TBDPS group to gave 
104 and this was followed by further hydrogenation to give the hydrochloride salt of 7a-
epi-hyacinthacine A2 (105), which was converted into the free base (97) by treatment 
with a basic resin. 
 
Pyrrolidine 96 was also used in similar chemistry to produce 5,7a-diepi-hyacinthacine A3 
(98) (Scheme 2). Again the route began with oxidation of the primary alcohol using 
TPAP to produce aldehyde 99. Wittig olefination of the aldehyde, this time with 1-
triphenylphosphoranylidene-2-propanone instead of (triphenylphosphoranylidene) 
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acetaldehyde, produced ketone 106. The final steps in the route were identical to those 
applied in Scheme 1. Thus, after hydrogenation 106 furnished saturated ketone 107 and 
cyclisation delivered the bicyclic enamine (108). Further hydrogenation produced the 
pyrrolizidine (109) and the route was completed by the removal of the TBDPS group with 
TBAF, affording 110, followed by further hydrogenation under acidic conditions to 
obtain the target as a hydrochloride salt (110). The latter was again converted into the free 
base, 5,7a-diepi-hyacinthacine A3 (98) by treatment with the basic resin. High 
stereoselectivity was observed in the key hydrogenation step that generated the 
pyrrolizidine core in intermediate 91 and this was attributed to delivery of hydrogen from 
the least hindered convex face of the bicyclic enamine 90. 
 
 
Scheme 2: (a) TPAP, NMO, CH2Cl2, 4 Å MS (85%); (b) Ph3P=CHCOCH3, CH2Cl2 
(57%); (c) H2, 10% Pd/C (60% of 109 from 106); (d) TBAF; (85%) (e) H2, 10% Pd/C, 
MeOH, HCl; (f) Amberlite IRA-400 (OH– form) (83% of 98 from 110). 
 
The Izquierdo group then applied the methodology developed in Schemes 1 and 2 to the 
synthesis of hyacinthacine A3 (53, Scheme 3)77 and hyacinthacine A2 (52, Scheme 4).78 
Access to these members of the hyacinthacine family required a modified pyrrolidine 
precursor however, and the group developed a suitably protected 2,5-dideoxy-2,5-imino-
D-mannitol (DMDP) derivative (112) from D-fructose for this purpose. The key 
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difference in the pyrrolidine precursor (112) used for synthesis of hyacinthacines A3 and 
A2 was the switch in the stereochemistry at the C-2 centre bearing the hydroxymethyl 
side arm. Additionally N-Boc protection rather than Cbz protection was applied in the 
route, but in other respects the steps were essentially the same as those applied previously 
in Schemes 1 and 2. Accordingly, the route to hyacinthacine A3 started with the TPAP-
catalysed oxidation of pyrrolidine 95, producing aldehyde 113. Wittig olefination of 
aldehyde 113 with 1-triphenylphosphoranylidene-2-propanone gave unsaturated ketone 
114, and subsequent hydrogenation in the presence of hydrochloric acid produced the 
fully deprotected, saturated ketone (115) after treatment with a basic resin. This was then 
subjected to a further hydrogenation to achieve a reductive cyclisation via enamine 116. 
Hydrogenaton from the less hindered β-face of 116 proceeded with very high 
steroselectivity to complete the first synthesis of hyacinthacine A3 (53). 
 
 
Scheme 3: (a) TPAP, NMO, CH2Cl2, 4 Å MS (90%); (b) Ph3P=CHCOCH3, toluene 
(100%); (c) H2, 10% Pd/C, MeOH, HCl then Amberlite IRA-400 (OH– form); (d) H2, 
10% Pd/C, MeOH, HCl then Amberlite IRA-400 (OH– form), (68% of 53 from 114).   
 
Shortly after disclosing the synthesis of hyacinthacine A3, Izquierdo et al. described the 
application of the DMDP derivative 112 in the synthesis of hyacinthacine A2 (52, Scheme 
4).78 A very similar strategy was used but aldehyde 113 was homologated by olefination 
with (triphenylphosphoranylidene)acetaldehyde to give 117. A first hydrogenation under 
neutral conditions, reduced the alkene side chain only. Deprotection of the O-TBDPS and 
N-Boc groups was achieved simultaneously with hydrochloric acid. A second 
hydrogenation, under acidic conditions, effected the reductive cyclisation and O-
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debenzylation, with hyacinthacine A2 (52) isolated in the free base form after treatment 
with basic resin. 
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Scheme 4: (a) TPAP, NMO, CH2Cl2, 4 Å MS; (b) Ph3P=CHCHO, toluene (57%); (c) H2, 
10% Pd/C; (d) HCl, then Amberlite IRA-400 (OH– form); (e) H2, 10% Pd/C, MeOH, HCl, 
then Amberlite IRA-400 (OH– form) (26% of 52 from 113). 
 
This methodology – homologation of a suitable pyrrolidinecarbaldehyde followed by 
Wittig olefination and then reductive cyclisation – has subsequently been applied to the 
synthesis of many other pyrrolizidines. Thus, Izquierdo et al. have developed routes to 3-
epi-hyacinthacine A3 (120) and 3-epi-hyacinthacine A2 (121),79 and three 
dihydroxypyrrolizidines (122, 123 and 124) (Figure 14).80 Synthesis of casuarine (46), 
6,7-diepi-casuarine (125),81 3-epi-hyacinthacine A5 (126) and (+)-3-epi-hyacinthacine A5 
(127),82 (+)-5-epi-hyacinthacine A5 (128) and ent-3-epi-hyacinthacine A4 (129)83 have 
also been descibed. 
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Figure 14. Series of pyrrolizidines synthesized by Izquierdo et al.83 
 
The earlier routes investigated by the Izquierdo group all targeted polyhydroxylated 
prrolizidines with trans relative stereochemistry across the C-1 and C-2 hydroxlated 
centres. A number of their later examples, as illustrated in Figure 14, possessed cis-1,2 
relative stereochemistry. Access to these compounds was achieved by essentially the 
same pyrrolidinecarbaldehyde homologation and reductive cyclisation strategy as 
described previously but required a suitably protected pyrrolidinecarbaldehyde precursor 
embodying the desired cis stereochemistry. The approach is illustrated for the group’s 
recent synthesis of hyacinthacine A1 (51) and hyacinthacine A6 (57) (Scheme 5).84 These 
two members of the alkaloid family were prepared from a common pyrollidine derivative 
(130) possessing three orthogonal protecting groups synthesised in multiple steps from D-
fructose.84,85 Protection of the free hydroxymethyl side chain by benzoylation followed by 
desilylation to remove the TBDPS protecting group exposed the required hydroxmethyl 
group for subsequent TPAP oxidation. This afforded the key pyrrolidinecarbaldehyde 
precursor (133). The latter was developed into hyacinthacine A6 (57) by similar chemistry 
to that shown in Schemes 2 and 3 through homologation by Wittig olefination with 1-
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triphenylphosphoranylidene-2-propanone followed by reductive cyclisation. In this case, 
an extra step was required to remove the benzoate protection and unmask the primary 
alcohol, and this was achieved by treatment with sodium methoxide in methanol 
following the reductive cyclisation and prior to hydrogenolysis of the benzyl groups. 
 
The synthesis of hyacinthacine A1 (51) (Scheme 5) was accomplished through a variation 
of the reductive cyclisation strategy previously discussed. Thus, pyrrolidincaraldehyde 
133 was homologated to afford the α,β-unsaturated ester (134) rather than an aldehyde or 
ketone. Mild hydrogenation under neutral conditions selectively reduced the side chain 
alkene group as previously described to givie saturated ester 136. N-Boc deprotection was 
achieved with trifluoroacetic acid, neutralising with sodium methoxide. The resulting 
intermediate was cyclised with concomitant O-debenzylation upon further treatment with 
sodium methoxide in boiling methanol, giving lactam 138. The latter was reduced with 
borane dimethylsulfide complex in THF and O-debenzylation, to unmask the alcohols at 
C-2 and C-3, was then carried out by hydrogenation under acidic conditions to complete 
the synthesis. 
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Scheme 5: (a) BzCl, CH2Cl2, TEA (78%); (b) TBAF, THF (88%); (c) NMO, TPAP, 
CH2Cl2, 4 Å MS (59%); (d) Ph3P=CHCOMe, toluene, 80 °C (71%); (e) 
Ph3P=CHCO2Me, toluene, 80 °C (59%); (f) H2, 10% Pd/C, MeOH; (g) i. TFA, DCM, ii. 
neutralization with MeONa in MeOH, iii. MeONa (cat.), MeOH, ∆ to cyclise lactam 
(86% from 133); (h) H3B.SMe2, THF then MeOH (59%); (i) H2, 10% Pd/C, MeOH, HCl 
then Amberlite IRA-400 (OH– form) (93%). 
 
In the preceding examples all of the pyrrolizidines were derived from pyrrolidine 
precursors that used the same protecting group for the alcohols that track through to the 
C-1 and C-2 positions of the target pyrrolizidine. This meant that the correct 
stereochemistry at these centres had to be included in the pyrrolidinecarbaldehyde on 
which a route was to be based. Greater synthetic versatility might be achieved if these 
alcohols carried distinct protecting groups, thereby allowing their separate manipulation 
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after construction of the pyrrolizidine core. For example, deoxygenation or 
stereochemical inversion might be applied at one or other of the C-1 and C-2 positions in 
principle. With these considerations in mind, the Izquierdo group have recently evaluated 
a differentially protected analogue (139) of pyrrolidine 96 (Schemes 1 and 2) and utilized 
it to produce both hyacinthacine A7 (58) and 1-epi-hyacinthacine A7 (150) via a common 
pyrrolizidine intermediate (145, Scheme 6).86  
 
 
 
Scheme 6: (a) TPAP, NMO, CH2Cl2, 4 Å MS (89%); (b) Ph3P=CHCOCH3, toluene, 80 
°C (78%); (c) H2, 10% Pd/C, MeOH, 60 psi (44% of 145 and 40% of 144). 
 
As before, TPAP-catalyzed oxidation of the free hydroxymethyl group in 139 was used to 
generate the key pyrrolidinecarbaldehyde precursor 140. Homologation via the Wittig 
olefination approach gave unsaturated ketone 141. A one-pot process was then used to 
achieve N-deprotection and reductive cyclisation under hydrogenation conditions. This 
process left the protecting groups on the more heavily substituted ring of the bicycle 
intact and furnished pyrrolizidine isomers 144 and 145 in 1:1 ratio. A key difference in 
the route described in Scheme 6 relative to those based on pyrrolidine 96 (Schemes 1 and 
2) is the inverted stereochemistry at the C-2 position of the pyrrolidinecarbaldehyde 
precursor. This difference resulted in loss of stereocontrol for the reductive cyclisation, 
though Izquierdo et al. did not comment on this feature in their paper.86 
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Intermediate 145 was subsequently separated from 144 and debenzoylated to give alcohol 
146 (Scheme 7). Further sequential deprotection of the remaining two masked hydroxyl 
groups led to 1-epi-hyacinthacine A7 (150). Implementation of an inversion strategy for 
the C-1 alcohol in 146 allowed access to hyacinthacine A7 (58) itself however. 
Unsuccessful initial attempts to invert the alcohol were made under Mitsunobu conditions 
(BzOH, DEAD, Ph3P, THF prior to hydrolysis of the benzoate). The failure of these 
conditions forced the group to undertake a Swern oxidation on 146 followed by 
borohydride reduction of the intermediate ketone. This yielded the inverted alcohol (147) 
and starting alcohol (146) as 1.5:1 mixture separable by chromatography. Deprotection of 
147 then afforded hyacinthacine A7 (58).  
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Scheme 7: (a) MeONa (cat.),MeOH (86%); (b) i. oxalyl chloride, DMSO, TFA, DCM, -
78°C ii. NaBH4, MeOH (46% of 147 and 29% of 146); (c) TBAF, THF (65% for 148 and 
85% for 149); (d) H2, 10%, Pd/C, MeOH, HCl then Amberlite IRA-400 (OH– form) (76% 
for 58 and 63% for 150); (e) i. BzOH, DEAD, Ph3P, THF, ii. MeONa (cat.), MeOH. 
 
Although not reported, it can be envisaged that intermediate 144 could be treated in the 
same manner as above to produce hyacinthacine A6 (57) and 1-epi-hyacinthacine A6 
(151) (Figure 15). 
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Figure 15. Potential hyacinthacine products from intermediate 134. 
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1.5.2 Ring closing metathesis 
 
The first synthesis of hyacinthacine A2 (52) was reported by Martin et al. in 2001, 
utilising ring-closing metathesis (RCM) as the key step in the route. (Scheme 8).87 
 
 
Scheme 8: (a) (CH2=CH)2Zn (95%); (b) BzCl, n-Bu4NI, CH2Cl2 / 1 N NaOH (1:1); (c) 
oxalyl chloride, DMSO, TFA, DCM, -78°C (63% from 153) ; (d) allylamine, AcOH, 
NaBH3CN, 3 Å MS, MeOH (78%);  (e) Grubbs I catalyst, toluene (30%); (f) H2, Pd/C, 
MeOH, THF, 6N HCl (82%). 
 
The synthesis started by addition of divinylzinc to commercially available D-arabinose 
derivative 152 to give 153. Benzoylation gave an inseparable 3.5:1 mixture of the desired 
product (154b) and side product 154a. The inseparable mixture was subjected to Swern 
oxidation and the required ketone (155) was isolated. Reductive amination of 155 with 
allylamine gave the amine intermediate, which underwent spontaneous intermolecular 
cyclisation by nucleophilic displacement of the allylic benzoate ester with the secondary 
amino group to provide RCM precursor 156 as a mixture of stereoisomers. RCM of the 
HCl salts of this epimeric mixture in the presence of Grubbs I catalyst resulted in the 
formation of 157 in an isolated yield of 30% based on the proportion of the appropriate 
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epimer in the precursor 156. Reduction of the double bond and debenzylation by 
hydrogenation gave hyacinthacine A2 (52). The key RCM step in this synthesis was low-
yielding and therefore this method has not been applied to the synthesis of many other 
hyacinthacines.  
 
Recently another synthesis of hyacinthacine A2 (52) starting from a D-arabinose derived 
nitrone (158) has been reported in which the RCM step has a much improved yield 
(Scheme 9).88 
 
 
 
Scheme 9: (a) vinylmagnesium bromide, Et2O (98%); (b) Zn, AcOH (100%); (c) allyl 
bromide, DMF, K2CO3, Bu4NI (81%); (d) Grubbs second generation catalyst, toluene 
(87%); (e) H2, 3 bar, Pd(OH)2-C, MeOH-HCl, then Dowex (96%). 
 
Nucleophilic addition of vinylmagnesium bromide to nitrone 158 gave hydroxylamine 
159 with nucleophilic attack occurring exclusively from the less hindered face of the 
nitrone. This step was followed by reductive scission of the hydroxylamine N-O bond and 
N-alkylation of intermediate 160 to produce the diallyl RCM precursor (156a). RCM was 
carried out using Grubbs second generation catalyst and bicycle 157 was obtained in 87% 
isolated yield. Finally, catalytic hydrogenation of 157 to reduce the double bond and 
remove the benzyl protection produced hyacinthacine A2 (52). 
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1.5.3 Nucleophilic substitution 
  
The method of using nucleophilic substitution as the key ring forming step has been 
applied to the synthesis of the pyrrolizidine, alexine (41) by Yoda et al. (Scheme 10). 89  
 
 
 
Scheme 10: (a) MPMNH2, benzene-CHCl3 (1:1), 4 Å MS, (quant.) (b) vinylmagnesium 
bromide, THF, (70%); (c) PCC, CH2Cl2, (98%); (d) i.OsO4, NMO, acetone-water (1:1); 
ii. NaIO4, Et2O-water (1:1); (e) allyltrimethylsilane, BF3.OEt2, CH2Cl2, (82 % over 2 
steps); (f) i. CAN, CH3CN-water (9:1), (71%); ii. MOMCl, N,N-diisopropylethylamine, 
CH2Cl2, (75%); (g) i. OsO4, NMO, acetone-water (1:1), (91%); ii. NaIO4, Et2O-water 
(1:1), iii. NaBH4, EtOH (90% over 2 steps);  iv. TBDPSCl, imidazole, DMF, (quant.); (h) 
i. vinylmagnesium bromide, THF; ii. NaBH4-CeCl3, MeOH (66% over 2 steps); (i) i. 
MsCl, TEA, DCM; ii, t-BuOK, THF, (84% over 2 steps); (j) i. OsO4, NMO, acetone-
water(1:1), (92%); ii. NaIO4, Et2O-water (1:1), iii. NaBH4, EtOH, (74% over 2 steps); iv. 
MOMCl, N,N-diisopropylethylamine, CH2Cl2, (99%); (k) i. TBAF, THF, (quant.); ii 
TsCl, pyridine, (92%); iii. c. HCl, MeOH; iv. K2CO3, MeOH, (94% over 2 steps); (l) H2, 
10% Pd/C, EtOH, (70%). 
 
The synthesis started with conversion of D-arabinose tribenzyl ether 152 into the aminal 
(161) by reaction with 4-methylbenzyl amine (MPMMH2). Nucleophilic attack of 
vinylmagnesium bromide on the aminal, followed by oxidation produced lactam 162. The 
terminal alkene in 162 then underwent oxidative cleavage to afford the aldehyde 
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intermediate (163), which was subjected to Lewis acid induced alkylation with 
allytrimethylsilane in the presence of boron trifluoride; this selectively led to the 
corresponding allylic alcohol (164) by attack of the carbonyl from the least hindered face. 
Removal of the MPM group and protection of the secondary alcohol function as its MOM 
ether gave 165. Oxidative cleavage of the alkene group of 165 followed by reduction 
produced the primary alcohol, which upon treatment with TBDPSCl and then (Boc)2O 
gave the N-Boc lactam (166). Addition of vinylmagnesium bromide to 166 and 
subsequent reduction of the resulting enone, from the least hindred face, gave the allylic 
alcohol 167 with 5 contigous stereocentres as the sole product. Mesylation and cyclisation 
under basic conditions produced pyrrolidine 168. Osmium tetroxide mediated oxidative 
cleavage of the vinyl group in the latter, with reduction of the resulting aldehyde and 
subsequent MOM protection of the alcohol formed, led to 169. The key cyclisation step 
was then achieved by removal of the silyl group and replacement with a tosyl moiety; 
cleavage of the N-Boc group with methanolic HCl triggered the nucleophilic substitution 
to afford bicycle 170. Finally catalytic hydrogenation unmasked the remaining protected 
hydroxyl groups to give alexine (41). 
 
Yoda’s group then extended this strategy to achieve the first synthesis of a hyacinthacine 
series member, 7a-epi-hyacinthacine A2 (7-deoxyalexine, 97), Scheme 11.90 
 
 
Scheme 11: (a) i. TBAF; ii. DMSO, DCM, -78 °C; (b) vinylmagnesium bromide, SmCl3; 
(c) i. TBDMSCl; ii. OsO4, NMO; iii. NaIO4; iv. NaBH4 (52 % from171); (d) i. TBAF; ii. 
TBDPSCl (87 %); (e) i. MsCl, TEA, CH2Cl2 (98 %); (f) i. BF3.OEt2; iii. KOH (73 %); (g) 
i. c. HCl; ii. H2, Pd/C (96 %). 
 
Aminal 161, obtained from D-arabinose derivative 152 as before, was subjected to 
nucleophilic attack by butenylmagnesium bromide. This was followed by a similar 
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sequence of oxidation and protecting group manipulation to that described in Scheme 10, 
producing pyrrolidine 171 over 5 steps. After silyl deprotection, to unmask the terminal 
hydroxyl group of the side chain, followed by Swern oxidation, an aldehyde was obtained 
which was directly reacted with vinylmagnesium bromide in the presence of SmCl3. The 
resulting allyl alcohol (not shown in Scheme 11) was silylated with TBDMSCl and the 
alkene cleaved by treatment with osmium tetroxide. Borohydride reduction of the 
resulting aldehyde then produced pyrrolidine 172. Removal of the secondary silyl 
protecting group and protection of the primary alcohol as the TBDPS ether gave 
compound 173. The free hydroxyl group of 173 was then derivatised as the mesylate to 
yield 174, which upon removal of the Boc group under mild acidic conditions underwent 
intramolecular nucleophilic substitution to afford the pyrrolizidine (175). Removal of the 
TBDPS group and the benzyl groups led to the desired 7a-epi-hyacinthacine A2 (7-
deoxyalexine, 87). 
 
The synthesis of both alexine (41) and 7-epi-alexine (42) has recently been reported from 
L-xylose using similar methodology to that presented above.91 Syntheses of 
hyacinthacines B1 (48) and B2 (49) have also since been reported by a method employing 
intramolecular nucleophilic substitution commencing from the starting material (S)-(-)-2-
pyrrolidone-5-carboxylic acid (176) (Schemes 12 and 13). 92  
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Scheme 12: (a) CH2=CH(CH2)2MgBr, THF, (83%); (b) NaBH4, CeCl3, EtOH 
(quantitative over 2 steps); (c) i. MsCl, Et3N, CH2Cl2 (90%); ii. t-BuOK, THF (91% of 
180 and 5% 179 from 178); (d) i. TBAF, THF (quantitative); ii. NaH, THF (quantitative); 
iii. CbzCl, NaHCO3,(97%); TBDMSCl, imidazole, DMF (97%). 
 
The route to hyacinthacines B1 and B2 involved construction of the key pyrrolidine (177) 
as a common intermediate. Thus, (S)-(–)-2-pyrrolidone-5-carboxylic acid (176) was 
converted into 17793, which was then subjected to nucleophilic attack from a but-1-en-4-
yl Grignard reagent. Reduction of the resulting ketone produced alcohol 178. 
Derivatisation of the free hydroxyl group as the mesylate followed by cyclisation 
produced a separable mixture of stereoisomeric pyrrolidines 179 and 180, with 180 being 
the major product. Desilylation of the latter was carried out to facilitate removal of the N-
Boc group, assisted by hydride deprotonation of the resulting alcohol. This allowed 
installation of N-CBz protection on the pyrrolidine and was followed by TBDMS 
silylation to reprotect the side chain alcohol in pyrrolidine 181. This pyrrolidine was 
applied to the synthesis of hyacinthacines B1 (48) and B2 (49) (Scheme 13). 
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Scheme 13: (a) AD-mix-α[(DHQ)2PHAL ligand], t-BuOH/H2O (1:1) (98%); (b) i. 
TBDMSCl, Et3N, DCM (97%); ii. MsCl, Et3N, DCM (92%); iii. H2, Pd/C, EtOH (69% 
for 183 and 28% for 185); (c) i. TBAF, THF (97%); ii. TFA, H2O (92%); (d) AD-mix-
β[(DHQD)2PHAL ligand], t-BuOH/H2O (1:1) (98%). 
 
Focusing first on the synthesis of hyacinthacine B1 (48), catalytic Sharpless asymmetric 
dihydroxylation (AD) of 181 with AD-mix-α [(DHQ)2PHAL ligand], produced diols 182 
and 184 with moderate stereoselectivity (182:184, 71:29) as an inseparable mixture. After 
selective silylation of the primary alcohol, mesylation and cyclisation (triggered by 
hydrolytic cleavage of the N-Cbz group), the major pyrrolizidine isomer (183) could be 
separated by column chromatography. Silyl deprotection and treatment with TFA to 
remove the isopropylidene group produced hyacinthacine B1 (48). The asymmetric 
dihydroxylation of 181 with AD-mix-β [(DHQD)2PHAL ligand] provided a mixture of 
182 and 184 with reverse selectivity favouring isomer 184. This allowed access to 
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hyacinthacine B2 (49) by application of the same series of transformations as described 
for hyacinthacine B1. 
 
A similar route, again using (S)-(–)-2-pyrrolidone-5-carboxylic acid (176) as the starting 
chiral building block, has very recently been applied to the synthesis of hyacinthacines C2 
(67), C3 (68), and their C5 epimers.94 
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1.5.4 Nitrone umpolung 
 
Desvergnes et al. have reported a synthesis of hyacinthacine A2 (52) in which nitrone 158 
served as the key intermediate for umpolung chemistry.71 This nitrone has, as discussed 
previously (vide supra Section 1.4.2), also provided the basis for a ring closing metathesis 
approach to the same hyacinthacine family member, where the nitrone was prepared from 
D-arabinose. In the work described by Desvergnes et al., the nitrone was synthesised by a 
different route commencing from L-xylose; both methods for synthesis of this nitrone are 
discussed in detail later. The key reaction in the umpolung approach to hyacinthacine A2 
was the samarium diiodide induced reductive coupling of the nitrone with ethyl acrylate 
(Scheme 14).95 
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Scheme 14: (a) ethyl acrylate, SmI2, H2O (64%);  (b) SmI2, THF; (c) K2CO3(59% from 
186); (d) LiAlH4, THF (79%); (e) H2, Pd/C, MeOH, HCl, DOWEX 1 x 8 (79%). 
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Nitrone 158 was treated with samarium diiodide and ethyl acrylate in the presence of 
water, as a proton source, to afford hydroxylamine 186 in which the acrylate had 
selectively closed to the the least hindered lower face of the nitrone. In this reaction, the 
samarium diiodide reduced the C=N bond to generate an α-aza-nucleophilic species 
(radical or anion). The ethyl acrylate was activated in the reaction by coordination of the 
samarium to the carbonyl group and this allowed the 1,4-addition step to take place. The 
N-hydroxylamine (186) produced was reduced by the further addition of samarium 
diiodide to the reaction mixture, which resulted in formation of pyrrolidine 187. Partial 
cyclisation to lactam 188 was observed and complete conversion to 188 was achieved by 
treating the crude product with potassium carbonate. Reduction of the lactam to the 
tertiary amine (189) was followed by hydrogenation to produce hyacinthacine A2 (52). 
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1.5.5 Nitrone 1,3-dipolar cycloaddition 
 
A useful method for obtaining isoxazolidine ring systems, with highly selective regio- 
and stereocontrol, in a single step is from the nitrone-alkene 1,3-dipolar cycloaddition 
(Scheme 15).96 
 
 
Scheme 15: Nitrone-alkene 1,3-dipolar cycloaddition 
 
It is possible to generate up to 3 new stereocentres using this 1,3-dipolar cycloaddition, 
and the isoxazolidine N-O bond can be reductively cleaved to afford synthetically 
versatile amino alcohols. The nitrone 1,3-dipolar cycloaddition is best described as a 
concerted reaction between 2π and 4π electron addends.97 As with the Diels-Alder 
reaction, the thermally allowed 1,3-dipolar cycloaddition is a  suprafacial [π2s+π4s] 
process. Regio- and stereocontrol in nitrone 1,3-dipolar cycloadditions have been 
reviewed in detail in the literature96, 98 and the scope of the following discussion will 
therefore be limited to 1,3- dipolar cycloadditions of cyclic nitrones with mono-
substituted alkenes, as these are particularly relevant to this project. 
 
1.5.5.1 1,3-Dipolar cycloaddition: regiochemistry and stereochemistry 
 
There can be two regiochemical outcomes for the cycloaddition of a cyclic nitrone with a 
mono-substituted alkene. In principle, a C-4 or C-5 substituted isoxazolidine can be 
obtained (Figure 16). However, it has been shown that steric and electronic factors 
conspire to control the regioselectivity of the reaction which substantially favour a 5-
substituted isoxazolidine product from alkenes bearing both electron donating and 
electron withdrawing substituents. 99 
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Figure 16. Regiochemical outcomes of 1,3-dipolar cycloaddition. 
 
The electronic control of nitrone cycloaddition regiochemistry is typically rationalised by  
analysis of frontier molecular orbital interactions, where maximum orbital overlap 
contributing to the transition state involves interaction of the most energetically proximal 
HOMO-LUMO pair combination (Figure 17), and determines the reaction outcome. For 
nitrone-alkene cycloadditions, both sets of interactions favour a 5-substituted 
isoxazolidine product except in the case of alkenes carrying the most electron demanding 
of substituents (such as nitroethylene).100 Reactions of monosubstituted alkenes with 5-
membered ring nitrones, such as 1-pyrroline-N-oxide, behave accordingly and 5-
substituted isoxazolidines are predominantly formed. 101 
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Figure 17. Frontier molecular orbital interactions in 1,3-dipolar cycloadditions. 
 
The 1,3-dipolar cycloaddition of a cyclic nitrone with a mono-substituted alkene can 
proceed with formation of two new stereogenic centres at C-3 and C-5, which can 
potentially yield four different diastereoisomers when 5-substituted isoxazolidines are 
formed.102 As cyclic nitrones do not have the capacity to exhibit E/Z isomerism, the 
stereocontrol in cycloadditions of these nitrones is typically higher than for their acyclic 
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counterparts. It is the dipolarophile orientation (endo or exo) and direction of approach 
(anti or syn) towards the 1,3-dipole that determines the product stereochemistry. 
 
The endo/exo selectivity of cycloaddition reactions can be influenced by the interactions 
of secondary π orbitals (Figure 18).103 In the Diels-Alder reaction, the endo isomer is 
usually dominant with dienophiles carrying functionality that allows formation of 
favourable secondary orbital interactions in the transition state. In 1,3-dipolar 
cycloadditions of nitrones, the interaction of the N-nitrone pz orbital with a vicinal pz 
orbital is small.104 Therefore, unlike Diels-Alder reactions, the endo/exo selectivity in 
nitrone cycloadditions is largely controlled by steric factors and hindrance between the 
nitrone and alkene substituents disfavours the endo transition state. The 1,3-dipolar 
cycloaddition of cyclic nitrones generally occurs via an exo transition state therefore. 
 
 
 
Figure 18. Orbital interactions of exo and endo approach. 
 
The stereochemical outcome of the cycloaddition is further complicated for cyclic 
nitrones bearing an existing stereogenic feature in the form of a substituent at one of the 
ring sp3 carbons. In this case, cycloaddition with a mono-substituted alkene may proceed 
to give a 5-substituted isoxazolidine product through four possible transition state 
combinations (Figure 19) and anti/syn selectivity, determined by the face from which the 
alkene preferentially attacks the cyclic nitrone, also has to be considered. This selectivity 
is usually determined by steric factors, with the dipolarophile attacking from the least 
sterically demanding anti face of the cyclic nitrone. The most favourable transition state 
for a 1,3-dipolar cycloaddition of this type is therefore generally exo-anti, and this has 
been observed by many groups. 115,105,106,107  Minor products resulting from the endo-anti 
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and exo-syn are often seen, whereas the highly sterically demanding endo-syn product is 
rarely observed.  
 
 
 
Figure 19. Possible approaches of dipolarophile in 1,3-dipolar cycloaddition. 
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1.5.5.2 Application to Hyacinthacine Synthesis 
 
Ishibashi et al.108 and Goti et al.109 have both described the development of routes to 
hyacinthacine A2 (52) in which a 1,3-dipolar cycloaddition step is used (Scheme 16). 
 
 
Scheme 16: (a) 191 in CH2Cl2, or 192 in C6H6 (78% 193), (64% 194); (b), Zn, AcOH-
H2O (80% 195), (64% 196); (c), PhOCSCl, py, DMAP, CH2Cl2 (80%); (d), Bu3SnH, 
AIBN, C6H6, ∆ (58%); (e), 3 N HCl, MeOH (84%); (f), MsCl, TEA, CH2Cl2, (100%); (g) 
LiAlH4, THF, ∆, (40%); (h), H2, Pd/C, MeOH (75%) 
 
Ishibashi prepared nitrone 190 from L-xylose, as will be discussed later, and this nitrone 
was used in a 1,3-dipolar cycloaddition with tert-butyl acrylate (192) to produce the 
desired anti-exo cycloadduct (194) in 64% yield and the endo product in 31% yield. The 
Goti group used the bulkier N,N-dimethylamide (191) along with nitrone 158; this 
reaction proceeded with high stereoselectivity affording only the desired anti-exo adduct 
(193). Lactams 195 and 196 were then isolated following N-O bond cleavage of their 
respective parent isoxazolidines using zinc in acetic acid. Both lactams required removal 
of the hydroxy group from the lactam ring. Ishibashi achieved this using the using the 
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Barton-McCombie deoxygenation protocol.110 Thus, lactam 196 was transformed into the 
thionocarbonate 197 and subsequent treatment with tributyltin hydride and a catalytic 
amount of AIBN afforded the deoxygenated lactam (198) in 46% yield. Finally the MOM 
group was removed under acidic conditions to produce lactam 199. The authors state that 
lactam 199 could be used as an intermediate to hyacinthacines A1 and A2 but this was not 
reported. The route to hyacinthacine A2 was completed by Goti et al. however. This 
group undertook the deoxygenation of lactam 195 by mesylation of the hydroxyl group to 
give 200 followed by reduction with lithium aluminium hydride to give 201. Finally 
hydrogenation to remove the O-benzyl groups produced hyacinthacine A2 (52). 
 
The synthesis of two new pentahydroxypyrrolizidines (202 and 203) involving a 1,3-
dipolar cycloaddition of the previously mentioned nitrone (158) with 3-buten-1,2-diol 
derivatives 204 and 205 has been described very recently [Scheme 17 and 18]. 111 The 
dipolarophiles were prepared by transesterification of 3-buten-1,2-diol (206) with vinyl 
acetate in the presence of Chirazyme L-2 in tert-butylmethyl ether at room temperature. 
This chemoenzmatic reaction produced a mixture of (R)-di-O-acetyl-3-butene-1,2-diol 
(204, 44%, 64% ee) and (S)-1-O-acetyl-3-butene-1,2-diol (205, 46%, 61% ee) (Scheme 
17) which was separated by column chromatography. 
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Scheme 17: (a) vinyl acetate, Chirazyme® L-2, TBME (44%, 64% ee, 204), (46%, 61% 
ee, 205); (b) 205, CH2Cl2, 70 °C, 2.5 h, (70%); (c) MsCl, py, CH2Cl2 (74%); (d) Zn, 
AcOH/H2O (9:1), 60 °C (60%); (e) Ambersep 900 (OH–), MeOH (83%); (f) i.Pd/C, H2, c. 
HCl, ii. Dowex 50W X8 NH4OH (85%). 
 
Initially nitrone 158 was reacted with derivative 205, producing the anti-exo 
cycloaddition product, pyrroloisoxazolidine 207, as the major adduct. Cycloadduct 207 
was converted into mesylate 208. Subsequent N-O bond cleavage in 208 using Zn/AcOH 
afforded pyrrolizidine 209.  Deacetylation of 209 with Ambersep 900 (OH– form) resin to 
diol 210 and subsequent hydrogenation afforded pyrrolizidine 202. Chiron 204 was then 
used in the synthesis of prrolizidine 203, the C-5 epimer of 202 (Scheme 18). 
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Scheme 18: (a) 204, DCM, 70 °C, 4, 74%; (b) Ambersep 900 (OH–), MeOH (83%) (c) 
TBDPSCl, imidazole, DMF, (92%); (d) MsCl, py, DCM (81%); (e) Zn, AcOH/H2O (9:1), 
60°C (76%); (f) TBAF, THF (61%); (g) i. Pd/C, H2, c.HCl, ii. Dowex 50W X8 NH4OH 
(85%). 
 
Reaction of nitrone 158 and chiral alkene 204 produced isoxazolidine 211 as the major 
cycloaddition adduct. Deacetylation to give diol 212 and subsequent protection of the 
primary alcohol function as the silyl ether afforded 213. The hydroxyl function in 213 
was then converted into a suitable leaving group, mesylate 214. This was followed by N-
O bond cleavage and intramolecular N-alkylation to afford pyrrolizidine 215. Fluoride 
deprotection of 215 to 216 followed by hydrogenation produced pyrrolizidine 203.   
 
1.6 Carbohydrate-derived cyclic nitrones 
As discussed above, carbohydrate-derived nitrones have utility in synthetic routes to 
pyrrolizidine systems, both through exploitation of the principal chemical reactivity of 
nitrones, cycloaddition chemistry (Section 1.4.5), as well other aspects of nitrone 
chemistry – organometallic addition (Section 1.4.2) and formal ‘umpolung’ behaviour 
(Section 1.4.4). The use of nitrones 158 and 190 in particular has been discussed above 
and, as the work described in this thesis is focused on developing the use of carbohydrate-
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derived nitrones for pyrrolizidine synthesis, the preparation of nitrones 158 and 190 is 
summarised below. 
1.6.1 Routes to nitrone 158 
 
Goti et al. employed two different approaches for the synthesis of nitrone 158 (Scheme 
19) which gave comparable results in terms of overall yield.109 The first route, which 
commenced with L-xylose as a chiral building block, has as its major drawback the 
expense of the starting carbohydrate. The second approach used D-arabinose as a building 
block and is preferred in terms of the lower cost involved. 
 
 
Scheme 19: (a) i. MeOH/H2SO4, anhydr. Na2SO4, rt, 21 h; ii BnCl/KOH, Na2SO4, reflux, 
8 h; iii. 6 N HCl, CH3COOH, 60-70 °C (50% over 3 steps); (b), NH2OTHP, no solvent, 
r.t., 6 d, (100%); (c) MsCl, TEA, CH2Cl2, r.t., 24 h (50-70%); (d) i. Dowex 50W X8, 
MeOH, r.t., 24 h (96%); ii. 0.1 M NaOH, dioxane, 0 °C, 2 h (55%); (e) i. NH2OH.HCl, 
py, rt, 24 h; ii. TBDPSCl, py, rt, 18 h (100%); (f) I2, ImH, Ph3P, toluene, reflux, 1 h 
(48%); (g) TBAF on silica gel, benzene, reflux, 1.5 h (91%). 
 
Benzyl furanose derivatives 217 and 220 were produced from L-xylose and D-arabinose 
respectively following the procedure reported by Fleet and Smith.112 Compound 217 was 
converted into tetrahydropyranyloxime 218 which was subsequently mesylated to give 
219. Removal of the THP protecting group by treatment with acidic resin in methanol, 
induced cyclisation to produce nitrone 158. A similar strategy was adopted for the D-
arabinose derivative (220) in that reaction with hydroxylamine followed by TBDPSCl 
was used to generate an O-protected oxime intermediate (221). The alcohol function in 
Introduction 
56 
 
221 was then replaced by iodide with the double purpose of introducing a good leaving 
group and inverting the C-4 position, producing 222. Fluoride deprotection of the silyl 
group in 222 induced spontaneous cyclisation with displacement of the iodide to furnish 
nitrone 158.  
 
Py et al. have also synthesized nitrone 158 from L-xylose (Scheme 20).95 This group first 
converted L-xylose (223) into the 2-O-methyl furanose derivative; benzyl protection of 
the remaining hydroxyl groups produced 224 in 90% yield over 2 steps. Cleavage of the 
acetal under acidic conditions to generate a hemiacetal (cf 217 in Scheme 19) was 
followed by reaction with TBDPSONH2 to generate O-protected oxime 225. The free 
alcohol function in 225 was derivatised as the mesylate (226) and subsequent treatment 
with TBAF afforded oxime 227. Displacement of the mesylate in 227 by hydroxylamine 
and cyclisation efficiently produced nitrone 158. 
 
 
Scheme 20: (a) i. 0.5% MeOH, MeOH, r.t, 15 h; i. NaH, BnBr, n-Bu4NI, DMF/THF, r.t, 
48 h (90% over 2 steps); (b) i. AcOH/1 M H2SO4, 100 °C, 1h; ii. TBDPSONH2, cat. 
PPTS, MgSO4, toluene, 110 °C, 30 min (79% over 2 steps); (c) MsCl, TEA, DCM, 0 °C, 
(93%); (d) TBAF, THF, 0 °C, 30 min (93%); (e) NH2OH.HCl, NaHCO3, MeOH/H2O 4:1, 
65 °C, 15h (92%). 
1.6.2 Route to nitrone 190 
 
As mentioned earlier, Ishibashi et al.113 have used nitrone 190 in the synthesis of a 
pyrrolizidine lactam precursor (199, Scheme 16) to hyacinthacine A2. Nitrone 190 
possesses the same absolute stereochemistry as 158 but embodies a potentially more 
versatile combination of MOM and benzyl protecting groups of the C-3 and C-4 
positions. We envisaged that this protecting group regime could be exploited to allow 
synthesis of a wider range of hyacinthacine family members through a common synthetic 
route with late stage divergency. Ishibashi et al. prepared nitrone 190 in a route 
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commencing from L-xylose. As the preparation of nitrone 190 formed the starting point 
for this project, the route is discussed in detail in the Results and Discussion that follows.  
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2 RESULTS & DISCUSSION 
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2.1 Project objectives 
A 1,3-dipolar cycloaddition reaction between a cyclic nitrone and a terminal alkene can be 
utilised for the synthesis of bicyclic pyrrolizidine alkaloids. Thus, the 1,3-dipolar 
cycloaddition of a suitable nitrone with a terminal alkene, which has a potential leaving 
group in the allylic position, will give a fused isoxazolidine. The N-O bond can be cleaved 
reductively allowing cyclisation to produce a pyrrolizidine (Scheme 21). If one isomer of the 
final product is to be achieved in high yield it is necessary to have control of stereochemistry 
in the cycloaddition. This strategy has been successfully utilised by several groups, including 
Ishibashi,113 Goti 114 and in our group where cycloaddition reactions of functionalised cyclic 
nitrones have been used to prepare hydroxylated pyrrolizidines.115   
 
 
 
Scheme 21: Route to pyrrolizidines via 1,3-dipolar cycloadditions between a cyclic nitrone 
and a terminal alkene bearing a leaving group in the allylic position. 
 
The aim of this PhD project was to investigate routes to hyacinthacine A1 and hyacinthacine 
B2 using a strategy related to that shown in Scheme 21. In principle, either nitrones of type 
190 or 228 could be employed in the cycloaddition reaction (Scheme 22). The differential 
protection of the C-3 position of nitrone 190 means that this position can be selectively 
deprotected after cycloaddition, liberating the C-1 hydroxyl group (hyacinthacine numbering) 
as a site for inversion. Inversion of the hydroxyl group would then provide the required 
stereochemical outcome for hyacinthacines A1 and B2, where the stereochemistry at C-1 and 
C-2 is cis. A nitrone of type 228, on the other hand, has the protected hydroxyl groups at the 
C-3 and C-4 positions cis to each other prior to cycloaddition and this would remove the 
requirement for subsequent inversion in the pyrrolizidine ring system. However, it was 
considered likely that cycloaddition reactions of nitrones of this type would proceed with less 
stereochemical control. Nitrone 190 was therefore selected as the preferred cyclic nitrone for 
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our work as high stereo- and regioselectivity had already been established for cycloaddition 
reactions employing its use (Section 1.5.5.2). 
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Scheme 22: Potential routes to hyacinthacine A1 and hyacinthacine B2 via 1,3-dipolar 
cycloadditions of nitrone 190 or nitrone 228. 
 
The initial scope of this work was to explore the literature for routes to nitrone 190 and 
compare these to alternative routes developed within our group. The application of nitrone 
190 in synthetic routes to hyacinthacine A1 and hyacinthacine B2 was then to be examined. 
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2.2 Routes to nitrone 190 
With nitrone 190 the key intermediate in the planned routes to hyacinthacines A1 and B2, 
efficient synthetic access was required. A synthesis starting from L-xylose has been 
discussed.113 An alternative synthetic route to nitrone 190 will be described here starting 
from L-xylose. In addition, a new route to 190 from D-arabinose, which has been developed 
by our group, will also be discussed.  
2.2.1 Ishibashi route to nitrone 190 from L-xylose 
 
 
 
 
Scheme 23: (a) 2,2,2-trichloroethanol, cat. TsOH, DCM, 39 °C (72%); (b) NaH, MOMCl, 
THF-DMF, -20 °C; (c) Zn, NaOAc, AcOH, (80%); (d) i. NH2OTBDPS, cat. PPTS, MgSO4, 
benzene, reflux; ii. MsCl, Et3N, toluene, 0 °C, (98%); (e) TBAF (1.05 equiv.), 4 Ǻ MS, THF, 
reflux, 15 min, (72%). 
 
 
Ishibashi et al.113 have synthesised nitrone 190 from L-xylose (Scheme 23) via the known 
derivative (229).116 Lactol 229 was treated with trichloroethanol in the presence of a catalytic 
amount of TsOH to give 230 as a 3:1 mixture of α- and β-anomers in 72% yield. The 
hydroxyl group of 230 was then protected as its MOM ether in 231 and the trichloroethyl 
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group reductively cleaved with zinc dust in acetic acid to produce lactol 232. Lactol 232 was 
then converted into oxime ether 233 by sequential treatment with NH2OTBDPS and mesyl 
chloride. Treatment of 233 with TBAF in the presence of 4 Ǻ MS in refluxing THF afforded 
the desired cyclic nitrone 190.  
 
Our initial approach to the synthesis of nitrone 190 involved using the Ishibashi route 
described above and therefore commenced with the synthesis of lactol 229. Accordingly, L-
xylose was initially protected as the isopropylidene xylofuranose derivative (234) [Scheme 
24] as this masked both hydroxyl groups at C-1 and C-2 but left the C-3 hydroxyl group free, 
allowing for itssubsequent differential protection by benzylation. Installation of the 
isopropylidine group was achieved by acid-catalysed reaction of L-xylose (223) with 
acetone.117 The hydroxyl functions remaining at the C-3 and C-5 positions of 234 were then 
protected as dibenzyl ethers to give 235.116 Finally lactol 229 was obtained as a 3:1 mixture 
of α- and β-anomers after hydrolysis of the isopropylidene function using 50% aqueous 
acetic acid solution at 80 °C for 24 hours. Following the Ishibashi route, lactol 229 was next 
converted into trichloroethyl acetal 230. TLC analysis of this reaction indicated that the lactol 
had been completely consumed but produced a mixture of at least 3 components. 
Examination of the crude material by 1H NMR spectroscopy indicated predominant 
formation of the desired acetal, albeit as an inseparable 3:1 mixture of the α- and β-
trichloroethyl isomers. The crude acetal 230 was then converted into MOM ether 231 by 
treatment with methoxymethyl chloride. TLC analysis showed complete consumption of 230 
and the 1H NMR spectrum of the crude product indicated >90% formation of target 231. 
Without purification, selective cleavage of the trichloroethyl group was next attempted using 
zinc dust in acetic acid. Disappointingly this reaction cleaved the MOM ether as well as the 
trichloroethyl ether and returned lactol 229 (Scheme 24). As we were unable to reproduce 
Ishibashi’s route to nitrone 190, an alternative route from L-xylose was developed. 
 
 
Results and Discussion 
63 
 
 
 
Scheme 24: (a) acetone, c. H2SO4, rt, 24 h (75%); (b) NaH, n-Bu4NI, dry THF, BnBr, 0 °C to 
rt, 24 h, (84%); (c) acetic acid:water (1:1), 80 °C, 24 h, (86%); (d) 2,2,2-trichloroethanol, cat. 
TsOH, DCM, 39 °C, (72)%; (e) NaH, MOMCl, THF-DMF, -20 °C, (92%); (f) Zn, NaOAc, 
AcOH, (0 % for 232 and (80% for 229). 
 
2.2.2 Modified route to nitrone 190 from L-xylose  
 
Our failure to reproduce the Ishibashi route to nitrone 190 was caused by the acid sensitivity 
of the MOM group in intermediate 231. We were unable to selectively cleave the 
trichloroethyl group with zinc in acetic acid despite using conditions buffered with sodium 
acetate. We therefore explored a modified route from L-xylose-derived lactol 229 in which 
the hemiacetal group at the anomeric position would be temporarily masked as a lactone 
[Scheme 25], allowing its regeneration under non-acidic conditions following installation of 
the MOM protecting group. 
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Scheme 25: (a) Ag2CO3/celite® (large excess), toluene, 80 °C, 1 h, (99%); (b) 
dimethoxymethane (large excess), chloroform dried over P2O5, 30 min, (92%); (c) DIBAL (8 
equiv.), THF, -78 °C, 3 h, (78%); (d) NH2OH.HCl, NaOMe, MeOH, r.t., 18 h, (82%); (e) 
TBDMS, dry py, 18 h, (73%); (f) H2NOTBDMS, MgSO4, dry toluene, reflux, 30 min, (89%); 
(g) MsCl, Et3N, DCM 0 °C, (93%); (h) TBAF or TBAT, THF or toluene (18-60%). 
 
There is literature precedent for use of bromine and barium carbonate for the selective 
oxidation of the anomeric position of carbohydrates.118,119 Furthermore, Fleet et al. 
successfully used bromine with a barium carbonate buffer for preparation of hydroxy 
lactones 241, 242, 243 and 244 in yields ranging from 66% and 76% (Scheme 26).120 
 
Scheme 26: (a) aqueous CF3CO2H; (b) Br2, BaCO3 in aqueous dioxane, (66-76%). 
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When the bromine/barium carbonate oxidation procedure was applied to diol 229, however, 
lactone 236 was produced only with low conversion and diol 229 was returned largely 
unreacted. Moreover, upon 1H NMR analysis of the crude product signal corresponding to 4-
bromobutan-1-ol were observed. This was possibly formed from the ring opening of the THF 
solvent by HBr. Unfortunately this compound could not be separated from the desired 
product as it had a very similar Rf value. Formation of the bromobutanol side product was 
subsequently confirmed by comparison with of the NMR spectrum from an authentic sample. 
In an attempt to increase the conversion of diol 229 and prevent the formation of the 
bromobutanol side product, the reaction was examined under a variety of different conditions 
where the solvent, molar ratio of Br2 to starting material and bromine addition procedure 
were varied. All reactions were carried out at room temperature with a reaction time of 70 
hours. The various conditions and isolated yields of 236 are summarised in Table 1. 
 
Solvent Br2 mol 
equiv. 
Br2 
addition 
Isolated 
Yield (%) 
% bromobutanol in 
isolated product 
Dioxane 1.5 Br2 water 51 0 
Dioxane 2 Br2 water 49 0 
Dioxane 3 Br2 water 36 0 
Dioxane 1.5 Br2 in ether 24 0 
Dioxane 2 Br2 in ether 22 0 
Dioxane 3 Br2 in ether 18 0 
Diethyl ether 1.5 Br2 water 16 0 
Diethyl ether 2 Br2 water 15 0 
Diethyl ether 3 Br2 water 21 0 
Diethyl ether 1.5 Br2 in ether 18 0 
Diethyl ether 2 Br2 in ether 24 0 
Diethyl ether 3 Br2 in ether 19 0 
THF/water (1:3) 1.5 Br2 in THF 5 5 
THF/water (1:3) 2 Br2 in THF 31 5 
THF/water (1:3) 3 Br2 in THF 34 6 
THF/water (1:3) 3 Br2 2 7 
THF/water (1:3)  3 Br2 in ether 6 3 
 
Table 1: Summary of attempts at selective oxidation of lactol 229 using Br2. 
 
Unsurprisingly, it was found that removing THF from the system prevented the formation of 
the bromobutanol side product. The maximum yield of lactone 236 obtained was 51%, where 
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1,4-dioxane was used as a solvent and 1.5 equivalents of Br2 were used. As the maximum 
yield observed for this step was relatively low this oxidation method was deemed unsuitable 
and an alternative method investigated. 
 
It has long been known that silver carbonate is an effective reagent for oxidations of alcohols 
to aldehydes and ketones.121 In 1968 Fetizon et al. reported that freshly prepared silver 
carbonate, obtained by reaction of silver nitrate with sodium carbonate, is a suitable oxidising 
agent.122 However, the reagent generated in this way is difficult to filter, wash, and handle 
and therefore the reproducibility of oxidations using it can be poor. It was subsequently 
found that these problems could be eliminated by precipitating the reagent in the presence of 
a celite®.123 The resultant Ag2CO3/celite® reagent is a versatile and useful oxidising reagent 
and has been thoroughly investigated by Mikillop and Young.124 This reagent is 
commercially available but it was prepared in our laboratory using the procedure originally 
reported by Fetizon.123 Pleasingly, treatment of lactol 229 with a large excess of the silver 
carbonate reagent in toluene produced lactone 236 in quantitative yield as a white crystalline 
solid. X-ray crystalography confirmed the structure of lactone 236 (Figure 20, data in 
Appendix A) with the stereochemistry as expected at this point of the synthesis. The structure 
was found to a monoclinic crystal system belonging to the P2(1) space group, with a zig-zag 
chain along the b axis. Pi stacking of the aromatic rings was not observed but intermolelcular 
hydrogen bonding is present between the hydroxyl hydrogen and the lactone oxygen atom.  
 
 
Figure 20: Crystal structure of lactone 236. 
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The free hydroxyl group in lactone 236 was then protected as the methoxymethyl ether using 
10 equivalents of dimethoxymethane and P2O5 in chloroform, forming ether 237 cleanly as a 
colourless oil in a 98% yield without any need for purification. The presence of a singlet 
resonance of  δ 3.37 in the 1H NMR spectrum of 237, corresponding to the methoxy group, 
confirmed the successful installation of the MOM ether. The MOM methylene group was not 
easily observed in the 1H NMR spectrum, but was more readily evident in the 13C NMR 
spectrum as a distinctive signal at δ 95.7.  
 
A reduction using DIBAL was next carried out on 237 to afford lactol 232 in 86% yield as a 
1.5:1 inseparable mixture of α- and β-isomers. The structure of 232 was confirmed by the 
disappearance of the lactone carbonyl signal in the 13C NMR spectrum of 237 at δ 172.6. 
Treatment of 232 with hydroxylamine hydrochloride then led to oxime 238 (E:Z ratio, 5:1 
with the E-isomer assumed to be the major product) in an 82% yield. The oxime was then 
converted into its O-TBDMS derivative (239) in 73% yield by treatment with TBDMSCl. In 
principle, it should be possible to transform lactol 232 directly into compound 239 by 
treatment with H2NOTBDMS, which can be prepared by a known procedure.125 In order to 
explore this we therefore prepared H2NOTBDMS by addition of tert-butyldimethylsilyl 
chloride to a mixture of hydroxylamine hydrochloride and ethylenediamine in 
dichloromethane. After stirring at room temperature for 24 hours, the silylated 
hydroxylamine was isolated in quantitative yield following work-up and distillation at 
reduced pressure. Ishibashi et al. had successfully transformed lactol 232 into the protected 
oxime 233 by treatment with H2NOTBDPS, MgSO4 and a catalytic amount of pyridinum p-
toluenesulfonate in benzene (Scheme 23). The formation of O-TBDMS protected oxime 239 
(Scheme 25) by similar treatment of 232 with H2NOTBDMS was unsuccessfuland produced 
oxime 238 quantitatively as the sole product. On consideration, this was not surprising as the 
catalyst employed is known to cleave TBDMS protecting groups.126 A second attempt to 
achieve the direct transformation of 232 into 239 was therefore made under the same 
conditions but omitting the acid catalyst. Gratifyingly, this produced the TBDMS protected 
oxime (239) in 89% yield.  
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Oxime silyl ether 239 was then smoothly converted into mesylate 240 in 93% yield by 
treatment with MsCl and triethylamine in DCM. Finally, treatment of 240 with 
tetrabutylammonium fluoride (TBAF) in dry toluene produced the target differentially 
protected nitrone (190) sucessfully in 85% yield on the first attempt. The yield of the 
cyclisation step using TBAF was subsequently found to be variable, however, ranging 
typically from 28%-60%. Ishibashi et al.127 described optimum cyclisation conditions for 
their analogue (233) of 240 involving the use of tetrabutylammonium 
triphenyldifluorosilicate (TBAT) as an alternative desilylating agent to TBAF. They reported 
that these conditions led to greater yields of nitrones compared to those using TBAF. In our 
hands, however, treatment of 240 with TBAT afforded nitrone 190 in a disappointing yield of 
only 30% with no remaining starting material or identifiable side products isolable. With the 
variable yields observed in the silyl deprotection and cyclisation step leading to 190, it was 
decided to attempt the conversion of lactol 232 to nitrone 190 in a ‘one-pot’ process through 
initial reaction with hydroxylamine and then treatment with mesyl chloride. A similar ‘one-
pot’ procedure for conversion of an analogous lactol (22a) into a nitrone has been reported 
by Goti et. Al. and this approach avoids the need for silyl protection of the intermediate 
oxime.128 Thus, under these conditions, the hemiacetal was to be converted into an oxime and 
the free hydroxyl group then derivatised as the mesylate [Scheme 27]. Under basic 
conditions, the oxime-mesylate was then expected to cyclise to the nitrone.  
 
When these conditions were applied to lactol 232, however, no nitrone 190 was formed and 
nitrile 245 was obtained cleanly in quantitative yield.  The presence of a signal at δ 116.4 in 
the 13C NMR spectrum was attributed to the nitrile group of 245, and the structure was 
further confirmed by IR spectroscopy, where an absorption corresponding to a nitrile group 
was observed at 2232 cm-1. A possible mechanistic explanation for this transformation is 
shown (Scheme 27). 
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Scheme 27: Attempted preparation of nitrone 190 and mechanistic formulation for the 
generation of nitrile 245. 
 
Formation of nitrile 245 was a disappointing outcome but this probably explains the 
preference of Goti (Scheme 19), Py (Scheme 20) and Ishibashi (Scheme 23) who all elect to 
adopt a strategy that proceeds via a silyl protected oxime when undertaking a similar 
sequence of reactions. In an effort to further streamline the route, it was next decided to 
attempt an alternative one-pot procedure for  transformation of lactol 229 into nitrone 190 
[Scheme 28]. This involved altering the successful route shown in Scheme 25 and is 
summarised in Scheme 28. Thus, the solvent was removed after completion of each reaction 
stage (as determined by TLC); the appropriate solvent for the next step and reagents required 
were then added for each subsequent reaction without any purification. A variable yield of 
18-43% of the desired nitrone 190 was achieved over the three steps.  
 
 
Scheme 28: Telescoping the lactol to nitrone transformation 
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This route was successful in the production of nitrone 190 and afforded reasonable yields at 
each step of the process. However, due to the modest overall yield and variability of the final 
step an alternative route to nitrone 190 from D-arabinose was also investigated. 
 
2.2.3 New route to nitrone 190 from D-arabinose 
 
The major drawbacks of the L-xylose-based routes described above are: (i) the high cost of 
the unnatural sugar employed as a starting material; (ii) the expense of preparing silver 
carbonate reagent employed as a selective oxidant and the large excess of this reagent used, 
and (iii) the variability in yield of the final step. Goti described routes to nitrone 158 starting 
from L-xylose or from the much cheaper D-arabinose 247 (Scheme 19).109 The route from D-
arabinose involved the transformation of alcohol 221 into an iodide (222), inverting the 
stereochemistry prior to the cyclisation step leading to the nitrone. As the displacement of the 
iodide proceeds with inversion of configuration, nitrone 158 is formed by a route with an 
overall double inversion of stereochemistry. A new route to nitrone 190 from D-arabinose 
247 was therefore planned involving a double inversion strategy commencing from alcohol 
256 via iodide 257 (Scheme 29). 
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Scheme 29: (a) TBDPSCl, imidazole, DMF (55%); (b) acetone, CuSO4, H2O (38%); (c) 
TBAF, THF (75%); (d) BnCl, Bu4NI, NaH, DMF (62%); (e) 20% aqueous AcOH, 60 °C, 5 h 
(92%); (f) Br2, BaCO3, THF-H2O (85%); (g) CH2(OMe)2, P2O5, CHCl3 (92%); (h) DIBAL, 
THF, -78 °C (98%); (i) NH2OTBDMS, toluene, MgSO4, reflux, 5 min (72%); (j) PPh3, I2, 
imidazole, toluene (88%); (k) anhydrous TBAF, toluene, ∆, 5 min (83%). 
 
D-Arabinose (247) was first protected at the 5-position as the TBDPS silyl ether 248 in 55% 
yield by the selective reaction of the primary alcohol function with TBDPSCl. The 1- and 2-
positions of 248 were subsequently protected by isopropylidene derivatisation to 249. 
Deprotection of the silyl group by TBAF led to 250; this released the hydroxy groups at the 
3- and 5-positions, allowing the benzyl groups in the target nitrone to be put in place in 
compound 251. The isopropylidene protection was then removed under acidic conditions to 
produce lactol 252 in 89% yield as a 1.3:1 mixture of α- and β-anomers. Given the success of 
our previous strategy to install MOM protection in the xylose route to nitrone 190 (Scheme 
25), by oxidation of the lactol to the lactone prior to MOM protection and then reduction 
back to the lactol, we decided to use a similar strategy here. Accordingly, lactol 252 was 
selectively oxidised at the anomeric position by treatment with bromine and barium 
carbonate in aqueous THF. Pleasingly, in contrast to the xylose route, where oxidation of 
lactol 229 with bromine had been problematic, the oxidation of arabinose-derived lactol 252 
proceeded reliably and reproducibly to give lactone 253 in high yields. This obviated the 
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need for the expensive silver carbonate/celite reagent. In addition, the formation of the 
bromobutanol side product, which was a problem in the L-xylose route, was not observed 
here. With the 2-position free, lactone 253 was then differentially protected as its 
methoxymethyl ether 254 in 76% yield by reaction with dimethoxymethane.  Reduction of 
lactone 254 by DIBAL produced lactol 255 in 97% yield as a mixture of anomers (α:β, 
1.5:1). Lactol 255 was subsequently converted into TBDMS protected oxime 256 in a 
reasonable yield (60%) by reaction with H2NOTBDMS in boiling toluene. The hydroxyl 
group was then replaced by iodide in 80% yield by treatment with triphenylphosphine and 
iodine, affording 257 with inversion at C-4. Finally, silyl deprotection with TBAF and SN2 
displacement of iodide furnished the desired nitrone (190) in a good yield (83%). The 
cyclisation step in this route was higher yielding and more consistent than cyclisation of 240 
to 190 in the L-xylose route. 
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2.2.4 Summary of routes to nitrone 190 
 
Three routes to differentially protected nitrone 190 have been described. The L-xylose route 
reported by Ishibashi et al.113 has successfully been implemented by that group. In our hands, 
however, attempts to install the MOM protection in lactol 232, by executing the Ishibari 
group’s three-step transformation from lactol 229 (Scheme 23), were unsuccessful. This 
necessitated the development of alternative strategies to access nitrone 190 efficiently. In the 
first approach, the Ishibashi synthesis was modified to avoid exposing the MOM-protected 
intermediate to acidic conditions. This was successfully accomplished [Scheme 25] via silver 
carbonate oxidation of lactol 229 to the corresponding lactone (236), protection of the 3-
hydroxyl group and reduction of the lactone (237) back to the lactol (232). The subsequent 
steps then broadly followed the Ishibari route except that O-TBDMS protection of the oxime 
(239) was employed prior to the final steps– formation of the methanesulfonate (240) and 
cyclisation to the nitrone– which completed a nine-step route from L-xylose. Unfortunately 
the final cyclisation step was somewhat capricious and low-yielding. This problem was 
compounded by the requirement for the use of both the expensive starting materialL-xylose 
and costly silver carbonate reagent which had to be used in large excess to achieve the 
oxidation of lactol 229 to lactone 236 in good yield. These issues led us to develop a second 
route to nitrone 190 [Scheme 29] commencing with the cheaper starting material, D-
arabinose. We have successfully developed a route which avoided the use of silver carbonate 
reagent, albeit in a slightly longer eleven-step sequence. With nitrone 190 available, we were 
then able to proceed with the exploration of the 1,3-dipolar cycloaddition chemistry planned 
for construction of our bicyclic iminosugar targets. 
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2.3 1,3-dipolar cyclisation routes to hyacinthacines from nitrone 190 
Routes to a differentially protected nitrone 190 have been described; such a nitrone can be 
useful in the synthesis of pyrrolizidine alkaloids with a hydroxymethyl group at C-3. The 1,3-
dipolar cycloaddition of nitrone 190 with a terminal alkene would allow the development of 
routes to pyrrolizidines such as hyacinthacines A1, hyacinthacine B2 etc, which have inverted 
stereochemistry at the C-1 position (hyacinthacine numbering system) [Scheme 22]. 
 
The differential protection at C-3 of the nitrone (destined to become the C-1 centre of the 
pyrrolizidines) was planned to enable its selective deprotection after construction of the 
bicycle in order to facilitate inversion or deoxygenation, thus allowing access to a range of 
hyacinthacines and polyhydroxylated pyrrolizidines from a single common synthetic 
precursor. This makes nitrone 190 a valuable synthetic intermediate and the application of 
nitrone 190 towards the synthesis of hyacinthacine A1 and B2 will be discussed in this thesis. 
The application of nitrone 190 in the first total synthesis of 1-epi-hyacinthacine B2 will be 
demonstrated. To the best of our knowledge this constitutes the first synthesis of this non- 
natural hyacinthacine. 
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2.3.1 Routes to hyacinthacine A1 
 
As the simplest hyacinthacine with a hydroxymethyl group at the C-3 position and the 
hydroxyl groups at C-1 and C-2 cis to each other, hyacinthacine A1 (51) was chosen as the 
first synthetic target (Figure 21).  
 
 
Figure 21: Reterosynthetic route to Hyacinthacine A1. 
 
Ishibashi's group have previously exploited nitrone 190 previously in the preparation of a 
pyrrolizidine lactam (199, Scheme 16) that could be converted, in principle, into 
hyacinthacine A1 through subsequent inversion of the stereochemistry at C-1 and reduction 
of the lactam.113 Surprisingly this sequence of reactions to conclude the synthesis has not 
been reported to date. The key step in the Ishibashi synthesis of pyrrolizidine lactam 199 was 
the 1,3-dipolar cycloaddition between nitrone 190 and tert-butyl acrylate (192), which 
proceeded with only modest selectivity to give the desired exo-anti cycloadduct (194) in 64% 
yield together with the endo-anti product (262) in 31% yield, [Scheme 30].  
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Scheme 30: Outcome of Ishibashi’s 1,3-dipolar cycloaddition between nitrone 190 and 
alkene 192. 
 
The Goti group have investigated the 1,3-dipolar cycladdition products formed upon reaction 
of a related nitrone (158) with maleic and acrylic acid derivatives 191, 263, and 264 (Scheme 
31).109 With dimethyl maleate (263), nitrone 158 reacted cleanly to afford exclusively the 
exo-anti adduct (265). In contrast, methyl acrylate (264) gave a mixture of the anti adducts 
with poor selectivity (2.4:1, favouring the exo product over the endo). Approaches of 
dipolarophiles 263 and 264 occured exclusively anti to both the benzyl group at C-3 and at 
C-5 of the nitrone, which are located on the same face of the ring. The benzyl group at C-4, 
which was expected to hamper formation of the endo cycloadducts was indeed effective with 
maleate 263, forming exclusively the exo cycloadduct 265, but not with acrylate 264, which 
gave a significant amount of endo adduct 266b. Goti et al. reasoned that by increasing the 
steric demand of the dipolarophile, the endo mode of approach should be disfavoured. This 
was confirmed in the reaction with the bulkier N,N-dimethylacrylamide dipolarophile (191), 
where the stereoselectivity of the cycloaddition was restored in favour of the exo-anti adduct 
193 (Scheme 31). 
 
 
 
Scheme 31: 1,3-dipolar cycloadditions of nitrone 158 with 263, 244 and 191 carried out by 
Goti et al.109 
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As nitrone 190 differs from nitrone 158 only in the protecting group at the C-3 position, it 
was thought that it should behave in a similar manner as nitrone 158 in 1,3-dipolar 
cycloaddition reactions. With this in mind and given the poor selectivity observed by 
Ishibashi’s group for the reaction of acrylate 192 with nitrone 190, we chose to use N,N-
dimethylacrylamide (191) as the dipolarophile in our synthetic strategy (Scheme 32).  
2.3.1.1 Attempted synthesis of hyacinthacine A1: Route A 
 
 
Scheme 32: Planned route to hyacinthacine A1 (51) – Route A. 
 
Based on the results of Goti et al. discussed above, then, the cycloaddition of nitrone 190 
with acrylamide 191 was expected to furnish isoxazolidine 267, (Scheme 32). We anticipated 
that the route to hyacinthacine A1 might then be completed by the following sequence of 
transformations. Firstly, after the cycloaddition, the N-O bond in 267 would be cleaved with 
subsequent cyclisation to form pyrrolizidinone 268. Mesylate derivatisation of the free 
hydroxyl group at C-6 would allow selective deprotection of the methoxymethyl ether, 
forming the key intermediate (270), where inversion at C-1 would subsequently put the 
oxygen functions at the 1- and 2-positions cis to each other. Hydrogenolytic cleavage of the 
remaining benzyl protecting groups would then lead to hyacinthacine A1 (51). Clearly the 
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efficiency of this route would be strongly dependent on the outcome of the initial 1,3-dipolar 
cycloaddition, with four isomeric 5-isoxazolidine cycloadducts, (Figure 22), possible 
depending on the endo-exo and syn-anti selectivity achieved. In principle, both exo-anti and 
endo-anti products might be transformed into hyacinthacine A1 by the route shown in 
Scheme 11, although it would be preferable to take a single isomer forward.  
 
 
Figure 22. Possible cycloadducts from reaction between nitrone 190 and acrylamide 191 
 
Pleasingly, when nitrone 190 was reacted with one equivalent of N,N-dimethylacrylamide 
(191) in dichloromethane at ambient temperature overnight only the exo-anti product was 
formed, and isoxazolidine 267 was obtained quantitatively as a pale brown oil following 
evaporation of the reaction mixture and column chromatography. The structure of the 
cycloadduct was confirmed by comprehensive 2-D NMR studies including NOESY,. In 
particular a key set of cross-peaks in the NOESY spectrum confirmed that H-2 of the 
hexahydropyrrolo[1,2-b]isoxazole heterocycle was located on the face anti-to the 4- and 6-
substituents were key NOESY interactions between CH-2 and CH-6, CH-2 and CH-3’’ and 
between CH-3’’ and CH-4 were observed (Figure 23). In addition, a NOESY interaction 
between CH-3a and CH-3’ was observed.The stereochemical outcome of the cycloaddition 
was further confirmed by the acquisition of a single crystal X-ray structure for a downstream 
intermediate in the route planned to hyacinthacine A1 from isoxazolidine 267 (vide infra). 
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Figure 23: Key NOE interactions observed in the NOESY spectrum for isoxazolidine 267. 
 
The remarkable selectivity in the reaction of nitrone 190 with acrylamide 191 can be 
explained by consideration of the steric interactions in the transition states for the 
cycloaddition modes leading to the four possible 5-substituted isoxazolidine products. Simple 
inspection of the structure of the nitrone and possible approaches of the alkene, shown for 
indicative purposes in Figure 24, clearly reveals that the exo-anti mode of addition should 
incur the least steric penalty of all the four modes however. The exo approach is favoured 
due to the bulk of the alkene substituent and the alkene approaches form the more open lower 
‘anti‘ face of the nitrone which is less hindered. 
 Figure 24: Chem3D image showing the 
190 in the cycloaddition reaction.
 
With the desired outcome from the 1,3
267 was then cleaved. There are various conditions commonly used to cleave the 
isoxazolidine N-O bond, including hydrogenation over Raney nickel, palladium or platinum 
catalysts,129 and reduction using zinc in acetic acid,
hydride.131 The conventional method of zinc dust and acetic acid was used in a first attempt 
with 267 and this afforded pyrrolizidine 
after work up and chromatographic isolation. As the yield was reasonable, no oth
of N-O bond cleavage were attempted and the structure of pyrrolizidine 
by X-ray crystallography
observed belonging to the P1 space group. Two molecules were found to be present in the 
asymmeteric unit and are linked via OH...H hydrogen bonds into a discrete dimer
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 (Figure 25, data in Appendix C). A triclinic crystal system was 
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Figure 25: Crystal structure of 268. 
 
The hydroxyl function in compound 268 was then derivatised by treatment with 
methanesulfonyl chloride and triethylamine in dichloromethane, producing mesylate 269 in 
98% yield. Deprotection of the MOM group by exposure to trifluoroacetic acid in 
dichloromethane at ambient temperature gave the key intermediate hydroxypyrrolizidinone 
(270) in 87% yield. We anticipated that inversion of the hydroxyl group in pyrrolizidinone 
270 might be achieved either by a redox procedure or by utilizing the Mitsunobu reaction. 132 
The redox procedure would involve oxidation to a ketone (271) [Scheme 32] followed by 
reduction back to the alcohol. Given the envelope-shaped structure of 271 we expected that 
the favoured trajectory for delivery of the hydride to ketone moiety of 271 would result in 
inversion of the C-1 stereocentre [Figure 26]. An attractive feature of this strategy was that 
simultaneous reductive deoxygenation of the mesylate group and lactam might then deliver 
the hyacinthacine A1 precursor (260) directly in a one-pot transformation. Goti et al. had 
already successfully employed such a dual deoxygenation process with lactam-mesylate 200 
in their route to hyacinthacine A2 (52) [Scheme 16].109 Moreover, Izquierdo and co-workers 
had also successfully applied the redox inversion procedure to an analogous pyrrolizidinone 
intermediate (146) [Scheme 7].86 Thus, armed with separate precedent for the individual 
components of the proposed transformation of ketone 271 into pyrrolizidinone 260, we felt 
that the ambitious one-pot procedure should be feasible. 
 Figure 26: Expected pre
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82 
ferred approach of reducing agent to ketone 
ation of a secondary alcohol to a ketone are potassium 
133 and Swern conditions.134 Initially Dess
to ketone 271 was attempted. The Dess-Martin periodinane (DMP), 
for the selective and very mild oxidation of 
rmed at room temperature in 
270, TLC analysis after 2 
had occurred and the alcohol remained unreacted. Further 
o reaction. NMR analysis of the material 
up confirmed that no reaction had taken place, 
present in the 13C NMR spectrum. The
of the secondary alcohol substrate
270 using the standard oxalyl 
 but, as with the Dess-Martin procedure, TL
Results and Discussion 
 
271. 
-Martin 
with no trace of a 
 failure of this 
. A Swern 
C 
 up indicated a 
Both the Dess-
 and as before 
Results and Discussion 
83 
 
there was no reaction in any of these experiments.  Finally, a PCC oxidation was attempted, 
but again without success, returning alcohol 270.  
 
With the oxidation attempts unsuccessful, direct inversion of the alcohol under Mitsunobu 
conditions was tried. Accordingly, compound 270 was treated with a mixture of benzoic acid, 
triphenylphosphine and diethyl azodicarboxylate (DEAD) in dry THF in an attempt to obtain 
the inverted benzoate ester derivative (272) [Scheme 33]. However, this was also nsucessful 
and the alcohol was returned.  
 
Scheme 33: (a) BzOH, PPh3, DEAD, THF (0%). 
 
As a last resort it was decided to further modify the planned route to hyacinthacine A1 
(Scheme 32) by attempting to derivatise the free alcohol group in hydroxypyrrolizidinone 
270 as a second mesylate, since this might then allow nucleophilic displacement with 
inversion by a suitable oxygen nucleophile such as an acetate anion, [Scheme 34]. Clearly the 
pre-existing mesylate at C-6 in the proposed dimesylate (273) might also suffer 
transformation under these conditions, but at this point we were keen to investigate the 
formation of the dimesylate to see if it was possible to secure any reaction at all on the C-1 
alcohol. In the event, however, attempts to form dimesylate 273 from 270 were also 
unsuccessful. 
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Scheme 34: MsCl, TEA, DCM (0%). 
 
The complete resistance of alcohol 270 to all of the reaction conditions described above came 
as a surprise. Although Izquierdo et al. had previously reported that the closely related 
pyrrolizidinol (146, Scheme 35) had been resistant to inversion of the 1-hydroxy group 
through a Mitsunobu strategy, they had successfully achieved the inversion to 147 by a redox 
procedure involving Swern oxidation followed by borohydride reduction.86 This yielded the 
inverted alcohol (147) and starting alcohol (146) as 1.5:1 mixture which was separable by 
chromatography. 
 
 
 
Scheme 35: (a) Swern oxidation, (not isolated); (b) NaBH4, MeOH; 147 (46%) and 146 
(29%) (1.5:1); (c) i. BzOH, DEAD, Ph3P, THF, ii. MeONa (cat.), MeOH, (no reaction). 
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2.3.1.2 Attempted synthesis of hyacinthacine A1: Route B 
 
Our route to pyrrolizidinol 270 is summarised in Scheme 36. Although we had no clear 
explanation for the lack of reactivity of this compound’s alcohol group, we were reluctant to 
abandon the route to hyacinthacine A1 altogether. It was therefore decided to investigate the 
deoxygenation procedure on the MOM-protected mesylate lactam intermediate (269) first 
and return to the issue of C-1 inversion subsequently as a separate step. According to this 
modified route then, pyrrolizidine 269 was treated with lithium aluminium hydride in boiling 
THF for 1.5 h. Following an aqueous work up and chromatographic isolation, the 
deoxygenated pyrrolizidine 275 was successfully isolated in 89% yield. Selective 
deprotection of the MOM ether was then achieved by treatment with trifluoroacetic acid in 
dichloromethane to afford pyrrolizidinol 276 in 90% yield after purification by column 
chromatography. Although not investigated here, hydrogenolytic debenzylation of 276 would 
produce hyacinthacine A2 (52). Rather than commit our material to this synthesis however, 
we focused attention on the inversion chemistry required to access hyacinthacine A1 (51).  
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Scheme 36: (a) DCM, r.t., 2 h (100%); (b) Zn/AcOH, ∆, 3 h (57%); (c) MsCl, TEA, DCM, 
0°C, 0.5 h (90%); (d) TFA, DCM, r.t., (87% for 270, 86% for 276); (e) Swern oxidation, 
(0%); (f) i. BzOH, DEAD, Ph3P, THF, ii. MeONa (cat.), MeOH, (0%); (g) LiAlH4, THF, ∆, 
1.5 h (89%). 
 
Surprisingly attempts at the Swern oxidation with 276 were also unsuccessful, returning 276 
unreacted (notwithstanding the successful application of the Swern oxidation to closely 
related pyrrolizidinol 146 by Izquierdo et al.86). Dess-Martin and PCC oxidations were then 
attempted on alcohol 276, but in both cases the alcohol remained unreacted. Mitsunobu 
inversion was then attempted (PPh3/DEAD/benzoic acid) but again no reaction occurred and 
alcohol 276 was returned unreacted.  
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Scheme 37: Attempted mesylation of alcohol 253; MsCl, TEA, DCM, 0 °C, (0%). 
 
A final attempt at inversion was made by derivatisation of alcohol 276 as mesylate 278 with 
a view to substituting the mesylate with a carboxylate nucleophile (Scheme 37). The 
mesylation of alcohol 276 was also unsuccessful, returning the unreacted alcohol.  
 
2.3.1.3 Attempted synthesis of hyacinthacine A1: Route C 
 
Frustrated by the failure of the C-1 inversion strategies in Routes A and B above, a final 
approach to hyacinthacine A1 was explored (Route C, Scheme 38), even though the route 
required extension of the synthetic sequence by a number of steps. Here the plan was to 
attempt the key stereocentre inversion on the hexahydropyrrolo[1,2-b]isoxazole cycloadduct 
(267) prior to cleavage of the isoxazolidine N-O bond and pyrrolizidine formation.  
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Scheme 38: Route C to Hyacinthacine A1 (51); (a) TFA, DCM, r.t., (78%); (b) Swern 
oxidation, (no reaction); (c) i. BzOH, DEAD, Ph3P, THF, (no reaction); ii. MeONa (cat.); (d) 
MsCl, DCM, TFA, (no reaction).   
 
Cycloadduct 267 was selectively MOM-deprotected to compound 279 by TFA in 78% yield. 
This alcohol was then used as a substrate for the inversion attempts. As before, inversion was 
first attempted by a redox procedure. Attempts to oxidise alcohol 279 to ketone 280 by 
Swern oxidation, Dess-Martin oxidation and PCC oxidation were all unsuccessful, however, 
returning unreacted alcohol 279 in each instance. Alcohol 279 also failed to react when 
subjected to direct inversion under Mitsunobu conditions (PPh3/DEAD/benzoic acid). 
Attempted conversion of alcohol 279 into mesylate 282 was also unsuccessful, and returned 
the unreacted alcohol. 
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2.3.1.4 Summary of attempted synthesis of hyacinthacine A1 (51) 
 
Three different routes have been explored towards the synthesis of hyacinthacine A1 (51) 
where the inversion of the C-1 hydroxyl group at various intermediate stages was attempted 
(Figure 27). A redox procedure was investigated initially in each route as literature precedent 
suggested that Swern oxidation followed by reduction should be possible, where inversion by 
a Mitsunobu strategy might not proceeed. However, when substrates 270, 276 and 279 were 
subjected to Swern oxidation conditions no reaction occurred and only the unreacted alcohol 
was returned in each case. These substrates were also found to be unreactive towards 
oxidations using Dess-Martin conditions and PCC. Unsurprisingly, these key intermediates 
were also resistant to inversion by the Mitsunobu reaction. Conversion of each substrate into 
the corresponding mesylate, with SN2 inversion and subsequent manipulation in mind, was 
similarly unsuccessful with each alcohol being returned unreacted. The failure of the 
inversion attempts on alcohols 270, 276 and 279 means that differentially protected nitrone 
190 is not a suitable precursor in the synthesis of hyacinthacine A1 (51), and it was therefore 
decided to explore the utility of the nitrone for synthesis of hyacinthacines bearing a carbon 
substituent at C-5. The apparent lack of reactivity found in the substrates tested could be that 
a hydrogen bond is forming between the bridgehead hydrogen and the oxygen of the free 
hydroxy group (Figure 26). 
 
Figure 27: Substrates investigated for inversion showing potential hydrogen bonding 
possibly explaining the lack of reactivity of these compounds.. 
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2.3.2 Routes to hyacinthacine B2  
 
Hyacinthacines B1 (48) and B2 (49) are identical to hyacinthacine A1 (51) in one half of their 
structures, retaining the cis relationship between the C-1 and C-2 hydroxyl groups, but they 
possess an additional hydroxymethyl substituent at the 5-position of the pyrrolizidine core. 
At the outset of the project we anticipated that nitrone 190 might also be exploited for the 
construction of hyacinthacines B1 and B2 through cycloaddition with appropriate 4-carbon 
dipolarophiles. The strategy is illustrated in Figure 28 for hyacinthacine B2, where a suitably 
protected but-3-ene-1,2-diol (287) would be used as the dipolarophile. An (R)-configured 
butenediol derivative would be required to establish the correct absolute stereochemistry at 
the C-5 centre in the case of hyacinthacine B2 (49). Given our experience of the reaction 
between nitrone 190 and acrylamide 191, we could now be confident that a cycloaddition 
between this nitrone and the butenediol derivative would give predominantly an exo-anti 
adduct (288), although the intrinsic preferences of the chiral dipolarophile might, in 
principle, either reinforce or work against the selectivity afforded by the chiral nitrone 
structure. According to the plan in Figure 28, the free hydroxyl group in the isoxazolidine 
ring side-chain of 88 would be activated as a leaving group by derivatisation as the mesylate 
so that reductive cleavage of the N-O bond would proceed with concomitant intramolecular 
substitution to afford the pyrrolizidine core in 290. Deoxygenation and MOM-deprotection 
would then expose the C-1 hydroxyl group in 291 required for an inversion procedure that 
would deliver the hyacinthacine B2 precursor (292). A final deprotection would afford the 
target pyrrolizidine (49), and we therefore anticipated using a benzyl protecting group in the 
butenediol dipolarophile (287) so that all three remaining protecting groups in intermediate 
293 could be removed in a single hydrogenation step at the end. Given the problems 
encountered with the attempted inversion chemistry described in the preceding sections for 
hyacinthacine A1, we were unsure at this stage whether the planned inversion step from 291 
to 292 would be achievable, although we expected that deprotection of intermediate 291 
would at least usefully furnish 1-epi-hyacinthacine B2 (293), a polyhydroxylated 
pyrrolizidine that, to the best of our knowledge, has not previously been synthesised.  
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Figure 28: Potential route from nitrone 190 to hyacinthacine B2. 
 
Before commencing the route to hyacinthacine B2, a suitable procedure for the synthesis of 
(R)-1-(benzyloxy)but-3-en-2-ol (294) was investigated. Mulzer et al.135 have reported two 
routes to (R)-1-methoxybut-3-en-2-ol (295) starting from (R,R)-dimethyl tartrate (296) 
(Scheme 39) and (S)-oxiran-2-ylmethanol (297) (Scheme 40Scheme 39).  
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Scheme 39: (a) 2,2-dimethoxypropane, DCM, p-toluenesulfonic acid, ∆, 4 h, (85%); (b) 
LiAlH4, Et2O, -10 °C, 4 h, (70%); (c) NaH, MeI, DMF,  r.t., 1 h, (65%); (d) TsCl, py, 0 °C, 1 
h, (88%); (e) acetonitrile, NaI, ∆, 5 h, (93%); (f) Zn, EtOH, ∆, 5 h, (70%).  
 
(R,R)-Dimethyl tartrate (296) was protected as the acetonide (298) which was subsequently 
reduced to diol 299. The monomethyl ether (300) was then formed by alkylation of 299 using 
methyl iodide and sodium hydride in DMF; only a small amount of the dimethyl ether were 
detected. The primary alcohol in 300 was then derivatised as the tosylate in 301 before being 
transformed into the iodide (302). Reductive elimination of the acetonide with activated Zn 
furnished allylic alcohol 295. Alternatively, a much shorter route was employed where (S)-
glycidol (297) was O-methylated and then treated with trimethylsulfonium ylide to give 
alcohol 295 directly (Scheme 40). 
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Scheme 40: (a) MeI, Ag2O, DCM, ∆, 24 h, (60%); (b) Me3S+I-, BuLi, THF, -15 °C, (76%). 
 
For convenience, we decided to synthesise (R)-1-(benzyloxy)but-3-en-2-ol (294) by the 
shorter route from the commercially available (R)-2-(benzyloxymethyl)oxirane (304). 
Pleasingly, the ring opening of the enantiopure oxirane by the sulphur ylide produced the 
desired allylic alcohol (294) in an excellent yield (91%), [Scheme 41]. With the chiral alkene 
in hand, we next investigated the key 1,3-dipolar cycloaddition with nitrone 190 in order to 
commence the route to hyacinthacine B2 (Scheme 41).  
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Scheme 41: (a) Me3S+I-, BuLi, THF, -15 °C, (91%); (b) 190, toluene, ∆, 24 h, (100% as 
inseparable mixture); (c) MsCl, TEA, DCM, 0 °C, 24 h (0%). 
 
The cycloaddition between nitrone 190 and alkene 294 was initially attempted in 
dichloromethane at room temperature as the previous reaction with acrylamide 191 had been 
found to proceed effectively without heating. Alkene 294 proved to be substantially less 
reactive as a dipolarophile, however, and under these conditions the reaction did not occur to 
any significant extent over 24 h. Reaction between the addends required reflux in toluene to 
proceed and afforded an inseparable two-component mixture in a 3:1 ratio and quantitative 
yield. Unfortunately, as the product mixture was inseparable, the identity of the structures of 
the products could not initially be confirmed on the basis of 2D NMR experiments. The 
major product was therefore assumed to the desired exo-anti adduct (304a) and the minor 
product the less favoured endo-anti product (304b), (Figure 29). In principle, the formation 
of a mixture of exo and endo products (though inconvenient) would not be detrimental to the 
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synthesis, so long as anti-selectivity was preserved. This is because the isoxazolidine ring C-
5 stereocentre would be removed in the later deoxygenation step of the planned route to 
hyacinthacine B2 (Figure 28). It was therefore decided to progress with the synthetic route as 
shown in Scheme 41, and the product mixture from the cycloaddition step was taken directly 
forward to the next stage. This involved treatment with methanesulfonyl chloride and 
triethylamine in dichloromethane. Surprisingly, however, this attempted conversion of the 
hydroxyl group into the mesylate only appeared to progress for the minor component within 
the cycloadduct mixture. This suggested that the minor adduct may in fact have been the exo-
anti product (304a) and the major adduct the endo-anti isomer (304b); the lack of reactivity 
of the latter can possibly be explained by formation of a stabilising intramolecular hydrogen 
bond interaction between the hydroxyl group and the oxygen of the isoxazolidine ring 
(Figure 29). The identity of the minor adduct as the exo-anti cycloaddition product (304a) 
was indeed confirmed subsequently by independent synthesis through a modified route (vide 
infra).  
 
 
 
Figure 29: Structure of assumed cycloadducts 304a and 304b provided from the reaction of 
nitrone 190 with alkene 294; an intramolecular hydrogen bond in the major adduct is 
tentatively proposed to account for the failure of the compound’s conversion into its mesylate 
derivative. 
 
The lack of reactivity of the major adduct within the product mixture derived from nitrone 
190 and alkene 294, tentatively identified as the endo-anti isomer (304b), necessitated 
modification to the route to increase the cycloaddition selectivity in favour of an adduct that 
could successfully be developed into the pyrrolizidine. With this in mind, the hydroxyl group 
of allylic alcohol 294 was derivatised as the bulky silyl ether in compound 309, (Scheme 42), 
by treatment with TBDPSCl and imidazole. The hope was that this radical change in the 
dipolarophile’s structure would lead to a more selective cycloaddition outcome, though it 
was difficult to predict at the outset whether the favoured product would have the appropriate 
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stereochemistry required for successful conversion through to the mesylate needed in the 
synthesis of hyacinthacine B2. 
 
 
Scheme 42: (a) TBDPSCl, imidazole, THF, r.t., 24 h, (96%); (b) toluene, reflux, 24 h, (92%). 
 
The presence of the bulky TBDPS group in the dipolarophile did indeed increase the 
selectivity of the 1,3-dipolar cycloaddition reaction. Thus, after boiling alkene 309 and 
nitrone 190 in toluene overnight a single cycloadduct (310) (Scheme 42) was obtained in 
92% yield after evaporation of the solvent and isolation by column chromatography. Adduct 
310 was identified as the desired exo-anti product on the basis of comprehensive 2D NMR 
experiments and the observation of key cross-peaks in the NOESY spectrum that confirmed 
the orientation of the isoxazolidine ring CH-5 atom on the opposite face of the bicycle to the 
methoxymethyl group. In addition, NOESY interactions between CH-3’ and CH-2 and 
between CH3’ and CH-4 were observed (Figure 30, spectra in Appendix D).  
 
 
Figure 30: Key NOESY interactions in cycloadduct 310. 
 
It was anticipated that removal of the TBDPS protecting group from cycloadduct 310 would 
furnish alcohol 304, thus allowing a return to the planned synthetic route for hyacinthacine 
B2 (Scheme 41). The silyl ether was successfully cleaved under standard conditions with 
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TBAF in THF at ambient temperature over 1 h, producing alcohol 304 in 85% yield, 
(Scheme 43). Comparison of the 1H NMR spectrum of the alcohol (304) thus obtained with 
that of the product mixture previously formed in the reaction of nitrone 190 with allyl alcohol 
294 confirmed the identity of the minor isomer from that reaction as the exo-anti product 
(304). Mesylation of alcohol 304 now proceeded smoothly, forming mesylate 305 in 
quantitative yield, (Scheme 43). Previously only the minor adduct provided from the 
cycloaddition of allyl alcohol 304 had successfully formed the mesylate. This finding was 
therefore also consistent with the identity of that minor adduct as the exo-anti product (304). 
Cleavage of the isoxazolidine N-O bond in 305 was next accomplished under standard 
conditions by treatment with Zinc dust in hot acetic acid. Pleasingly this reaction proceeded 
efficiently with concomitant substitution of the mesylate to form pyrrolizidinol 306 in 87% 
yield after work up and chromatographic isolation.  
 
Two methods for the deoxygenation of alcohol 306 to 307 were then attempted– firstly, by 
derivatisation of the alcohol as the mesylate (311) with subsequent reduction by hydride, and 
secondly, by a Barton-McCombie procedure. The mesylation-reduction route was attempted 
initially in order to avoid the toxic conditions used in the Barton-McCombie deoxygenation. 
Mesylate 311 was formed quantitatively from alcohol 306 under standard conditions with 
methanesulfonyl chloride and triethylamine in dichloromethane. Attempts at reducing 
mesylate 311 with lithium aluminium hydride in boiling THF over 12 h produced target 
pyrrolizidine 308 in only very low yield (ca. 2%), however, with mesylate 311 returned as 
the principal component. The use of Super-Hydride® increased the yield of 308 modestly to 
ca. 10% but again returned the mesylate. The Barton-McCombie deoxygenation was 
therefore investigated. Initial attempts at converting alcohol 306 into xanthate 312 using 
sodium hydride, carbon disulfide and methyl iodide in THF were largely unsuccessful, 
providing 312 in only 5% yield, this was despite taking rigorous precautions to ensure 
operation under anhydrous conditions. Changing the base to potassium hydride, however, 
allowed successful conversion of the alcohol into xanthate 312 in good yield (70%). Xanthate 
312 was then subjected to treatment with AIBN and tributyl tin hydride in toluene at reflux to 
produce the deoxygenated pyrrolizidine (307) in a reasonable yield of 59%. Deprotection of 
the methoxymethyl ether in 307 was achieved with trifluoroacetic acid in dichloromethane 
and furnished alcohol 308 as the substrate for the key inversion step. As in the attempted 
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synthesis of hyacinthacine A1, the alcohol inversion was tried, in the first instance, by a redox 
procedure. Swern oxidation of alcohol 308 to ketone 313, attempted under standard 
conditions (oxalyl chloride/dimethylsulfoxide), was unsuccessful and returned the alcohol 
unreacted. Disappointingly the application of Dess-Martin and PCC reagents also failed to 
effect the necessary oxidation, once again returning alcohol 308. Inversion by a Mitsunobu 
strategy was then attempted (benzoic acid/PPh3/DEAD), but again no reaction took place, 
and the configurationally inverted carboxylate intermediate was not formed. As with the 
attempted synthesis of hyacinthacine A1, all inversion attempts of C-1 on alcohol 308 were 
unsuccessful. 
 
Scheme 43: Synthetic route to hyacinthacine B2; (a) 309 and 190, toluene, reflux, 18 h, 
(92%); (b) TBAF, THF, r.t., 1 h, (85%); (c) MsCl, TEA, DCM, r.t., (99%); (d) Zn dust, 1/1 
acetic acid/water, 85 °C, (87%); (e) MsCl, TEA, DCM, r.t., (99%); (f) Super-Hydride®, THF, 
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r.t., 24 h, (10%); (g) KH, CS2, MeI, THF, r.t., 20 min, (70%); h) AIBN, Bu3SnH, toluene, 
reflux, 1 h, (59%); (i) TFA, DCM, r.t., 48 h, (81%).  
 
2.3.3 Synthesis of 1-epi-hyacinthacine B2. 
 
Given the remarkable resistance of alcohol 308 to derivatisation and the complete failure of 
the planned inversion step, final efforts were committed to the debenzylation of 308 in order 
to furnish the previously unknown pyrrolizidine, 1-epi-hyacinthacine B2 (293) (Scheme 44).  
Initially the hydrogenation was attempted using a ThalesNano H-cubeTM, whereby a 
methanolic solution of 308 was pumped through a 10% Pd/C catalyst cartridge at a flow rate 
of 0.5 mL/min at 30 bar. This failed to effect the debenzylation to 293, however, and the 
experiment was therefore repeated with the addition of a little acetic acid to the solvent. As 
before no debenzylation was observed and only the starting material 308 was recovered.  
Successful deprotection was finally achieved by hydrogenation under acidic conditions using 
the conventional balloon technique. Thus, an acidic solution of compound 308 in methanol 
was hydrogenated over a 10% Pd/C catalyst for 48 hours at ambient temperature and 
pressure. After removal of the catalyst by filtration and evaporation of the solvent, the target 
pyrrolizidine, 1-epi-hyacinthacine B2 (293), was obtained in 88% yield following ion 
exchange chromatography over a basic resin. 
 
 
 
Scheme 44: (a) i. H2/Pd/C, MeOH, HCl, r.t., 48 h; ii. Amberlite resin IR-400 (OH– form) 
(88%). 
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2.4 Conclusions 
The synthesis of differentially protected nitrone 190 has been successfully achieved and 
reported in this thesis. A route to nitrone 190 from L-xylose over nine synthetic steps has 
been described (Scheme 25). An alternative route involving eleven synthetic steps starting 
from D-arabinose has also been presented (Scheme 29). The L-xylose route has the advantage 
of being the shorter one, but D-arabinose is a less expensive starting material. The D-
arabinose route has the added advantage of avoiding an expensive silver carbonate oxidation 
that was necessary in the L-xylose route. Overall, the D-arabinose route to nitrone 190 would 
be the recommended one for reliable preparation of the nitrone for further development of the 
synthetic routes to biologically active polyhydroxylated pyrrolizidines. 
 
Nitrone 190 was found to be remarkably selective in its 1,3-dipolar cycloaddition reactions 
with N,N-dimethylacrylamide (191) and (R)-(1-(benzyloxy)but-3-en-2-yloxy)(tert-
butyl)diphenylsilane (309), forming exclusively the desired exo-anti cycloadducts 267 and 
310 respectively. 
 
Figure 31 
 
The differential protection built into nitrone 190 allowed these cycloadducts to be 
successfully manipulated and transformed into pyrrolizidinols 276 and 308, (Figure 32), 
possessing structures suitable for the preparation of hyacinthacines A1 and B2 respectively. 
The key feature of the synthetic design here was to allow access to compounds with an 
unmasked alcohol at the pyrrolizidine C-1 position in order to perform a configurational 
inversion at the penultimate stage in the route; thereby establishing the correct 
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(1S,2R,3R,7aR)-absolute stereochemistry in the right-hand ring of these hyacinthacine 
alkaloids. 
 
Figure 32. Substrates on which inversion was attempted. 
 
To our considerable surprise, however, the hydroxy group in pyrrolizidinols 276 and 308 
proved completely resistant to derivatisation and attempts to facilitate the inversion. With the 
work directed towards synthesis of hyacinthacine A1, we also examined the suitability of 
other intermediates (270 and 279, Figure 32) as substrates for the inversion chemistry. 
However, in each case the secondary alcohol resisted derivatisation and we were ultimately 
unable to complete the routes to either of the natural compounds, hyacinthacines A1 and B2. 
The apparent lack of reactivity found in the substrates tested could be due to the presence of 
a hydrogen bond between the bridgehead hydrogen and the oxygen of the free hydroxy 
group. 
 
Pyrrolizidinol intermediate 278 was, however, successfully transformed into 1-epi-
hyacinthacine B2 (293, Figure 33) by hydrogenolytic cleavage of the benzyl ether protecting 
groups. This, to the best of our knowledge, completed the first total synthesis of 1-epi-
hyacinthacine B2, which has yet to be isolated from a natural source and would therefore be 
an interesting candidate for biological testing. 
  
Figure 33: Formation of 1-epi-hyacinthacine B2. 
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2.5 Future Work 
The apparent lack reactivity of the free hydroxyl group in the substrates investigated is likely 
due to hydrogen bonding between the bridge head hydrogen and the oxygen of the free 
hydroxyl group (figure 34). 
 
N
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Figure 34: Potential Hydrogen bonding of invesion substrates. 
 
Since the oxidation (Swern, and Dess-Martin) and inverstion stratagies (Mitsunobu and via a 
mesylate) involved reactions at low temperature (ambient to -78 °C) their lack of reactivity is 
perhaps not surprising. Therefore, higher temperature oxidations (e.g. Oppenauer oxidation) 
and inversions (e.g. via tosyl group) could be attempted in the hope that the hydrogen bond 
interaction could be overcome. Conversion to a tosylate could provide routes not only to the 
desired inverted alcohol, but also opens up the substrate to nucleophilic attack allowing a 
wide variety of functional changes at the C-1 position (e.g alkyl, halide, sulfide and alkyl 
sulfide) (Figure 35). Additionally, deoxygenation of these sustrates would provide novel 
compounds (Figure 35). 
Results and Discussion 
103 
 
 
Figure 35: Further reactivity of inversion substrates to be explored leading to desired and 
alternative structures. 
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Instrumentation 
 
NMR spectra were recorded on a Bruker AC200 at 200 MHz (1H) and 50 MHz (13C), or a 
Bruker DPX400 at 400 MHz (1H) and 100 MHz (13C). Coupling constants (J) are quoted in 
Hz. Accurate mass measurements (electrospray) were performed using Finnigan MAT 900 
XLT and Finnigan MAT 95 XP instruments at the EPSRC National Mass Spectrometry 
Service Centre, University of Wales, Swansea. Elemental analyses were conducted using an 
Exeter CE-440 elemental analyser. Infrared spectra were recorded using a Perkin-Elmer RX 
Fourier Transform spectrometer as a thin film on NaCl plates. Specific rotations were 
measured at room temperature using a Bendix-NPL 143D automatic polarimeter (path length 
1 cm) with solvent as stated; units for [α]D values are 10-1 deg cm2 g-1. 
 
Chromatography 
 
Analytical t.l.c. was performed on Merck aluminium-backed Kieselgel 60 silica plates 
(0.25mm), visualised with UV light (254nm) and developed with 5% aqueous ammonium 
molybdate solution to which concentrated sulfuric acid had been added. Flash 
chromatography was carried out with the indicated solvents using 230-400 mesh Kieselgel 60 
silica as the stationary phase. 
 
General Details 
 
All reagents used were purchased from Aldrich, Avocado or Lancaster chemical companies 
unless otherwise stated. Solvents were routinely distilled before use and, where indicated, 
dried by standard procedures. Light petroleum refers to material of boiling range 40-60 ºC. 
All air and moisture sensitive reactions were carried out using usual inert atmosphere 
techniques under an argon atmosphere. All glassware was flame-dried, and then cooled under 
argon prior to use. Reactions with H2 were carried out at 1 atm. pressure, using a balloon 
unless otherwise stated. 
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1,2-O-Isopropylidene-α-L-xylofuranose (234)
 
 
  
 
 
L-xylose (5.00g, 33.32 mmol) was added to acetone (130 mL) containing conc. H2SO4 (5 
mL) and the mixture was stirred at room temperature for 30 minutes. A solution of Na2CO3 
(6.50 g) in water (50 ml) was added with external cooling and the mixture was left to stir for 
a further 5 h. The mixture was then neutralised with Na2CO3. Filtration and concentration 
produced an oil, which was chromatographed on silica gel, eluting with  DCM containing a 
MeOH gradient (5-10 %), to generate the title compound 234 (4.95 g, 75 %) as a white solid.  
 
Rf 0.33 (DCM/methanol, 95:5); m.p 46-47 °C (lit. m.p 42-43 °C)136; δH (200 MHz, CDCl3):  
1.23 (3H, s, CMe2), 1.42 (3H, s,CMe2), 2.83 (1H, b. s, OH-3), 3.93-4.19 (4H, m, C4-H, C5-
H2, C5-OH), 4.28 (1H, d, J = 2.5, C3-H), 4.48 (1H, d, J = 3.7, C2-H), 5.93 (1H, d, J = 3.7, 
C1-H); δc (50 MHz): 26.4 (CH3), 27.0 (CH3), 61.2 (CH2), 77.0 (C-3), 79.1 (C-4), 85.8 (C-2), 
105.1 (C-1), 112.1 (C); IR νmax 3401.4 (br OH), 2988.7, 1377.4, 1217.6, 1165.4, 1074.3, 
1016.8 cm-1; LRMS (ES): 208.2, 191.1, 173.1, 150.1, 133.0, 115.1, 76.3; HRMS (ES): 
208.1177 [(M+NH4)+; requires 208.1179]; Anal. Calcd for C8H14O5: C, 50.52; H, 7.54. 
Found: C, 50.72; H, 7.53. 
 
3,5-Di-O-benzyl-1,2-iso-O-propylidene-α-L-xylofuranose (235)
 
 
 
 
 
Compound 234 (4.10 g, 23.67 mmol) in THF (10 mL) was added to a suspension of NaH 
(60% dispersion in oil, 3.00 g, 25.60 mmol) and n-Bu4NI (6.80 g, 18.41 mmol) in anhydrous 
THF (100 mL) at 0 °C. The mixture was stirred at this temperature for 20 min then allowed 
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to warm up to room temperature and left to stir for 30 minutes. Subsequently, the mixture 
was cooled to 0 °C and treated with a solution of BnBr (5.70 mL, 47.99 mmol) in THF (5 
mL). The mixture was then warmed up to ambient temperature and left to stir for 5 h. The 
mixture was quenched with water (50 ml) and extracted with ethyl acetate (2 x 60ml). The 
combined organic layers were washed with brine (30 ml), dried over MgSO4, filtered and 
evaporated to produce an orange oil. The cude material was purified by flash 
chromatography using hexanes containing ethyl acetate gradient (10-20 %) to produce 235 
(6.70 g, 84 %) as an orange oil.  
 
Rf 0.36 (light petrol/ethyl acetate, 5:1); δH (200 MHz, CDCl3): 1.29 (3H, s, CCH3), 1.46 (3H, 
s, CCH3), 3.75 (2H, m, C5-H2), 3.96 (1H, d, J = 3.2 , C3-H), 4.27 (1H, dt, J = 6.1, 3.2, C4-
H), 4.56 (5H, m, 2 x OCH2Ph, C2-H), 6.18 (1H, d, J = 3.05 , C1-H), 7.47-7.51 (10H, m, Ph); 
δc (50 MHz): 26.5 (CH3), 28.00 (CH3), 69.8 ( OCH2), 73.4 (OCH2), 75.3 (OCH2), 78.6 (C-4), 
80.9 (C-3), 82.2 (C-3), 106.5 (C-1), 110.4 (C), 127.7, 127.6, 127.8, 128. 3, & 128.4 (CHar), 
137.5 & 137.9 (C); IR νmax 3065.8, 3029.7, 2932.3, 2336.6, 1497.1, 1451.1, 1374.1, 1309.4, 
1075.4, 1018.5, 888.8, 858.5, 736.3, 697.5 cm-1. Anal. Calcd for C22H26O5: C, 71.33; H, 7.07. 
Found: C, 71.02; H, 7.01. 
 
3, 5-Di-O-benzyl-L-xylofuranose (229)
 113
 
 
 
 
A stirred solution of 3,5-di-O-benzyl-1,2-iso-O-propylidene-α-L-xylose 235 (4.01 g, 10.81 
mmol) in acetic acid-water (1:1, 30 mL) was heated to 80 °C and stirred for 24 h. The 
mixture was cooled, diluted with water (30 ml), and extracted with DCM (60 ml). The 
organic layer was washed with saturated sodium bicarbonate (20 ml), brine (20 ml), dried 
over Na2SO4, filtered and concentrated to give the diol 229 (3.09 g, 86 %) as a white wax.  
 
Rf 0.11 (light petrol/ethyl acetate 6:4); m.p 67-70 °C (no lit. value); δH (200 MHz, CDCl3): 
3.38-3.65 (2H, m, C5-H2), 3.83-4.11 (4H, m, C2-H, C3-H, 2x OH), 4.30-4.60 (1H, m, C4-H), 
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4.33-4.61 (4H, m, 2 x OCH2Ph), 5.12 (α-anomer, s, C1-H), 5.39 (β-anomer, d, J = 3.3, C1-
H), 7.13-7.33 (10H, m, Ph); δc (50 MHz): 68.5 & 68.7 (α & β CH2), 71.6 & 72.5 (α & β 
CH2), 73.2 & 73.4 (α & β CH2), 77.24 & 79.1 (α & β CH), 82.5 & 83.2 (α & δ CH), 95.7 (α 
C1-H), 103.2 ( δ CH), 127.3, 127.4, 127.5, 127.6, 127.8, 128.1 & 128.3 (CHar), 137.5 & 
137.6 (c); IR νmax 3365.8 (br. OH), 3061.6, 2893.3, 1497.4, 1453.9, 1356.0, 1279.3, 1096.6, 
1045.3, 977.0, 913.6,  734.1, 697.0 cm-1. LRMS (ES): 348.3, 330.3, 240.3, 198.2, 168.2, 
108.2, 91.2; HRMS (ES): 348.1805 [(M+NH4)+; requires 348.108]. Anal. Calcd for 
C19H22O5: C, 69.07; H, 6.71. Found: C, 68.88; H, 6.66. 
 
3,5-Di-O-benzyl-L-xylono-1,4-lactone (236) 
 
 
 
Method 1:   
 
Barium carbonate (490 mg, 2.48 mmol) and bromine (100 µL, 1.94 mmol) were added to a 
stirred ice cold solution of 229 (0.50 g, 1.51 mmol) in THF-water (1:3, 25 mL). The mixture 
was allowed to warm to ambient temperature and was left to stir overnight. The mixture was 
then filtered through Celite® and the filtrate concentrated under reduced pressure. The 
remaining aqueous solution was removed by extraction with DCM (2 x 30ml) and the 
combined organic layers were concentrated to give the crude material. This was purified by 
chromatography, eluting with light petroleum with an ethyl acetate gradient (10- 40 %) to 
produce the lactone 236 (0.089 g, 18%) as a white solid. 
 
Method 2: 
 
A mixture of diol 229 (3.96g, 11.99 mmol) and Ag2CO3/Celite® (7.50g, 12.50 mmol) were 
heated at 80 °C in toluene (200 mL) for 1 h. The mixture was filtered and washed with DCM 
(100 ml). The filtrate was then evaporated and the residue was purified by flash 
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chromatograpy, using light petroleum/ethyl acetate (7:3) as the eluent, to give the pure 
lactone 236 (1.75 g, 45 %) as a white solid. 
 
Method 3: 
 
A mixture of diol 229 (1.32g, 3.99 mmol) and Ag2CO3/Celite® (7.50g, 12.50 mmol) were 
heated at 80 °C in toluene (200 mL) for 1 h. The mixture was filtered and washed with DCM 
(100ml). The filtrate was then evaporated and the residue was purified by flash 
chromatograpy, using light petrol/ethyl acetate (7:3) as the eluent, to give the pure lactone 
236 (1.29 g, 99%) as a white solid. A small sample of the white solid was recrystalised from 
a 1:1 mixture of heptane/ethyl acetate providing crystals which were analysed by x-ray 
crystallography. 
 
Rf 0.2 (light petroleum/ethyl acetate 7:3); m.p 84-87 °C; δH (200 MHz, CDCl3): 2.68 (1H, d, 
J =3.1, C2-H), 3.51 (2H, 2 dd, J = 10.9, 2.3, 5a-H,),  3.53 (2H, 2 dd, J = 10.9, 2.7, C5b-H), 
4.15-4.72 (6H, m, 2 OCH2Ph, C3-H, C4-H), 7.02-7.25 (10H, m, Ph); δc (50 MHz): 66.4 (C-
5), 71. 1 (C-3), 72.1 (OCH2), 73.0 (OCH2), 77.1 (C-2), 79.8 (C-4), 126.9, 127.2, 127.5, 
127.7, 127.9 &  127.9 (CHar), 136.7 (C), 136.9 (C), 174.7 (CO); IR νmax 3450.7 (br OH), 
3034.5, 2866.3, 1777.8, 1654.2, 1318.9, 1124.2, 1020.3, 763.2 cm-1. LRMS (ES): 346.4, 
330.4, 256.3, 222.3, 168.2, 106.3; HRMS (ES): 346.1655 [(M+NH4)+;  C19H23NO5 requires 
346.1649]. Anal. Calcd for C19H20O5: C, 69.50; H, 6.14. Found: C, 69.39; H, 6.14. 
 
Preparation of Ag2CO3/Celite
®
 reagent
124
 
Celite® (30 g) was added to a stirred solution of silver (I) nitrate (30 g) in distilled water (200 
mL). To this mixture was added slowly a solution of sodium carbonated decahydrate (30 g) 
in distilled water (300 mL). The precipitate was collected by filtration and washed well with 
distilled water (500ml). The solid was then dried on the rotary evaporator for 4 h in the dark. 
It has been estimated that 0.6 g of this material contains roughly 1 mmol Ag2CO3. 
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3,5-Di-O-benzyl-2-O-methoxymethyl-L-xylono-1,4-lactone (237) 
 
 
 
To a stirred solution of 236 (0.23g, 0.97 mmol) in chloroform (22 mL) at ambient 
temperature was added dimethoxymethane (4.40 mL, 48.41 mmol) and phosphorous 
pentoxide (20.24 g, 5.72 mol). The mixture was stirred for 30 min, the solids decanted and 
the filtrate poured in to an ice cold solution of saturated sodium bicarbonate (17 mL). The 
two phases were separated and the aqueous phase was extracted with chloroform (2 x 20 ml) 
and the combined organic layers were washed with brine (20 ml), dried over Na2SO4, and 
evaporated in vacuo to give the ether 237 ( 354 mg, 98 %) as a yellow oil. 
 
Rf 0.76 (light petroleum/ethyl acetate 1:1); δH (200 MHz, CDCl3): 3.37 (3H, s, OMe), 3.59 
(1H, dd, J =10.93, 3.12, C5a-H), 3.61 (1H, dd, J =10.93, 3.25, C5b-H), 4.21-4.69 (8H, m, 2 x 
OCH2Ph, OCH2O, C3-H, C4-H), 4.93 (1H, d, J =6.65, C2-H), 7.01-7.29 (10H, m, Ph); δc (50 
MHz): 55.81 (OCH3), 66.66 (C-5), 71.92 (OCH2), 72.59 (OCH2), 73.22 (C-3), 76.98 (C-2), 
79.14 (C-4), 95.74 (OCH2O), 127.22, 127.38, 127.44, 127.67, 127.82, 128.06, 128.16 & 
128.24 (CHar) 136.78 (C), 137.20 (C), 172.595 (C=O); IR νmax 2898.3, 1789.9, 1496.5, 
1453.8, 1244.8, 1165.8, 1123.7, 1023.3,  736.8 cm-1. LRMS (ES): 372.3, 341.4, 327.5, 299.2, 
281.8, 265.3, 249.6, 235.3, 228.1, 220.8, 108.6, 91.7; HRMS (ES): 390.1908 [(M+NH4)+;  
C21H28NO6 requires 390.1911]. Anal. Calcd for C21H24O6: C, 67.73; H, 6.50. Found: C, 
67.91; H, 6.78. 
 
3,5-Di-O-benzyl-2-O-methoxymethyl-L-xylofuranose (232)
113  
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Lactone 237 (1.00 g, 2.69 mmol) was dissolved in THF (80 mL) and cooled to -78 °C. A 
solution of DIBAL in toluene (1.5M, 3.60 mL, 5.40 mmol) was added dropwise over 30 min 
and the mixture allowed to stir for 1.5 h. A further portion of the DIBAL solution (5.00 mL, 
7.50 mmol) was then added dropwise over 30 min. The mixture was then stirred until TLC 
analysis showed no remaining starting material. The reaction was then quenched with 
saturated ammonium chloride (22 mL), filtered through celite® and the residue was washed 
well with DCM (200 mL). The filtrate was then concentrated in vacuo to produce hemiacetal 
232 (0.78g, 78%) as a pale yellow/green oil. 
 
Rf 0.48 (light petroleum/ethylacetate 1:1); δH (400 MHz, CDCl3): 3.22 (3H, 2 s, OMe α- and 
β-anomers), 3.51-3.72 (2H, m, C5-H), 3.88-4.07 (3H, m, C2-H, C3-H & C4-H), 4.21-4.62 
(6H, m, 2 x OCH2Ph & OCH2O), 5.09-5.11 (1H, 2 x s, C1-H, α and β), 5.38 (1H, br OH), 
7.08-7.29 (10H, m, Ph); δc (100 MHz): 55.9 & 56.2 (α & β OMe), 68.9 & 69.1 (ά & β CH2), 
72.6 & 72.9 (α & β CH2), 73.7 & 73.9 (α & β CH2), 77.6 (β-anomer C-2), 80.0 & 80.3 (α & β 
C-3), 81.5 & 81.6 (α & β C-4), 84.2 (α–anomer C-2), 96.2 & 96.9 (α & β OCH2O), 96.6 (β-
anomer C-1), 102.3 (α-anomer C-1), 127.9, 128.0, 128.1, 128.2, 128.4, 128.6, 128.7 & 128.8 
(CHar), 137.6 (C), 138.1 (C); IR νmax 3430.0 (br. OH), 3063.5,  2931.4, 1718.3, 1496.7, 
1454.3, 1367.9, 1271.8, 1209.9, 1156.9, 1103.4, 1041.7, 918.1, 738.2, 698.5 cm-1.  
 
3,5,-Di-O-benzyl-2-O-methoxymethyl-L-xylose oxime (238) 
 
 
 
A solution of Lactol 232 (158 mg, 0.422 mmol), hydroxylamine hydrochloride (553 mg, 7.91 
mmol), and sodium methoxide (442 mg, 7.92 mmol) were stirred in methanol (15 mL) for 16 
h at ambient temperature. The reaction mixture was then concentrated in vacuo and the 
residue was dissolved in DCM (20ml). The resulting solution was washed with water (2 x 
20ml) and the combined organic layers were dried over Na2SO4 and filtered. The filtrate was 
concentrated in vacuo to give 238 (134mg, 82 %) as a dark yellow oil.  
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Rf 0.27 (light petroleum/diethyl ether 1:1); δH (200 MHz, CDCl3): 3.21 (3H, s, OMe), 3.25 
(1H, d, J = 5.73, E-isomer, 4-OH), 3.29 ( 3H, m, C5-H & Z-isomer, 4-OH), 3.8-3.74 (1H, m, 
C4-H), 3.75 -3.91 (1H, m, C3-H), 4.09-4.23 (1H, m, C2-H), 4.28-4.77 (6H, m, 2 x OCH2Ph, 
OCH2O), 6.25 (1H, d, J = 6.22, C1-H, Z-isomer), 7.12-7.28 (10H, m, Ph), 7.34 (1H, d, J 
=7.71, C1-H, E-isomer), 9.02 (1H, br. N-OH); δc (50 MHz): 55.6 (E-isomer, OCH3), 55.9 (Z-
isomer, OCH3), 68.9 (CH), 69.6 (CH), 70.6 (Z-isomer, CH2), 71.0 (E-isomer, OCH2), 73.2 
(OCH2),  74.4 (E-isomer, CH2), 74.8 (Z-isomer, CH2), 78.5 (CH), 94.9 (E-isomer, OCH2O), 
95.8 (Z-isomer, OCH2O), 127.6, 127.8, 128.2 & 128.2 (CHar), 137.6 ( E-isomer, C), 137.6 
(Z-isomer, C); IR νmax 3327.7 (br. OH), 3080.4, 3024.8, 2865.8, 1458.8, 1093.1, 1067.4, 
732.6, 695.7 cm-1. 
 
3,5-Di-O-benzyl-2-O-methoxymethyl-L-xylose-O-(tert-butyldimethylsilyl)oxime (239) 
 
Method 1: 
 
 
Oxime 238 (118 mg, 304 mmol) was dissolved in dry pyridine (35 mL) and tert-
butyldimethylsilyl choride (46 mg, 304 mmol) was added. The mixture was allowed to stir 
for 12 h at ambient temperature. Concentration left a residue which was dissolved in DCM 
(50 ml) and washed with water (2 x 20 ml). The organic layers were washed with 1M HCl (5 
ml), Sodium Bicarbonate (10ml) and brine (20 ml) before being dried over MgSO4, filtered 
and evaporated in vacuo to give 239 (0.262 g, 34 %) (E:Z, 5:1)  as a white/green oil. 
 
Method 2: 
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To a stirred solution of lactol 232 (577 mg, 1.54 mmol) in dry toluene (6 mL) was added 
MgSO4 (670 mg). The suspension was brought to reflux for 5 min then tert-
butyldimethylsilylhydroxylamine (340 mg, 1.54 mmol) was added. The reaction mixture was 
left at reflux for a further 30 min before being allowed to cool. The filtrate was washed with 
saturated sodium bicarbonate (5ml), brine (10ml) then dried over MgSO4 and fitered. The 
filtrate was concentrated to give 239 (0.114 g, 89%) (E:Z, 5:1) as a yellow/green oil. 
  
Rf 0.68 (light petroleum/diethyl ether 1:1); δH (200 MHz, CDCl3): 0.00 (6H, s, SiMe2), 0.78 
(9H, s, SiCMe3), 2.34 (1H, br s, OH), 3.13 (3H, s, OMe), 3.23- 3.41 (2H, m, C5-H), 3.55- 
3.89 (3H, m, C2-H, C3-H, C4-H), 4.28-4.65 (6H, m, 2 x OCH2Ph & OCH2O), 6.89 (1H, d, J 
=5.11, Z-isomer C1-H), 7.08-7.21 (10H, m, Ph), 7.40 (1H, d, J =7.7, E-isomer C1-H); δc (50 
MHz): (E-isomer) -8.1 (2x CH3), 17.9 (CMe3), 25.8 (3 x CH3), 55.6 (OCH3), 69.1 (CH-4), 
69.9 (CH2), 73.1 (CH2), 73.8 (CH-3), 74.1 (CH2), 77.5 (CH-2), 94.7 (OCH2O), 127.5, 127.6, 
127.7, 128.0 & 128.2 (CHar), 137.5 & 137.7 (C), 152.0 (CH-1); 148.8 (E-isomer, H-1), 150.0 
(Z-isomer, H-1); IR νmax 3352.8 (br. OH), 3069.2, 3030.6, 2935.3, 2854.5, 1428.9, 1113.7 
1069,4, 920.5, 732.4, 701.1 cm-1, HRMS (ES): 504.2760 [(M+H)+, requires 504.2776. 
 
Preparation of tert-butyldimethylsilylhydroxylamine
125
 
 
Ethylenediamine (30.22 g, 0.50 mol) was dissolved in DCM (150 mL) and hydroxylamine 
hydrochloride (35.32 g, 0.50 mol) was added. This mixture was stirred at ambient 
temperature for 6 h. A condenser with water cooling was fitted and tert-
butyldimethylsilylhychloride (75.32 g, 0.50 mol) was added portionwise down the condenser 
over a 1 h period. The mixture was allowed to cool, the condenser was removed, the flask 
was stoppered and the mixture allowed to stir for 24 h. The reaction mixture was filtered and 
the filtrate was distilled under vacuum, product distilled at 80-90 °C to produce the product 
as a white solid (24 g, 83 %). 
 
δH (200 MHz, CDCl3): 0.00 (6H, s, SiMe2), 0.79 (9H, s, CMe3), 4.98 (2H, s, br. NH2). 
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3,5-Di-O-benzyl-4-O-methanesulfonyl-2-O-methoxymethyl-L-xylose-O-(tert-
butyldimethylsilyl) oxime (240)
113
 
 
 
 
Compound 239 (0.26 g, 0.52 mmol) was dissolved in DCM (1.5 mL), cooled to 0 °C and 
stirred under an argon atmosphere. Triethylamine (113 µL, 0.81 mmol), and methanesulfonyl 
chloride (49 µL, 0.62 mmol) were added successively. The mixture was stirred for 30 min at 
0 °C and then water (0.5 mL) was added. The layers were separated and the aqueous layer 
was extracted with DCM (2x 2 ml). The combined organic layers were washed with brine (5 
ml), dried over MgSO4, filtered and evaporated to give 240 (0.270 g, 93%) (E:Z, 5:1) as a 
yellow oil. 
 
Rf 0.72 (light petroleum/diethyl ether 1:1); δH (200 MHz, CDCl3): 0.00 (6H, s, SiMe2), 0.79 
(9H, s, CMe3), 2.78 (3H, s, SO2Me), 3.11 (3H, s, OMe), 3.58-3.66 (2H, m, C5-H), 3.75-3.83 
(1H, m, C3-H), 4.16-4.49 (7H, 2 x OCH2Ph, OCH2O, C4-H), 4.72-4.89 (1H, m, C2-H), 6.92 
(1H, d, J =5.11, Z-isomer C1-H), 7.08-7.22 (10H, m, Ph), 7.32 (1H, d, J =7.36, E-isomer H-
1); δc (50 MHz): (E-isomer) -7.9 (2 x CH3), 18.5 (CMe3), 26.4 (3 x CH3), 38.7 (SCH3), 56.6 
(OCH3), 68.9 (C-5), 73.6 (CH), 73.80 (OCH2), 75.5 (OCH2), 79.1 (CH), 81.2 (CH) 94.7 
(OCH2O), 128.3, 128.3, 128.5 128.7 & 128.9 (CHar), 137.6 & 137.7 (C), 152.62 (CH-1); IR 
νmax 3031.8, 2930.5, 2888.3, 1497.2, 1471.8, 1454.8, 1361.1, 1252.2, 1176.7, 1099.9, 1028.4, 
924.4, 838.2, 818.5, 794.2 cm-1.   
 
5-O-tert-Butyldiphenylsilyl-D-arabinofuranose (248)
137 
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D-Arabinose (7.67 g, 51.06 mmol) was added to a solution of tert-butyldiphenylsilyl chloride 
(13.65 g, 49.65 mmol) and imidazole (6.78 g, 99.59 mmol) in dry DMF (105 mL). The 
suspension was heated to 60 ºC and stirred for 2 h. The reaction mixture was then cooled to 
ambient temperature then poured into  aqueous HCl solution (1M, 225 mL) and extracted 
with DCM (150 mL). The organic phase was washed with water (75 mL), saturated sodium 
bicarbonate (75 mL) and brine (75 mL). The organic layer was dried over MgSO4, filtered 
and evaporated to give a yellow oil. The crude oil was purified by flash chromatography (3:2 
light petroleum:EtOAc) to give the silylated product 248 (10.90 g, 55%) (3:1, α:β) as a 
viscous pale yellow oil.  
 
Rf 0.10 (3:2 Light petroleum:EtOAc); δH (200 MHz): 1.03 (9H, s, α-anomer CMe3), 1.05 
(9H, s, β-anomer, CMe3), 3.66-4.35 (2x 7H, m, C2-H, C3-H, C4-H, C5-H and 2x -OH), 5.34 
(1H, dd, J = 8.7, 4.2, β-anomer, C1-H), 5.43 (1H, pseudo d, J = 4.6, α-anomer C1-H), 7.32-
7.46 (2x 6H, m, CHar), 7.62-7.74 (2x 4H, m, CHar); δC (50 MHz): 18.9 (α-anomer CSi), 19.0 
(β-anomer CSi), 26.6 (α-anomer CMe3), 26.7 (β-anomer CMe3), 64.0 (α-anomer C-5), 64.5 
(β-anomer C-5), 78.0 (CH), 78. 8 (CH), 82.9 (β-anomer C-2), 86.9 (α-anomer C-2), 96.8 (β-
anomer C-1), 103.4 (α-anomer C-1), 127.8, 130.0 & 130.1 (CHar), 131.6 & 131.8 (α-anomer 
C), 132.0 & 132.2(β-anomer C), 135.5 & 135.5 (CHar); IR υmax 3400.3 (br. OH), 3072.3, 
2931.7, 2858.5, 1659.9, 1428, 1113.2, 1069.4, 702.7 cm-1. 
 
5-O-(tert-Butyldiphenylsilyl)-1,2-O-isopropylidene-β-D-arabino-furanose (249)
136
 
 
 
 
Anhydrous copper (II) sulfate (7.97 g, 49.93 mmol) and sulfuric acid (sp. gr. 1.84, 0.36 mL, 
6.40 mmol) were added to a solution of 248 (7.02 g, 18.07 mmol) in anhydrous acetone (80 
mL). After stirring for 17 h at ambient temperature, the blue reaction mixture was filtered 
and neutralised with ammonia gas. The precipitated ammonium sulfate was filtered off and 
the filtrate was concentrated to dryness. The product was purified by flash chromatography 
(4:1 light petroleum:EtOAc) to give the acetal 249 (2.93 g, 38%) as a yellow oil.  
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Rf 0.32 (4:1 Light petroleum:EtOAc); δH (200 MHz): 1.06 (9H, s, CMe3), 1.28 & 1.32 (2x 
3H, 2s, CMe2), 2.04 (1H, s, OH), 3.81 (2H, d, J = 6.6, C5-H), 4.01 (1H, dd, J = 6.6, 2.5, C4-
H), 4.40-4.45 (1H, m, C3-H), 4.53 (1H, d, J = 4.1, C2-H), 5.87 (1H, d, J =4.1, C1-H), 7.32-
7.45 (6H, m, CHar), 7.62-7.70 (4H, m, CHar); δC (50 MHz): 19.1 (C-Si), 26.0 and 26.7 
(CMe2), 63.5 (CH2), 76.2 (C-4), 86.9 (C-3), 87.3 (C-2), 105.5 (C-1), 112.4 (CMe2), 127.7 
(CH), 129.7 (CH), 133.0 (C), 135.5 (CH); IR υmax 3452.2 (br. OH), 3071.9, 2932.8, 2858.3, 
1428.1, 1113.6, 1066, 1018.5, 702.7 cm-1. 
 
1,2-O-Isopropylidene-β-D-arabinofuranose (250)
136 
 
 
 
To a solution of 249 (2.88 g, 6.72 mmol) in dry THF (120 mL) was added tetra-n-
butylammonium fluoride in THF (1M, 13.44 mL, 13.44 mmol). The reaction mixture was 
stirred for 1 h at ambient temperature, then evaporated to give a brown oil. The crude residue 
was purified by flash chromatography (100% EtOAc) to give the diol 250 (0.94 g, 75%) as 
an off-white crystalline solid.  
 
Rf 0.34 (100% EtOAc); m.p.: 113-116 ºC (no lit. m.p given); δH (200 MHz, CD3OD): 1.30 & 
1.48 (2x 3H, 2s, CMe2), 3.68 (2H, d, J =6.8, C5-H), 3.97 (1H, dt, J4 = 6.6, 2.5, C4-H), 4.13 
(1H, d, J =2.1, C3-H), 4.50 (1H, d,  J= 4.2, C2-H), 5.87 (1H, d, J= 4.2, C1-H); δC (50 MHz, 
CD3OD): 26.3 (CH3), 27.2 (CH3), 63.5 (C-5), 76.6 (CH), 88.4 (CH), 89.9 (CH), 107.2 (C-1), 
113.5 (C); IR υmax 3391.7 (br. OH), 2940.2, 1378.4, 1213.6, 1163.3, 1066.1, 1015.1 cm-1. 
 
3,5-Di-O-benzyl-1,2-O-isopropylidene-β-D-arabinofuranose (251)
136
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To an ice cold solution of 250 (5.52g, 31.52 mmol) in DMF (100 mL) was added NaH in 
mineral oil (60% w/w, 3.64 g, 91.0 mmol). The mixture was stirred for 15 min, allowed to 
warm to ambient temperature and stirred for a further 15 min. Tetrabutylammonium iodide 
(11.2 g, 30.32 mmol) was added, followed by benzyl bromide (10 mL, 84.18 mmol) and the 
mixture was stirred for 4 h. The reaction was quenched with MeOH (4 mL), reduced in vacuo 
and the resultant residue was dissolved in EtOAc (20 mL). The organic solution was washed 
with brine (20 mL), dried over Na2SO4, filtered and concentrated. The residue was purified 
by flash chromatography (8:1 light petroleum:EtOAc) to give the dibenzyl ether 251 (7.2 g, 
62%) as a colourless oil. 
 
Rf 0.32 (8:1 Light petroleum:EtOAc); δH (200 MHz): 1.33 & 1.43 (2x 3H, 2s, CMe2), 3.64 
(2H, d, J 6.2, C5-H), 4.03 (1H, d, J = 3.3, C3-H), 4.27 (1H, dt, J = 6.2, 2.9, C4-H), 4.54 (1H, 
d, J = 12.0, OCH2Ph), 4.56 (1H, d, J = 11.6, OCH2Ph), 4.60 (1H, d, J = 12.0, OCH2Ph), 4.63 
(1H, d, J = 11.6, OCH2Ph), 4.63 (1H, d, J = 3.7, C2-H), 5.90 (1H, d, J = 3.7, C1-H), 7.22-
7.37 (10H, m, Ph); δC (50 MHz): 26.2 (CH3), 26.9 (CH3), 69.9 (C-5), 71.5 (CH2), 73.2 (CH2), 
82.9 (CH), 83.5 (CH), 85.1 (CH), 105.6 (C-1), 112.6 (O-C-O), 127.6, 127.6, 127.8, 128.3 & 
128.4 (CHar), 137.2 & 137.9 (C); IR υmax 3063.9, 3031.1, 2937.3, 2865.3, 1454.3, 1374.1, 
1211.5, 1098.5, 1072.6, 1027.2, 737.9, 698.3 cm-1. 
 
3,5-Di-O-benzyl-D-arabinofuranose (252)
136
 
 
 
 
A solution of the isopropylidene derivative 251 (6.60 g, 17.83 mmol) in acetic acid-water 
(1:1, 50 mL) was heated at 60 ºC for 5 h. The reaction mixture was cooled to ambient 
temperature, diluted with water (125 mL), and extracted with DCM (2 x 125 mL). The 
combined organic layers were washed with saturated sodium bicarbonate (125 mL) and brine 
(125 mL), dried over Na2SO4, filtered and concentrated in vacuo to give the diol 252 (5.38 g, 
92%) (1:1, α:β) as a colourless syrup.  
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Rf 0.56 (1:1 Light petroleum:EtOAc); δH (200 MHz): 3.38-3.65 (2H, m, C5-H), 3.83-4.11 
(4H, m, C2-H, C3-H, 2x OH), 4.30-4.60 (1H, m, C4-H), 4.37-4.65 (4H, m, OCH2Ph), 5.24 
(α-anomer, s, C1-H),  5.30 (β-anomer, d, J = 3.3, C1-H), 7.15-7.33 (10H, m, Ph); δC (50 
MHz): 69.1 & 69.9 (α and β CH2), 71.4 & 71.8 (α and β CH2), 73.5 (CH2), 75.4 & 76.2 (α 
and β CH), 80.7, 82.9, 83.2 & 84.2 (α and β 2x CH), 97.3 (β-anomer C-1), 103.6 (α-anomer 
C-1), 127.3, 127.5, 127.8, 128.0 & 128.2 (CHar), 136.1, 136.1, 136.3 & 137.1 (C); IR υmax 
3401.6 (br. OH), 3063.7, 2925.8, 2867.9, 1454.3, 1364.1, 1272.3, 1208.8, 1072.4, 1027.7, 
738, 698.2 cm-1. 
 
3,5-Di-O-benzyl-D-arabinono-1,4-lactone (253)
136 
 
 
 
To an ice cold solution of 252 (3.90 mg, 12 mmol) in THF-water (1:3, 200 mL), was added 
barium carbonate (39 g, 19 mmol) and bromine (8 mL, 16 mmol). The reaction mixture was 
allowed to warm to ambient temperature and was left stirring overnight. The mixture was 
filtered through Celite® and the filtrate was reduced under pressure. The residue was purified 
via flash chromatography (7:3 light petroleum:EtOAc) to give the lactone 253 (3.34 g, 85%) 
as a white solid.  
 
Rf 0.36 (7:3 Light petroleum:EtOAc); m.p.: 83-85 ºC; δH (200 MHz): 3.28 (1H, br. s, OH), 
3.53 (1H, dd, J = 11.6, 3.7, H-5a), 3.69 (1H, dd, J  =11.6, 2.5, C5-Hb), 4.16 (1H, t, J3,2 = 6.6, 
C3-H), 4.34 (1H, ddd, J= 6.6, 3.7, 2.5, C4-H), 4.43 (1H, d, J =12.0, OCH2Ph), 4.44 (1H, dd, 
J = 6.6, C2-H) 4.50 (1H, d, J = 12.0, OCH2Ph), 4.52 (1H, J = 11.6, OCH2Ph), 4.72 (1H, J = 
11.6, OCH2Ph), 7.17-7.32 (10H, m, Ph); δC (50 MHz): 67.9 (C-5), 72.5 (CH2), 73.7 (CH2), 
74.3 (C-4), 79.8 (C-3), 80.2 (C-2), 127.9, 128.1, 128.2 & 128.6 (CHar), 137.1 (C), 137.2 (C), 
174.6 (C=O); IR υmax 3446.4 (br. OH), 3031, 2866.4, 1771.3, 1653.9, 1453.9, 1318.2, 1127.6, 
1026.6, 762.6, 737, 698.1 cm-1. 
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3,5-Di-O-benzyl-2-O-methoxymethyl-D-arabinono-1,4-lactone (254)
136
 
 
 
 
To a solution of 253 (3.00 g, 8.8 mmol) in dry chloroform (200 mL) at ambint temperature 
was added dimethoxymethane (40 mL, 440 mmol) and phosphorus pentoxide (184 g, 52.8 
mmol). After stirring for 30 min, the mixture was decanted and the filtrate poured into an ice-
cold saturated sodium bicarbonate solution (160 mL). The mixture was extracted with 
chloroform (2 x 30 mL), and the combined organic layers were washed with brine (50 mL), 
dried over Na2SO4, and evaporated to give the product 254 (3.20 g, 92%) as a colourless oil.  
 
Rf 0.69 (1:1 Light petroleum:EtOAc); [α]D +23.88 (c 0.49 CHCl3); δH (200 MHz): 3.47 (3H, 
s, OMe), 3.56 (1H, dd, J = 11.2, 3.7, C5-Ha), 3.71 (1H, dd, J =11.2, 2.9, C5-Hb), 4.29-4.37 
(2H, m, C2-H& C3-H), 4.49-4.77 (5H, m, C4-H & OCH2Ph), 4.75 (1H, d, J =6.6, OCH2O), 
5.09 (1H, d, J  =6.6, OCH2O), 7.18-7.37 (10H, m, Ph); δC (50 MHz): 55.9 (OCH3), 67.6 (C-
5), 72.6 (CH2), 73.2 (CH2), 76.1 (CH), 78.7 (CH), 79.1 (CH), 95.7 (OCH2O), 127.4, 127.6, 
127.9, 128.2 & 128.2 (CHar), 126.9 (C), 137.1 (C), 171.8 (C=O); IR υmax 2899.3, 1791.8, 
1454.9, 1211.6, 1151.4, 1123.7, 1026.4, 739.4, 689.6 cm-1. 
 
3,5-Di-O-benzyl-2-O-methoxymethyl-D-arabinofuranose (255)
136
 
 
 
 
Lactone 254 (2.52 g, 9 mmol) was dissolved in anhydrous THF (120 mL) and cooled to -78 
ºC. DIBAL (1M solution in toluene, 10.2 mL, 10.2 mmol) was slowly added and the reaction 
mixture was stirred for 20 min. The reaction was then quenched by the careful addition of 
ammonium chloride (60 mL). The mixture was filtered through Celite®, washed well with 
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DCM and then reduced under vacuum to give 255 as a 1:1 mixture of α:β anomers (2.57 g, 
98%). 
 
Rf 0.43 (1:1 Light petroleum:EtOAc); δH (200 MHz): 3.26 & 3.35 (3H, 2 s, OMe), 3.38-3.57 
(2H, m, C5-H), 3.66-3.85 (1H, m, CH), 3.97-4.12 (2H, m, 2x CH), 4.35-4.68 (6H, m, 2 x 
OCH2Ph & OCH2O), 5.17-5.32 (1H, m, C1-H); δC (50 MHz): 55.7 & 55.9 (α and β OCH3), 
70.0 & 70.2 (α and β C-5), 71.9, 72.2, 73.3 & 73.5 (α and β 2x CH2), 80.2, 81.5, 82.2, 82.6, 
82.8 & 83.9 (α and β 3x CH), 95.8 (β-anomer C-1), 96.4 & 96.5 (α and β OCH2O), 101.6 (α-
anomer C-1), 127.7, 127.9, 128.3, 128.5 & 128.5 (CHar), 137.3 & 137.8 (C); IR υmax 3413.9 
(br. OH), 2926.7, 1453.8, 1366, 1151.9, 1104.7, 1035.2, 738.3, 698.2 cm-1. 
 
3,5-Di-O-benzyl-2-O-methoxymethyl-D-arabinose-O-(tert-butyldimethylsilyl)oxime 
(256)
136
 
 
 
 
To a solution of Lactol 255 (2.5 g, 6.68 mmol) in dry toluene (35 mL) was added MgSO4  
(1g). The suspension was stirred at reflux for 5 minutes then tert-butyldimethylsilyl 
hydroxylamine (1.84 g, 12.51 mmol) was added. The reaction mixture was allowed to heat at 
reflux for 30 minutes then cooled to ambient temperature and filtered. The filtrate was 
washed with saturated sodium bicarbonate (25 mL) and brine (30 mL), dried over MgSO4 
then filtered. The filtrate was concentrated to give an oily residue. Purification by column 
chromatography (light petroleum:EtOAc 7:3) yielded silyl oxime 256 (2.41 g, 72%) (E:Z, 
2:1) as a yellow/green oil. 
 
Rf 0.42 (light petroleum:EtOAc 1:1); δH (200 MHz, CDCl3): δH (200 MHz): 0.11 (6H, SiMe3, 
E-isomer), 0.13 (6H, SiMe3, E-isomer), 0.81 (9H, s, Z-isomer, 3x CH3), 0.85 (9H, s, E-
isomer, 3x CH3), 2.05 (1H, d, J = 6.6, Z-isomer, OH), 2.13 (1H, d, J = 5.8, E-isomer, OH), 
3.27 (3H, s, E-isomer, OMe), 3.29 (3H, s, Z-isomer, OMe), 3.56-3.67 (2x 2H, m, C5-H), 3.68 
(1H, dd, J = 6.6, 3.3, E-isomer, C3-H), 3.89-3.95 (2x 1H, m, C4-H), 4.29-4.42 (2x 1H, m, Z-
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isomer C3-H and E-isomer C2-H), 4.43-4.63 (2x 4H, m, OCH2Ph), 5.15 (1H, dd, J = 5.8, 2.5, 
Z-isomer, C2-H), 7.11 (1H, d, Z-isomer, H-1), 7.14-7.29 (2x 10H, m, Ph), 7.45 (1H, d, E-
isomer, H-1); δC (50 MHz): 25.4 (CMe3, Z-isomer), 25.5 (CMe3, Z-isomer), 55.5 (OCH3) 
68.9 (C-4), 69.9, 70.8, 73.3 & 74.0 (CH2), 75.9 (CH), 79.9 (CH), 94.6 & 96.1 (2 x OCH2O E-
and Z-isomers), 125-140 (CHar), 154.1 (C-1); IR νmax 3352.8 (br. OH), 3069.2, 3030.6, 
2935.3, 2854.5, 1428.9, 1113.7 1069,4, 920.5, 732.4, 701.1 cm-1. 
 
(2R,3S,4S,E)-3,5-Bis(benzyloxy)-4-iodo-2-(methoxymethoxy)pentanal O-tert- 
butyldimethylsilyl oxime (257)
136
 
 
 
 
A suspension of alcohol 256 (2.20 g, 4.35 mmol), triphenylphosphine (4.57 g, 19.85 mmol), 
imidazole (1.18 g, 17.41 mmol) and iodine (3.32 g, 13.06 mmol) in toluene (175 mL) was 
heated at reflux for 1.5 h. The dark brown reaction mixture was then cooled to 0 ºC. Sodium 
bicarbonate (175 mL) was added and the mixture was stirred for 10 min until the organic 
layer became yellow. Excess iodine was added in small portions until the colour of the 
organic layer became burgundy. This excess iodine was then removed via the addition of 
saturated sodium thiosulfate until the organic layer retained its original yellow colour. The 
two phases were then separated and the organic layer was washed with water (50mL). The 
combined organic layers were evaporated and the resultant oil was dissolved in diethyl ether. 
The crystalline triphenylphosphine oxide was filtered off and the filtrate was concentrated in 
vacuo to give an oil. The crude residue was purified by flash chromatography (light 
petroleum:EtOAc 8:2) to afford product 257 (2.94 g, 88%) (E:Z, 7:3) as a pale yellow oil. 
With careful chromatography the two isomers were separated as pale oils, with the E-isomer 
eluting first. 
 
E-isomer 
Rf 0.49 E-isomer (8:1 Light petroleum:EtOAc); δH (200 MHz): 0.3 (6H, s, SiMe2), 1.18 (9H, 
s, SiMe3), 3.41 (OCH3), 3.61 (1H, dd, J = 7.5, 2.9, C3-H), 3.79-3.91 (2H, m, C5-2H), 4.22-
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4.28 (2H, m, C4-H and C2-H), 4.45 (2H, s, OCH2Ph), 4.51-4.71 (2H, m, OCH2Ph), 5.45 (2H, 
s, OCH2O), 7.19-7.46 (10H, m, Ph), 7.63 (1H, d, J = 8.2, C1-H); δC (50 MHz): 18.5 (SiC), 
26.5 (SiMe3), 31.7 (CH), 56.1 (0CH3), 72.9 (CH2), 73.1 (CH2), 75.1 (CH2), 78.1 (CH), 78.8 
(CH), 95.5 (OCH2O), 125.2, 127.6, 127.7, 127.9, 128.2, 128.4, 128.9 & 129.7 (CHar), 133.0 
(C), 133.2 (C), 135.5 (CHar), 137.4, 137.6 & 138.3 (C), 151.9 (C-1); IR υmax 3069.8, 3030.6, 
2930.8, 2857.8, 1428, 1115, 1071.7, 922, 739.3, 699.1 cm-1. 
 
Z-isomer 
Rf 0.44 Z-isomer (8:1 Light petroleum:EtOAc); δH (200 MHz): 0.13 (6H, s, SiMe2), 0.88 
(9H, s, SiMe3), 3.21 (OCH3), 3.45 (1H, dd, J = 7.5, 2.9, C3-H), 3.62-371 (2H, m, C5-H2), 
3.87 (1H, t, J = 5.0, C3-H), 4.20-4.30 (1H, m, C4-H), 4.39-4.61 (2H, m, OCH2Ph), 4.71- 4.75 
(2H, m, OCH2Ph), 5.26 (1H, m, C2-H), 7.07 (1H, d, J = 6.2, C1-H), 7.36-7.44 (10H, m, Ph); 
δC (50 MHz): 18.1 (SiC), 26.1 (SiMe3), 31.4 (C4-H), 56.1 (0CH3), 72.6 (CH2), 74.7 (CH2), 
74.8 (CH2), 78.4 (CH), 78.5 (CH), 95.5 (OCH2O), 125.2, 127.6, 127.7, 127.9, 128.2, 128.4, 
128.9 & 129.7 (CHar), 133.04 (C), 133.24 (C), 135.49 (CHar), 137.40, 137.55 & 138.25 (C), 
154.1 (C-1); IR υmax 3069.8, 3030.6, 2930.8, 2857.8, 1428, 1115, 1071.7, 922, 739.3, 699.1 
cm-1. 
 
(3R,4R,5R)-3-Methoxymethyl-4-benzyloxy-5-benzyloxymethyl-∆-pyrroline-N-Oxide 
(179)
113
 
 
Method 1: 
 
 
To a solution of 240 (0.25 g, 0.43 mmol) in dry toluene (8 mL) was added 
tetrabutylammonium fluoride solution in THF (1M, 0.65 mL, 0.65 mmol). The mixture was 
heated at reflux and held for 30 min then cooled to ambient temperature. Concentration in 
vacuo produced a brown residue (300 mg) which was purified by flash chromatography 
(EtOAc) to give nitrone 179 as a brown oil (0.135 g, 84%). 
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Method 2: 
To a solution of 240 (715 mg, 1.23 mmol) in dry THF (50 mL) was added 
tertbutylammonium triphenyldifluorosilicate (TBAT) (682 mg, 1.23 mmol). The mixture was 
heated and held at reflux for 7 min then concentrated in vacuo to give a brown residue. The 
residue was purified by flash chromatography (EtOAc) to give nitrone 179 as a brown oil 
(137 mg, 30 %). 
 
Method 3: 
 
To a solution of 257 (528 mg, 0.86 mmol) in dry THF (25 mL) was added 
tetrabutylammonium fluoride 1M solution in THF (1.3 mL, 1.3 mmol). The mixture was 
refluxed for 10 minutes, cooled to ambient temperature then concentrated in vacuo to give a 
brown residue. The residue was purified by flash chromatography (EtOAc) to give nitrone 
179 as a brown oil (83 %). 
 
Rf 0.15 (light petroleum/ethyl acetate 1:1); δH (200 MHz, CDCl3): 3.28 (3H, s, OMe), 3.65 
(1H, dd, J = 2.22, 9.71, C5’-Ha), 3.94 (1H, m, C5’-Hb), 4.23-4.54 (7H, m, 2 x PhCH2O, C3-
H, C4-H& C5-H), 6.91 (d, J = 1.92, C2-H), 7.19-7.31 (10H, m, Ph); δc (50 MHz): 55.3 
(OCH3), 65.3 (CH2), 71.5 (CH2), 72.9 (CH2), 76.7 (CH), 80.3 (CH), 81.4 (CH), 95.9 
(OCH2O), 127.2, 127.3, 127.4, 127.6, 127.9 & 128.1 (CHar), 133.34 (CH-1), 136.68 & 
137.23 (C); LRMS (ES): 372.2, 242.2, 102.0; HRMS (ES):372.1806 [(M+H)+; C21H26NO5 
requires 372.1805]. 
 
 (2R,3aR,4R,5R,6R)-5-(benzyloxy)-6-(benzyloxymethyl)-4-(methoxymethoxy)-N,N-
dimethylhexahydropyrrolo[1,2-b]isoxazole-2-carboxamide (267) 
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To a solution of nitrone 179 (1.50 g, 4.04 mmol) in DCM (29 mL) was added N, N-
Dimethyacrylamide (0.43 mL, 4.04 mmol). The mixture was stirred at ambient temperature 
overnight then concentrated in vacuo producing a brown residue. Purification by flash 
chromatography (EtOAc) yielded a isoxazole 267 as a brown oil (2.21 g, 100 %). 
Rf 0.33 (ethyl acetate); δH (400 MHz, CDCl3): 2.33 (1H, m, C3-H), 2.92(3H, s, NCH3), 2.93-
3.02 (1H, m, C3’-H), 3.03 (3H, s, NCH3), 3.30-3.33 (1H, m, C6-H), 3.34 (3H, s, OCH3), 
3.58-3.63 and 3.68-3.73 (2 x 1H, m, C7-CH2), 3.75-3.80 (1H, m, C3a-H), 3.95-3.97 (1H, dd, 
J = 3.9, 2.2, C5-H), 4.09-4.11 (1H, t, J = 3.9, C4-H), 4.54-4.61 (4H, m, 2 x OCH2Ph), 4.62 
(2H, s, OCH2O), 4.82 (1H, t, J = 7.1,  C2-H), 7.19-7.31 (10H, m, Ph); δc (100 MHz): 35.8 
(NCH3), 35.9 (CH2--3), 36.9 (NCH3), 55.6 (OCH3), 68.8 (CH-3a), 69.98 (CH-6CH2), 70.0 
(CH-6), 72.3 (OCH2Ph), 73.3 (OCH2Ph), 74.5 (CH-2), 83.9 (CH-5), 84.7 (CH-4), 95.8 
(OCH2O), 127.5 (CH-Ar), 127.7 (CH-Ar), 127.7 (CH-Ar), 128.2 (CH-Ar), 128.2 (CH-Ar), 
128.3 (CH-Ar), 137.8 (CH-Ar), 137.8 (C-Ar), 138.2 (C-Ar), 168.3 (C=O); IR νmax 3362.3, 
3030.8, 2931.6, 2867.8, 1645.7 (C=O), 1496.7, 1453.9, 1403.0, 1361.5, 1260.2, 1102.1, 
1028.4, 912.1, 800.1, 738.9, 699.2 cm-1; LRMS (ES): 439.1, 425.4, 398.2, 371.5, 354.3, 
349.2, 327.8, 310.3; HRMS (ES):  471.2484 [(M+H)+;  C26H35N2O6 requires 471.2490]. 
 
(1R,2R,3R,6R,7aR)-2-(Benzyloxy)-3-(benzyloxymethyl)-6-hydroxy-1-(methoxymethoxy)-
hexahydropyrrolizin-5-one (268) 
 
 
 
To compound 267 (1.8 g, 3.83 mmol) was added 10M AcOH (12 mL, 120 mmol) and Zinc 
dust (6.00 g, 91.22 mmol). The mixture was stirred at 80 °C for 3 hrs and then the pH was 
adjusted to 14 using aqueous NaOH. The product was extracted into DCM (2x 10ml) and the 
combined organic layers were dried over MgSO4, filtered and concentrated. Purification by 
column chromatography (EtOAc) yielded 268 a white solid (0.793 g, 57 %). The solid was 
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recrystalised form heptanes and ethyl acetate to provide crystals for x-ray crystallography 
analysis. 
 
Rf 0.46 (ethyl acetate); m.p 135-138 °C; δH (400 MHz, CDCl3): 1.91 (1H, ddd, J 12.5, 10.3, 
8.5, C7-H), 2.85 (1H, ddd, J 12.5, 7.8, 6.1, C7’-H), 3.19 (1H, br s, OH), 3.37 (3H, s, OCH3), 
3.53, (1H, dd, J = 9.9, 3.9, C3-CH2-Ha’), 3.66 (1H, dd, J = 9.9, 3.9, C3-CH2-Hb’), 3.82-3.87 
(1H, m, C7a -H), 3.83 (1H, dd, J = 7.1, 5.5, C1-H), 4.09 (1H, dd, J = 9.1, 4.7, C3-H), 4.34 
(1H, t, J = 4.9, C2-H), 4.54-4.59 (3H, m, OCH2Ph, C6-H), 4.62-4.65 (2H, m, C5-
CH2OCH2Ph), 4.67 (2H, m, OCH2O), 7.28-7.42 (10H, m, Ph); δc (100 MHz): 36.9 (CH2-7), 
55.6 (OCH3), 58.2 (CH-3), 59.6 (CH-7a), 68.7 (C3-CH2), 71.8 (CH-6), 72.5 (OCH2Ph), 72.6 
(OCH2Ph), 85.6 (CH-2), 87.7 (CH-1), 96.6 (OCH2O), 127.6, 127.6, 127.7, 127.8, 128.4 & 
128.4 (CHAr), 137.8 & 137.9 (Car), 174.2 (C=O); IR νmax 3350.5, 3030.6, 2892.3, 1675.9, 
1458.6, 1360.5, 1319.1, 1213.1, 1128.8, 1041.0, 911.8, 733.8, 696.7, 604.0 cm-1; LRMS 
(ES): 428.4, 412.4, 338.3, 91.2;  HRMS (ES)  428.2070 [(M+H)+;  C24H30NO6 requires 
428.2068]; Anal. Calcd for C24H29NO6: C, 67.43; H, 6.84; N, 3.28. Found: C, 67.38; H, 6.82; 
N, 3.21. 
 
(1R,2R,3R,6R,7aR)-2-(Benzyloxy)-3-(benzyloxymethyl)-1-(methoxymethoxy)-5-oxo-
hexahydro-7H-pyrrolizin-6-yl methanesulfonate (269) 
 
 
 
268 (0.76 g, 1.77 mmol) was dissolved in DCM (10 mL) and stirred at 0 °C under an argon 
atmosphere. Triethylamine (0.44 mL, 3.88 mmol), and methanesulfonyl chloride (2 mL, 3.00 
mmol) were added successively. The mixture was stirred for 30 min and water (5 mL) was 
added and the layers separated. The aqueous layer was extracted with DCM (2 x 10ml) and 
the combined organic layers were washed with brine (10ml), dried over MgSO4, filtered and 
evaporated to give mesylate 269 (0.270 g, 100 %). 
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Rf 0.33 (ethyl acetate); δH (400 MHz, CDCl3): 2.12 (1H, m, C7-H), 2.97 (1H, ddd, J = 13.0, 
8.3, 6.2, C7’-H), 3.31 (3H, s, CH3SO3), 3.37 (3H, s, OCH3), 3.52, (1H, dd, J  = 10.0, 3.7, C3-
CH2-Ha’), 3.67, (1H, dd, J  = 9.9, 4.6, CH-3CH2-Hb’), 3.72 (1H, dd, J = 7.7, 6.3, C7a-H), 3.81 
(1H, dd, J  = 7.4, 5,6, C1-H), 4.07 (1H, dd, J = 8.6, 4.4, C3-H), 4.36 (1H, t, J = 4.9, C2-H), 
4.54-4.62 (2H, m, OCH2Ph), 4.64-4.66 (2H, m, CH2OCH2Ph), 4.67-71 (2H, m, OCH2O), 
5.40 (1H, dd, J  9.8, 8.6), 7.28-7.42 (10H, m, Ph); δc (100 MHz): 34.6 (CH2-7), 39.8 
(SO2CH3), 55.6 (OCH3), 58.4 (CH-3), 59.4 (CH-7a), 68.4 (C3-CH2), 72.6 (OCH2Ph), 73.2 
(OCH2Ph), 78.5 (CH-6), 85.4 (CH-2), 87.9 (CH-1), 96.7 (OCH2O), 127.5, 127.6, 127.7, 
127.71, 127.8, 128.84 & 128.9 (CHAr), 137.6 & 137.7 (Car), 167.9 (C=O); IR νmax 3030.0, 
2936.6, 1713.9, 1496.1, 1358.9, 1271.4, 1176.1, 1046.0, 844.9, 737.0, 699.2, cm-1; LRMS 
(ES): 506.4, 412.4, 322.3, 134.1, 108.2; HRMS (ES): 506.1848 [(M+H)+;  C25H32NO8S 
requires 506.1843]. Anal. Calcd for C25H31NO8S: C, 59.39; H, 6.18; N, 2.77. Found: C, 
59.31; H, 6.15; N, 2.68. 
 
(1R,2R,3R,6R,7aR)-2-(Benzyloxy)-3-(benzyloxymethyl)-1-hydroxy-5-oxo-hexahydro-7H-
pyrrolizin-6-yl methanesulfonate (270) 
 
 
 
To a solution of 269 (100 mg, 0.198 mmol) in DCM (2.5 mL) was added TFA (0.2 mL). The 
reaction mixture was stirred at ambient temperature for 48 hours. The mixture was washed 
with sodium bicarbonate (2 mL) and extracted with DCM (3 x 3 mL). The Organic phase 
was dried over MgSO4, filtered and the filtrate concentrated. Purification by column 
chromatography (petrol/EtOAc 1:1) yielded 270 (78 mg, 86 %) as a yellow oil.  
 
Rf 0.20 (heptane:ethyl acetate, 1:1); δH (400 MHz, CDCl3): 2.07 (1H, m, C7-H), 2.95 (1H, m, 
C7’-H), 3.26 (3H, s, SO2CH3), 3.64 (1H, dd, t, J  = 10.0, 2.8, C3CH2-Ha), 3.68 (1H, dd, J  5.6, 
3.3, C7a-H),  3.72 (1H, dd, t, J = 10.0, 3.5, C3CH2-Hb), 3.97 (1H, t, J = 3.7, C1-H), 4.10 (1H, 
t, J = 3.1, C2-H), 4.23 (1H, q, J = 3.0, C3-H), 4.54-4.58 (2H, m, OCH2Ph), 4.59-4.63 (2H, d, 
J = 4.9, OCH2Ph), 5.42 (1H, dd, J = 10.4, 8.0, C6-H), 7.32 (10H, m, Ph); δc (100 MHz): 34.9 
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(CH2-7), 39.8 (SO2CH3), 59.7 (CH-3), 62.8 (CH-7a), 70.0 (C3-CH2), 71.9 (OCH2Ph), 73.8 
(OCH2Ph), 78.2 (CH-6), 80.9 (CH-1), 87.6 (CH-2), 127.7, 127.8, 127.9, 128.0, 128.3, 128.5, 
128.6 & 128.6 (CHAr), 136.7 & 137.3 (Car), 169.46 (C=O); HRMS (ES): 462.1584 [(M+H)+;  
C23H28NO7S requires 462.1581]. Anal. Calcd for C23H28NO7S: C, 59.85; H, 5.90; N, 3.03. 
Found: C, 59.31; H, 5.79; N, 2.97. 
 
Attempted preparation of (2R,3R,6R,7aR)-2-(Benzyloxy)-3-(benzyloxymethyl)-1,5-
dioxo-hexahydro-7H-pyrrolizin-6-yl methanesulfonate (271) 
 
 
 
Method 1: Dess-Martin Periodinane Oxidation 
270 (50 mg, 0.11 mmol) and Dess – Martin periodinane in DCM (15 % w/w, 70 mg, .25 
mmol) were stirred in DCM (2 mL) at ambient temperature. The reaction progress was 
mnitored by TLC (petrol/EtOAC 1:1) and on completion was diluted with ether (3 mL).  A 
mixture of Na2S2O3 and Sodium bicarbonate was added and the mixture stirred until 
homogeneous and the products isolated by extraction with DCM (2 x 5 mL). TLC and Crude 
NMR showed no reaction had taken place after 18 hours. (0 mg, 0 %). 
 
Method 2: Swern Oxidation 
To a stirred solution of 2M oxalyl chloride (33 µL, 0.38 mmol) in anhydrous DCM (3 mL) 
was added DMSO (52 µL, 0.74 mmol) dropwise under a nitrogen atmosphere and the 
mixture stirred for 30 mins. A solution of 270 (1.5 mg, 0.32 mmol) in DCM (2 mL) was 
added and the reaction stirred at -78 °C for 1 h. TEA (134 µL, 0.96 mmol) was added and the 
reaction stirred until it reached ambient temperature then water (5 mL) was added. The 
product was extracted with DCM (5 mL), washed with brine (5 mL) and concentrated. TLC 
and Crude NMR showed no reaction had taken place after 18 hours. (0 mg, 0 %).  
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Attempted preparation of (1S,2R,3R,6R,7aR)-2-(Benzyloxy)-3-(benzyloxymethyl)-6-
(methylsulfonyloxy)-5-oxohexahydro-1H-pyrrolizin-1-yl benzoate (272) 
 
 
 
A solution of alcohol 271 (50 mg, 0.11 mmol) in PPh3 (83 mg, 0.32 mmol) and benzoic acid 
(15 mg, 0.13 mmol), in dry THF (4 mL) was stirred at 0 °C under an atmosphere of nitrogen. 
DEAD (50 µL, 0.32 mmol) was added dropwise and the mixture stirred at 0 °C for 1 h, 
allowed to warm to ambient temperature then stirred overnight. The solvents were 
evaporated under reduced pressure to give an orange oil. No reaction was observed from 
NMR and TLC analysis of the crude product. 
 
(1R,2R,3R,7aR)-2-(Benzyloxy)-3-(benzyloxymethyl)-1-(methoxymethoxy)hexahydro-
1H-pyrrolizine (275) 
 
 
 
To a solution of amide 269 (450 mg, 0.89 mmol) in anhydrous THF (5 mL) was added 
LiAlH4 (118 mg, 3.12 mmol) and mixture heated at reflux for 1.5 hr. The reaction was 
quenched by addition of NaOH, the solids were solids filtered off and the filtrate partitioned 
between EtOAc (5 mL) and water (5 mL). The organic phase was separated and aqueous 
layer extracted with EtOAc (5 ml). The combined organic phases were concentrated to give a 
dark yellow oil. Purification by column (EtOAc) yielded 275 (297 mg, 84 %) as a yellow oil. 
 
Rf 0.15 (ethyl acetate); δH (400 MHz, CDCl3): 1.83-1.91 (3H, m, C6-H2, C7-H), 2.03-2.08 
(1H, m, C7’-H), 2.81-2.84 (1H, m, C5-H), 2.98 (1H, ddd, J = 7.5, 7.0, 3.7, C3-H), 3.10-3.13 
(1H, m, C5’-H), 3.40 (3H, s, OCH3), 3.46-3.49 (1H, m, CH-7a), 3.51-3.58 (2H, m, C3-H2), 
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3.92 (1H, t, J = 6.1, H-1), 4.05 (1H, dd, J = 7.5, 6.2, H-2), (1H, d, J = 3.4,), 4.55-4.59 (3H, m, 
CH2OCH2Ph, OCH2Ph-Ha), 4.61-4.72 (3H, m, OCH2Ph-Hb, OCH2O7.28-7.42 (10H, m, Ph); 
δc (100 MHz): 25.4 (CH2-6), 31.0 (CH2-7), 55.2 (CH2-5), 55.5 (OCH3), 67.3 (CH-7a), 68.0 
(CH-3), 71.8 (C5-CH2), 72.7 (OCH2Ph), 73.2 (C5-CH2OCH2Ph), 85.5 (CH-2), 86.6 (CH-1), 
91.9 (OCH2O), 127.4, 127.5, 127.6, 127.6, 127.6, 127.65, 127.68, 127.7, 128.2, 128.2, 128.3, 
128.3, & 128.4 (CHAr), 138.42 & 138.5 (Car); IR νmax 3030.4, 2889.6, 1721.8, 1496.4, 
1452.9, 1361.7, 1309.3, 1260.7, 1207.7, 1107.3, 1035.1, 844.9, 917.8, 736.7, 698.2, cm-1; 
LRMS (ES): 398.2 ;HRMS (ES):  398.2318 [(M+H)+;  C24H12NO4 requires 398.2326]. Anal. 
Calcd for C24H31NO4: C, 72.52; H, 7.86; N, 3.52. Found: C, 72.49; H, 7.77; N, 3.48. 
 
(1R,2R,3R,7aR)-2-(Benzyloxy)-3-(benzyloxymethyl)hexahydro-1H-pyrrolizin-1-ol (276) 
 
 
 
To a solution of 275 (297 mg, 0.75 mmol) in DCM (18 mL) was added TFA (1.75 mL, 22.74 
mmol). The reaction mixture was stirred at ambient temperature for 48 h. The mixture was 
washed with sodium bicarbonate (2 mL) and extracted with DCM (3 x 3 mL). The combined 
organics were dried over MgSO4, filtered and the filtrate concentrated. Purification by 
column chromatography (EtOAc) yielded the alcohol 276 (237 mg, 90 %) as a yellow oil.  
 
Rf 0.03 (ethyl acetate); δH (200 MHz, CDCl3): 2.16-2.23 (4H, m, C6-H2, C7-H2), 2.83 (1H, 
dt, J = 10.7, 6.6, C5 -Ha), 2.98 (1H, ddd, J = 7.5, 7.0, 3.7, C3-H), 3.10 (1H, dt, J = 12.1, 6.1, 
C5-Hb), 3.46 (1H, m, C7a-H), 3.59-3.64 (2H, m, C3-H2), 3.92 (1H, t, J = 6.1, C1-H), 4.05 
(1H, dd, J = 7.5, 6.2, C2-H), 4.55-4.59 (2H, m, CH2OCH2Ph), 4.59-4.62 (1H, m, OCH2Ph-
Ha), 4.70-4.73 (1H, m, OCH2Ph-Hb), 7.28-7.42 (10H, m, Ph); δc (50 MHz): 23.8 (CH2-6), 
27.9 (CH2-7), 55.2 (CH2-5), 67.3 (CH-7a), 68.03 (CH-3), 71.8 (C5-CH2), 72.7 (OCH2Ph), 
73.2 (C5-CH2OCH2Ph), 85.5 (CH-2), 86.6 (CH-1), 91.9 (OCH2O), 127.4, 127.5, 127.59, 
127.61, 127.63, 127.65, 127.68, 127.7, 128.22, 128.24, 128.27, 128.30, & 128.35 (CHAr), 
138.34 & 138.40 (Car); IR νmax 3413.9 (br. OH), 3030.8, 2888.9, 1721.7, 1496.2, 1453.3, 
1361.7, 1309.5, 1260.1, 1208.2, 1107.1, 1035.2, 845.3, 917.2, 736.5, 698.2, cm-1; LRMS 
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(ES): 353.2, 328.1, 292.2, 276.2, 248.1, 232.1, 91.0; HRMS (ES): 354.2062 [(M+H)+;  
C22H28NO3 requires 354.2069]; Anal. Calcd for C22H28NO3: C, 74.55; H, 7.96; N, 3.95. 
Found: C, 74.50; H, 7.98; N, 3.87. 
 
Attempted preparation of (1R,2R,3R,7aR)-2-(Benzyloxy)-3-(benzyloxymethyl) 
hexahydro-1H-pyrrolizin-1-one (277) 
 
 
 
Method 1: Dess-Martin Periodinane Oxidation 
276 (50 mg, 0.11 mmol) and Dess – Martin periodinane in DCM (15 % w/w, 70 mg, .25 
mmol) were stirred in DCM at ambient temperature. The reaction was mnitored by TLC 
(petrol/EtOAC 1:1) and on completion was diluted with ether. A mixture of Na2S2O3 and 
Sodium bicarbonate was added and the mixture stirred until homogeneous and the products 
isolated by extraction. TLC and Crude NMR showed no reaction had taken place after 18 h. 
(0 mg, 0 %). 
 
Method 2: Swern Oxidation 
To a stirred solution of 2M oxalyl chloride (33 µL, 0.38 mmol) in anhydrous DCM (3 mL) 
was added DMSO (52 µL, 0.74 mmol) dropwise under a nitrogen atmosphere and the 
mixture stirred for 30 mins. A solution of 276 (1.5 mg, 0.32 mmol) in DCM (2 mL) was 
added and the reaction stirred at -78 °C for 1 h. TEA (134 µL, 0.958 mmol) was added and 
reaction stirred until it reached ambient temperature then water (5 mL) was added. Product 
was extracted with DCM, washed with brine and concentrated. TLC and Crude NMR 
showed no reaction had taken place after 18 hours. (0 mg, 0 %).  
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Attempted preparation of (1S,2R,3R,7aR)-2-(Benzyloxy) -3- (benzyloxymethyl) 
hexahydro-1H-pyrrolizin-1-ol (260) 
 
 
 
A solution of alcohol 276 (50 mg, 0.11 mmol), PPh3 (83 mg, 0.32 mmol) and benzoic acid 
(15 mg, 0.13 mmol), in dry THF (4 mL) was stirred at 0 °C under an atmosphere of nitrogen. 
DEAD (50 µL, 0.32 mmol) was added dropwise and mixture stirred at 0 °C for 1 h then at 
ambient temperature overnight. The solvents were evaporated under reduced pressure to give 
an orange oil. No reacton was observed from NMR and TLC analysis of the crude product. 
 
(2R,3aR,4R,5R,6R)-5-(Benzyloxy)-6-(benzyloxymethyl)-4-hydroxy-N,N-
dimethylhexahydropyrrolo[1,2-b]isoxazole-2-carboxamide (279) 
 
 
 
To a solution of 267 (150 mg, 0.32 mmol) in DCM (5 mL) was added TFA (0.5 mL). The 
reaction mixture was stirred at ambient temperature for 48 h. The mixture was washed with 
sodium bicarbonate (2 mL) and extracted with DCM (3 x 3 mL). The combined organic 
layers were dried over MgSO4, filtered and the filtrate concentrated. Purification by column 
chromatography (petrol/EtOAc 1:1) yielded alcohol 279 (78 mg, 86 %) as a yellow oil. 
 
Rf 0.33 (ethyl acetate); δH (400 MHz, CDCl3): 2.38 (1H, ddd, J = 12.7, 7.5, 5.5, C3-H a), 2.86 
(1H, ddd, J = 12.4, 9.2, 7.3, C3-Hb), 2.94 (3H, s, NCH3), 2.99 (3H, s, NCH3), 3.38-3.43 (1H, 
m, C6-H), 3.69 (1H, dd, J = 9.6, 3.7, C7-Ha), 3.73 (1H, dd, J = 9.6, 3.7, C7-Ha),  3.86 (1H, 
m, CH-3a), 3.92 (1H, dd, J = 3.7, 2.2, C5-H), 4.21 (1H, t, J = 3.7, 2.2, C4-H), 4.55-4.62 (2H, 
m, OCH2Ph), 4.66-4.73 (2H, m, OCH2Ph), 4.83 (1H, t, J = 7.4, C2-H), 7.19-7.31 (10H, m, 
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Ph); δc (100 MHz): 35.8 (NCH3), 36.3 (CH2-3), 36.9 (NCH3), 70.8 (CH-6CH2), 72.1 
(0CH2Ph), 72.55 (CH-7a), 72.6 (CH-6), 73.7 (OCH2Ph), 74.8 (CH-2), 79.3 (CH-5), 86.7 
(CH-4), 127.75 (CH-Ar), 127.88 (CH-Ar), 128.5 (CH-Ar), 137.8 (CH-Ar), 137.4 (C-Ar), 
137.6 (C-Ar), 168.3 (C=O); IR νmax 3380.2 (br. OH), 3362.7, 3030.7, 2931.1, 2866.7, 1646.0 
(C=O), 1496.9, 1453.9, 1403.3, 1361.3, 1260.3, 1101.8, 1028.1, 912.3, 800.2, 738.7, 699.0 
cm-1; HRMS (ES)  427.2223 [(M+NH4)+;  C26H35N2O6 requires 427.2227]; Anal. Calcd for 
C26H35N2O6: C, 66.22; H, 7.48; N, 5.94. Found: C, 66.17; H, 7.39; N, 5.87. 
 
 
Attempted preparation of (2R,3aR,5R,6R)-5-(Benzyloxy)-6-(benzyloxymethyl)-N,N-
dimethyl-4-oxohexahydropyrrolo[1,2-b]isoxazole-2-carboxamide (280) 
 
 
 
Method 1: Dess-Martin Periodinane Oxidation 
279 (50 mg, 0.108 mmol) and Dess – Martin periodinane in DCM (15 % w/w, 70 mg, 0.25 
mmol) were stirred in DCM at ambient temperature. The reaction was mnitored by TLC 
(petrol/EtOAC 1:1) and on completion was diluted with ether. A mixture of Na2S2O3 and 
Sodium bicarbonate was added and the mixture stirred until homogeneous and the products 
isolated by extraction. TLC and Crude NMR showed no reaction had taken place after 18 h. 
(0 mg, 0 %). 
 
Method 2: Swern Oxidation 
To a stirred solution of 2M oxalyl chloride (33 µL, 0.38 mmol) in anhydrous DCM (3 mL) 
was added DMSO (52 µL, 0.74 mmol) dropwise under a nitrogen atmosphere and the 
mixture stirred for 30 min. A solution of 279 (1.5 mg, 0.32 mmol) in DCM (2 mL) was added 
and the reaction stirred at -78 °C for 1 h. TEA (134 µL, 0.96 mmol) was added and reaction 
stirred until it reached ambient temperature then water (5 mL) was added. Product was 
extracted with DCM, washed with brine and concentrated. TLC and Crude NMR showed no 
reaction had taken place after 18 hours. (0 mg, 0 %).  
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Attempted preparation of (2R,3aR,4S,5R,6R)-5-(benzyloxy)-6-(benzyloxymethyl)-4-
hydroxy-N,N-dimethylhexahydropyrrolo[1,2-b]isoxazole-2-carboxamide (281) 
 
 
 
A solution of alcohol 279 (50 mg, 0.11 mmol) in PPh3 (83 mg, 0.32 mmol) and benzoic acid 
(15 mg, 0.13 mmol), in dry THF (4 mL) was stirred at 0 °C under an atmosphere of nitrogen. 
DEAD (50 µL, 0.32 mmol) was added dropwise and mixture stirred at 0 °C for 1 h then at 
ambient temperature overnight. The solvents were evaporated under reduced pressure to give 
an orange oil. No reaction was observed from NMR and TLC analysis of the crude product. 
 
(R)-1-(Benzyloxy)but-3-en-2-ol (294)
135
 
 
 
 
Trimethylsulfonium iodide (4.95 g, 24.23 mmol) was suspended in toluene (30 mL) and 
heated at reflux for 30 min on a Dean-Stark trap. Toluene was removed and residue dried 
under high vacuum. After flushing with nitrogen, THF (50 mL) was added and solution 
cooled to -15 ºC in an ice/salt bath and butyllithium (2.5 M, 8.7 mL, 21.75 mmol) was added 
over 30 min. After stirring at -15 ºC for 30 min (R)-Glycidol-benzyl ether (1g, 0.93 mL, 6.09 
mmol) in THF (10 mL) was added within 15 min. The mixture was stirred at -10 ºC for 1 h 
then at ambient temperature overnight. The reaction was quenched with water (50 mL) and 
extracted with diethyl ether (2 x 50 mL). Concentration and purification by column 
chromatography (petroleum ether:EtOAc 8:1) yielded the product  294 ( 1.01 g, 91 %) as a 
clear oil. 
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Rf 0.17 (petroleum ether:EtOAc 8:1); δH (400 MHz, CDCl3): 2.59 (1H, br. s, OH), 3.42 (1H, 
dd, J = 9.6, 7.9, C1-Ha), 3.58 (1H, dd, J = 9.6, 3,4, C1- H b), 4.39 (1H, m, C2-H), 4.61 (2H, s, 
OCH2Ph), 5.24 (1H, dt, J = 10.6, 1.5 Hz, C4-Ha), 5.40 (1H, dt, J = 17.3, 1.5 Hz, C4-Hb), 5.88 
(1H, ddd, J = 17.3, 10.6, 5.6 Hz, C3-H), 7.39 (10H, m, Ph); δc (100 MHz): 71.5 (CH-2), 73.3 
(OCH2Ph), 73.9 (CH2-1), 116.4 (CH2-4), 127.72, 127.73, 127.79, 128.38, 128.43, 128.46, & 
128.48 (CHAr), 136.5 (CH-3), 137.8 (Car); IR νmax 3346 (br. OH), 3049.4, 2931.6, 2857.1, 
1589.7, 1487.1, 1427.2, 1390.3, 1360.9, 1259.4, 1112.5, 1028.2, 998.2, 822.2, 739.2, 699.2, 
cm-1; m/z (ES)  178.0992 [(M+H)+;  C11H14NO2 requires 178.0994]. Anal. Calcd for 
C11H14O2: C, 74.13; H, 7.92. Found: C, 74.32; H, 7.99. 
 
(R)-1-(Benzyloxy)but-3-en-2-yloxy)(tert-butyl)diphenylsilane (309) 
 
 
To a solution of alcohol 294 (0.9 g, 5.05 mmol) in anhydrous DMF (15 mL) and imidazole 
(1.02 g, 15 mmol) was added TBDPSCl (2.08 mL, 7.58 mmol) and mixture attired at room 
temperature overnight. The reaction was quenched with 1M HCl (20 mL), extracted with 
ethyl acetate (2 x 15 ml), washed with water (20 ml), sodium bicarbonate (20 ml) and brine 
(10 ml) then dried over MgSO4, filtered and concentrated. Purification by flash 
chromatography (light petroleum ether: EtOAc 9:1) yielded 309 (2.03 g, 96 %) as a 
green/yellow oil. 
 
Rf 0.58 (light petroleum ether: EtOAc 9:1); δH (200 MHz, CDCl3): 0.99 (9H,s, 3 x CH3), 3.27 
(1H, dd, J = 9.7, 7.9, C1-Ha), 3.36 (1H, dd, J = 9.6, 3.4, C1-Hb), 4.26-4.31 (1H, m, C2-H), 
4.29 (2H, s, OCH2Ph), 4.99 (1H, dt, J = 10.8, 1.6 Hz, C4-Ha), 5.10 (1H, dt, J = 17.4, 1.6 Hz, 
C4-Hb), 5.81 (1H, ddd, J = 17.4, 10.8, 5.4 Hz, C3-H) 7.36-7.42 (10H, m, Ph), 7. 69-7.82 (5H, 
m, Ph); δc (50 MHz): 19.1 (CSi), 26.7 (CH3), 72.8 (CH-2), 73.0 (OCH2Ph), 74.3 (CH2-1), 
115.4 (CH2-4), 127.7, 127.73, 127.8, 128.4, 128.43, 128.46, & 128.48 (CHAr), 135.6 (CH-3), 
133.9, 134.5 & 138.0 (Car); IR νmax 3049.3, 2931.0, 2857.4, 1589.6, 1487.6, 1472.1, 1427.8, 
1390.5, 1361.9, 1259.8, 1112.9, 1028.2, 998.2, 822.0, 739.4, 700.8, cm-1.  
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(2R,3aR,4R,5R,6R)-5- (Benzyloxy)-2-((S)-2-(benzyloxy)-1-(tertbutyldiphenylsilyloxy) 
ethyl)-6-(benzyloxymethyl)-4-(methoxymethoxy)hexahydropyrrolo[1,2-b] isoxazole. 
 
 
 
To a solution of nitrone 179 (800 mg, 2.15 mmol) in toluene (50 mL) was added alkene 309 
(740 mg, 1.78 mmol) and the mixture was heated at reflux overnight. The mixture was 
cooled and concentrated in vacuo and purification by column chromatography (hexane: Et2O, 
7:3) yielded 310 (1.287 g, 92%) as a brown oil.  
 
Rf 0.28 (heptane: EtOAc, 7:3); δH (400 MHz, CDCl3): 1.09 (9H, s, SiMe3), 2.28 (1H, ddd, J = 
12.5, 7.3, 5.4,  C3-H), 2.50 (1H, ddd, J = 12.3, 9.2, 7.8, C3’-H), 3.27 (1H, dd, J = 10.8, 6.0, 
C6-H), 3.37 (3H, s, OCH3), 3.39, (2H, m, C8-CH2O), 3.62-3.69 (2H,m, C7-Ha, C3a-H), 
3.72-3.76, (1H, m, C7-Hb ), 3.97-4.03 (2H, m, C5-H, C8-H), 4.08 (1H, t, J = 4.1, C4-H), 
4.21-4.24 (2H, m, OCH2O), 4.38 (1H, td, J= 7.5, 4.6, C2-H), 4.59-4.69 (6H, m, 3 x 
OCH2Ph), 7.12-7.77 (35H, m, Ph); δc (100 MHz): 19.4 (SiC), 26.9 (CMe3), 35.4 (CH2-3), 
55.5 (OCH3), 68.2 (CH-7a), 68.9 (CH-6), 69.76(CH-7CH2), 69.77 (CH-6CH2), 71.9 (CH2), 
72.3 (CH-5), 72.34 (OCH2Ph), 72.9 (OCH2Ph), 73.3 (OCH2Ph), 83.5 (CH-2CH), 84.9 (CH-
4), 95.9 (OCH2O), 127.3 (CHar), 127.4 (CHar), 127.42 (CHar), 127.51 (CHar), 127.58 (CHar), 
127.6 (CHar), 127.68 (CHar), 127.74 (CHar), 127.83 (CHar), 128.1 (CHar), 128.2 (CHar), 128.3 
(CHar), 128.5 (CHar), 129.6 (CHar), 133.2 (Car), 134.4 (Car), 135.8 (CHar), 136.2 (CHar), 138.1 
(Car), 138.2 (Car), 138.5 (Car); IR νmax 3066.3, 2930.9, 1417.9, 1453.8, 1427.8, 1361.8, 
1149.9, 1111.6, 1042.1, 916.0, 822.3, 737.5, 699.6, 611.0 cm-1; LRMS (ES): 788.2, 730.3, 
242.2; HRMS (ES): 788.3979 [(M+H)+;  C48H58NO7Si requires 788.3977].  
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(S)-2-(Benzyloxy)-1-((2R,3aR,4R,5R,6R)-5-(benzyloxy)-6-(benzyloxymethyl)-4-
(methoxymethoxy)hexahydropyrrolo[1,2-b]isoxazol-2-yl)ethanol (304) 
 
 
 
To a solution of silyl ether (0.48 g, 0.61 mmol) in dry THF (10 mL) was added TBAF (1M, 
1.20 mL, 1.20 mmol). The reaction mixture was stirred at ambient temperature for 1 h then 
evaporated to give a brown residue. Purification by column chromatography (light 
petroleum:EtOAc, 3:7) yielded 304 as an orange oil (0.283g, 85 %). 
 
Rf 0.42 (heptane: EtOAc, 3:7); δH (200 MHz, CDCl3): 2.28 (1H, ddd, J = 12.4, 7.2, 5.0, C3-
H’), 2.44 (1H, ddd, J = 12.6, 8.9, 7.5, C3-H), 2.68 (1H, d, J = 2.9, OH), 3.18-3.22 (1H, m, 
C6-H), 3.31 (3H, s, CH2OCH3), 3.40-3.73 (5H, m, 2 x CH2, C3a-H) 3.86-4.26 (4H, m, C5-H, 
C2-H, C8-H, C4-H), 4.44-4.64 (8H, m, OCH2O, 3x OCH2Ph), 7.12-7.77 (35H, m, Ph); δc 
(100 MHz): 34.4 (CH2-b), 55.4 (OCH3), 68.2 (CH-7a), 69.1 (CH-6), 69.3 (CH-6CH2), 70.2 
(CH-6), 70.9 (OCH2Ph), 72.0 (OCH2Ph), 73.1 (OCH2Ph), 73.2 (OCH2Ph), 76.8 (CH-5), 83.2 
(CH-2CH), 85.2 (CH-4), 95.7 (OCH2O), 127.3 (CHar), 127.5 (CHar), 127.51 (CHar), 128.0 
(CHar), 128.1 (CHar), 128.2 (CHar), 137.6 (Car), 137.8 (Car), 138.0 (Car); IR νmax 3413.9 (br. 
OH), 3069.3, 2930.6, 1417.1, 1454.1, 1427.6, 1360.9, 1150.3, 1111.3, 1041.8, 916.4, 822.7, 
737.2, 699.6, 610.6 cm-1; LRMS (ES): 549.2, 458.1, 428.1, 398.1, 276.1, 91.0; HRMS (ES) 
550.216 [(M+H)+;  C32H40NO7 requires 550.280]. Anal. Calcd for C32H39NO7: C, 69.92; H, 
7.32; N, 2.55. Found: C, 69.88; H, 7.35; N, 2.59. 
 
(S)-2-(Benzyloxy)-1-((2R,3aR,4R,5R,6R)-5-(benzyloxy)-6-(benzyloxymethyl)-4-
(methoxymethoxy)hexahydropyrrolo[1,2-b]isoxazol-2-yl)ethyl methanesulfonate (305) 
 
N
O
OBn
OBn
OMOM
305
MsO
BnO
N
O
OBn
OBn
OMOM
304
HO
BnO
H H
 
 
Experimental 
137 
 
Alcohol 304 (200 mg, 0.36 mmol) in DCM (20 mL) was stirred at 0 °C under an atmosphere 
of argon. Et3N (0.10 mL, 0.90 mmol) and MsCl (0.04 mL, 0.70 mmol) were successively 
added. The mixture was stirred at 0 °C for 30 min then the reaction was quenched by the 
addition of water (10 ml). The phases were separated and the aqueous layer extracted with 
DCM (2 x 15 ml), washed with brine (10 ml), dried over MgSO4, filtered and concentrated. 
Purification by flash chromatography (light petroleum:EtOAc, 1:1) yielded mesylate 305 
(221 mg, 97 %) as a yellow oil.  
 
Rf 0.47 (heptane:EtOAc, 4:6); δH (200 MHz, CDCl3): 2.23-2.56 (2H, m,C3-H2), 3.01 (3H, s, 
SMe), 3.24-3.38 (1H, m, C6-H), 3.29 (3H, s, CH2OCH3), 3.45-3.70 (5H, m, CH2, CH2, C3a -
H,), 3.91 (1H, m, C5-H), 4.04-4.18 (1H, m, C2-H), 4.29-4.37 (1H, m, C4-H), 4.41-4.59 (8H, 
m, OCH2O, 3x OCH2Ph), 4.79 (1H, q, J = 5.2, C-2CH), 7.12-7.77 (35H, m, Ph); δc (100 
MHz): 34.6 (CH2-3), 38.2 ( SO2Me), 55.3 (OCH3), 68.3 (CH-7a), 69.2 (CH2), 69.3 (CH2), 
69.6 (CH-6), 71.9 (CH2), 72.9 (CH2), 73.1 (CH2), 75.31 (CH-6), 80.02 (CH-5), 83.40 (C2-
CH), 84.31 (CH-4), 95.57 (OCH2O), 127.25 (CHar), 127.35 (CHar), 127.41 (CHar), 127.59 
(CHar), 127.97 (CHar), 128.03 (CHar), 128.15 (CHar), 136.93 (Car), 137.49 (Car), 137.80 (Car); 
IR νmax 3030.6, 2935.9, 2892.3, 1496.4, 1454.0, 1358.3, 1208.6, 1174.8, 1104.4, 1038.0, 
971.1, 919.2, 808.2, 739.9, 698.9 cm-1; LRMS (ES): 628.2, 506.2, 413.2, 354.1, 344.1, 108.0, 
91.0, 79.0; HRMS (ES) 628.2575 [(M+H)+;  C33H42NO9S requires 628.2575].  
 
(1R,2R,3R,5R,6R,7aR)-2-(Benzyloxy)-3,5-bis(benzyloxymethyl)-1-(methoxymethoxy) 
hexahydro-7a-H-pyrrolizin-6-ol (306) 
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To isoxazole 306 (950 mg, 1.51 mmol) was added AcOH (10 M, 2 mL, 20.00 mmol) and Zn 
dust (1 g, 30.42 mmol). The mixture was stirred at 85 °C for 2h then the pH was adjusted to 
14 by addition of saturated NaOH solution. The layers were separated and the mixture 
extracted with DCM (2 x 13 ml). The combined organic layers were dried over MgSO4, 
filtered and concentrated. Purification by column chromatography (EtOAc) yielded alcohol 
306 (668 mg, 87 %) as a pale green oil. 
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Rf 0.20 (EtOAc); δH (400 MHz, CDCl3): 1.89 (1H, ddd, J = 14.1, 5.6, 3.0, C7-H’), 2.32 (1H, 
ddd, J = 14.0, 9.7, 6.3, C7-H), 3.32 (1H, m, C5-H), 3.33 (3H, s, OCH3), 3.49 (2H, m, C3-
CH2), 3.59 (1H, m, C7a-H), 3.79 (1H, ddd, J = 14.1, 5.6, 3.0, C3-H), 3.92 (2H, ddd, J = 14.1, 
5.6, 3.0, C5-CH2), 3.98 (1H, t, J = 2.9, C2-H), 4.20 (1H, t, J = 2.9, C1-H), 4.27 (1H, s, C6-H) 
4.49-4.67 (8H, m, 4 x OCH2), 7.28-7.35 (15H, m, 3 x Ph); δc (100 MHz): , 39.4 (CH2-7), 
55.4 (0Me), 62.9 (CH-3), 65.9 (CH-5), 67.2 (C5-CH2), 67.8 (CH-7a), 71.9 (OCH2), 72.6 
(OCH2),  72.9 (OCH2), 73.4 (OCH2), 74.3 (CH-6), 85.5 (CH-1), 86.4 (CH-2), 95.5 (OCH2O), 
127.4 (CHar), 127.6 (CHar), 127.61 (CHar), 127.8 (CHar), 127.88 (CHar), 127.89 (CHar), 128.2 
(CHar), 128.22 (CHar), 128.3 (CHar), 128.36 (CHar) 128.4 (CHar), 137.9 (Car), 138.4 (Car); IR 
νmax 3413.9 (br. OH), 3030.7, 2889.7, 1496.6, 1453.8, 1174.9, 1103.3, 1037.3, 971.8, 919.5, 
739.1, 698.9 cm-1; LRMS (ES): 533.3, 502.2, 488.2, 472.2, 442.2, 426.2, 413.2, 91.0; HRMS 
(ES): 533.2778 [M+;  C32H39NO6 requires 533.2772]. Anal. Calcd for C32H39NO6: C, 72.02; 
H, 7.37; N, 2.63. Found: C, 72.12; H, 7.42; N, 2.68. 
(1R,2R,3R,5R,6R,7aR)-2-(Benzyloxy)-3,5-bis(benzyloxymethyl)-1-(methoxymethoxy) 
hexahydro-1H-pyrrolizin-6-yl methanesulfonate (311) 
 
Alcohol 306 (400 mg, 1.12 mmol) in DCM (20 mL) was stirred at 0 °C under an atmosphere 
of argon. Et3N (0.35 mL, 3.14 mmol) and MsCl (0.14 mL, 2.46 mmol) were successively 
added. The mixture was stirred at 0 °C for 30 min then the reaction was quenched by the 
addition of water (10 ml). The layers were separated and the aqueous layer extracted with 
DCM (2 x 10 ml), washed with brine (10ml), dried over MgSO4, filtered and concentrated. 
Purification by flash chromatography (light petroleum:EtOAc, 3:7) yielded mesylate 311 
(458 mg, 100 %) as a pale green oil. 
 
Rf 0.34 (heptanes:EtOAc, 3:7); δH (200 MHz, CDCl3): 2.35-2.41 (2H, m, C7-H2), 2.83 (3H, s, 
SO2CH3), 3.31 (3H, s, OCH3), 3.38-3.57 (5H,m, C3-CH2, C7a-H, C3-H, C5-H), 3.78 (2H, d, 
J = 5.5, C5-CH2), 3.98 (1H, t, J = 5.1, C2-H), 4.08 (1H, t, J = 5.1, C1-H), 4.49-4.55 (4H, m, 
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2 x OCH2), 4.59-4.63 (4H, m, 2 x OCH2), 5.21 (1H, q, J  5.1 , H-6), 7.31-7.41 (15H, m, 3 x 
Ph); δc (100 MHz): 35.8 (CH2-7), 38.2 (SCH3), 55.4 (OCH3), 61.6 (CH-3), 64.1 (CH-5), 65.7 
(C5-CH2), 66.6 (CH-7a), 72.2 (OCH2), 72.4 (OCH2), 73.3 (OCH2), 73.5 (OCH2), 82.8 (CH-
6), 85.1 (CH-1), 86.6 (CH-2), 95.9 (OCH2O), 127.6 (CHar), 127.7 (CHar), 127.9 (CHar), 128.3 
(CHar), 137.8 (Car), 138.3 (Car), 138.4 (Car); IR νmax 3063.0, 3030.2, 2888.5, 1496.3, 1453.8, 
1358.5, 1175.0, 1103.5, 1037.8, 970.0, 918.3, 861.6, 738.6, 698.9 cm-1; LRMS (ES): 611.2, 
490.2, 424.2, 396.2, 352.2, 163.0, 107.0, 79.0; HRMS (ES): 611.2547 [M+; C33H41NO8S 
requires 611.2547]; Anal. Calcd for C33H41NO8S: C, 63.35; H, 7.03; N, 2.38. Found: C, 
63.47; H, 7.12; N, 2.51. 
 
(1R,2R,3R,5R,6R,7aR)-2-(Benzyloxy)-3,5-bis(benzyloxymethyl)-1-(methoxymethoxy) 
hexahydro-1H-pyrrolizin-6-yl S-methyl carbonodithioate (312) 
 
Method 1: 
Alcohol 306 (800 mg, 1.50 mmol) was added to a suspension of NaH (30 % in mineral oil, 
158 mg, 3.95 mmol) in dry THF (30 mL) at 0 °C and then the mixture was stirred at rt for 20 
min. The suspension was then cooled to 0 °C and CS2 (0.25 mL, 303 mg, 3.95 mmol) was 
added and the reaction mixture allowed to stir at 0 °C for 10 min. Iodomethane (0.25 mL, 
565 mg, 3.95 mmol) was then added and mixture stirred at ambient temperature for 20 min. 
The reaction was then quenched by careful addition of water until effervescence had stopped. 
The layers were separated and the organic layer was extracted with diethyl ether (10 ml), 
dried over MgSO4, filtered and concentrated to give a yellow residue. Purification by column 
chromatography (light petroleum:EtOAc 7:3) produced the xanthate 312 (47 mg, 5 %) as a 
yellow oil. 
Method 2: 
Alcohol 306 (800 mg, 1.50 mmol) was added to a suspension of KH (30 % in mineral oil, 
533 mg, 3.98 mmol) in dry THF (30 mL) at 0 °C and then the mixture stirred at RT for 20 
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min. The suspension was then cooled to 0 °C and CS2 (0.25 mL, 303 mg, 3.95 mmol) was 
added and the reaction mixture allowed to stir at 0 °C for 10 min. Iodomethane (0.25 mL, 
565 mg, 3.95 mmol) was then added and mixture stirred at ambient temperature for 20 min. 
The reaction was then quenched by careful addition of water until effervescence had stopped. 
The organic layer was extracted with diethyl ether (3 mL), dried over MgSO4, filtered and 
concentrated to give a yellow residue. Purification by column chromatography (light 
petroleum:EtOAc 7:3) produced the xanthate 312 ( 649 mg, 70 %) as a yellow oil. 
 
Rf 0.26 (light petroleum:EtOAc 7:3); δH (200 MHz, CDCl3): 2.29 -2.51 (2H, m, C7-H2), 2.41 
(3H, s, SCH3), 3.25 (3H, s, OCH3), 3.37-3.64 (5H, m, C1-H, C2-H, , C7a-H, C3-H, C5-H), 
3.71-3.80 (2H, m, C3-CH2), 3.98-4.07 (2H, m, C5-CH2), 4.59-4.65 (8H, m, 8 x OCH2), 5.97 
(1H, dt, J = 6.6, 5.1, C6-H), 7.25 (15H, m, 3 x Ph); δc (100 MHz): 18.9 (SCH3), 35.5 (CH2-
7), 55.4 (OCH3), 61.7 (CH-3), 63.5 (CH-5), 65.9 (C5-CH2), 66.5 (CH-7a), 71.9 (OCH2), 72.6 
(OCH2), 73.2 (OCH2), 73.4 (OCH2), 85.1 (CH-6), 85.4 (CH-1), 86.7 (CH-2), 95.8 (OCH2O), 
127.4 (CHar), 127.5 (CHar), 127.51 (CHar), 127.57 (CHar), 127.7 (CHar), 128.2 (CHar), 128.3 
(CHar), 137.9 (Car), 138.4 (Car), 138.6 (Car); IR νmax 3087.7, 3062.5, 3029.7, 2923.3, 2855.5, 
1495.9, 1453.5, 1363.8, 1212.0, 1148.3, 1104.1, 1069.9, 1039.0, 966.0, 917.5, 819.0, 735.9, 
697.8 cm-1; LRMS (ES): 623.2, 503.2, 394.2, 332.2, 274.1, 108.1; HRMS (ES): 623.2370 
[M+;  C34H41NO6S2 requires 623.2370]. 
 
(1R,2R,3R,5S,7aR)-2-(Benzyloxy)-3,5-bis(benzyloxymethyl)-1-
(methoxymethoxy)hexahydro-1H-pyrrolizine (307) 
 
Method 1: 
To a solution of mesylate 311 (800 mg, 1.31 mmol) in anhydrous THF (10 mL) was added 
LiAlH4 (56 mg, 1.48 mmol) and the mixture heated at reflux for 12 h. The reaction was 
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quenched with the careful addition of NaOH and partitioned between EtOAc (10 mL) and 
water (10 mL). The organic phase was separated and aqueous phase extracted with EtOAc (2 
x 5 mL). The combined organic phases were concentrated and purified by column 
chromatography (light petroleum:EtOAc 8:2) yielded the product 307 (18 mg, 2 %) as a 
yellow oil. 
 
Method 2: 
To a solution of mesylate 311 (600 mg, 0.98 mmol) in anhydrous THF (40 mL) was added 
super hydride (1M, 5 mL, 5 mmol) at ambient temperature and the reaction left to stir for 24 
h. The reaction was quenched with addition of water and the organic phase extracted with 
EtOAc (30 mL) and concentrated. Purification by column chromatography (light 
petroleum:EtOAc 8:2) yielded the product 307 (48 mg, 9 %) as a yellow oil. 
 
Method 3: 
 
To a solution of xanthate 312 (600 mg, 0.96 mmol) in toluene (21 mL) at reflux was added  a 
mixture of AIBN (60 mg, 0.36 mmol) and Bu3SnH (0.618 mL, 2.29 mmol) in toluene (3 mL) 
over 2 h. The mixture was left at reflux for a further 1 h after addition then allowed to cool to 
ambient temperature. The solvent was then removed under reduced pressure to produce a 
brown oil. Purification by column chromatography (light petroleum:EtOAc 8:2) yielded 
product 307 (291 mg, 59 %) as a yellow oil. 
 
Rf 0.29 (light petroleum:EtOAc 8:2); δH (400 MHz, CDCl3): 1.78-1.87 (2H, m, C6-H2), 1.88-
1.99 (2H, m, C7-H), 3.29 (3H, s, OCH3), 3.38 (2H, br. s, C3-H, C5-H), 3.46-3.49 (3H, m, 
C5-CH2, C7a -H), 3.58-3.43 (2H, m, C3-CH2), 3.89 (1H, t, J = 5.0, C1-H), 3.98 (1H, t, J = 
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5.0, C2-H), 4.43 (2H, s, OCH2), 4.48 (2H, s, OCH2), 4.58 (2H, s, OCH2O), 4.59-4.64 (2H, m, 
OCH2), 7.25-7.40 (15H, m, 3 x Ph); δc (100 MHz): 28.7 (CH2-7), 28.3 (CH2-6), 55.4 (0CH3), 
61.1 (CH-3), 61.2 (CH-5), 68.5 (CH-7a), 70.7 (C3-CH2), 71.9 (C5-CH2), 72.7 (OCH2), 73.1 
(OCH2), 73.2 (OCH2), 85.4 (CH-1), 87.3 (CH-2), 95.6 (OCH2O), 127.4 (CHar), 127.41 
(CHar), 127.47 (CHar), 127.5 (CHar), 127.6 (CHar), 127.7 (CHar), 128.1 (CHar), 128.2 (CHar), 
128.24 (CHar), 128.27 (CHar), 128.3 (CHar), 138.3 (Car), 138.55 (Car), 138.59 (Car); IR νmax 
3087.7, 3062.9, 3030.0, 2924.5, 2854.7, 1496.1, 1453.6, 1363.6, 1209.3, 1103.0, 1038.0, 
918.5, 819.2, 736.2, 697.9 cm-1;  
 
(1R,2R,3R,5S,7aR)-2-(Benzyloxy)-3,5-bis(benzyloxymethyl)hexahydro-1H-pyrrolizin-1-
ol (308) 
 
To a solution of 307 (270 mg, 0.52 mmol) in DCM (10 mL) was added TFA (1 mL, 12.91 
mmol). The reaction mixture was stirred at ambient temperature for 48 h. The mixture was 
washed with sodium bicarbonate (2 mL) and extracted with DCM (3 x 3 mL). The Organic 
phase was dried over MgSO4, filtered and the filtrate concentrated to give brown residue. 
Purification by column chromatography (EtOAc) yielded the product 308 as an orange oil 
(200 mg, 81 %). 
 
Rf 0.21 (EtOAc); δH (200 MHz, CDCl3): 1.78-1.86 (2H, m, C6-H2), 1.88-1.95 (2H, m, C7-
H2), 3.38-3.41 (2H, br. s, C3-H, C5-H), 3.46-3.58 (3H, m, C5-CH2, C7a-H), 3.58-3.67 (2H, 
m, C3-CH2), 3.89 (1H, t, J  5.0, C1-H), 3.98 (1H, t, J  5.0, C2-H), 4.43 (2H, s, OCH2Ph), 
4.48 (2H, s, OCH2Ph), 4.59-4.63 (2H, m, OCH2Ph), 7.25-7.38 (15H, m, 3 x Ph); δc (100 
MHz): 26.28 (CH2-7), 26.98 (CH2-6), 63.79 (CH-3), 64.70 (CH-5), 68.49 (C3-CH2), 70.93 
(C5-CH2), 71.70 (OCH2), 73.12 (OCH2), 73.29 (CH-7a), 73.56 (OCH2), 77.92 (CH-1), 88.45 
(CH-2), 127.47 (CHar), 127.72 (CHar), 127.79 (CHar), 127.95 (CHar), 128.10 (CHar), 128.39 
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(CHar), 137.61 (Car), 137.65 (Car), 137.00 (Car); IR νmax (br. OH), 3301.58, 3087.6, 3062.4, 
3030.4, 2869.0, 1672.9, 1454.8, 1365.6, 1199.1, 1098.0, 1070.3, 1026.7, 736.2, 697.9 cm-1. 
1-epi-hyacinthacine B2 (293) 
 
To a solution of benzyl ether 308 (40 mg, 0.085 mmol) in methanol was added HCl (4 
drops). The mixture was hydrogenated in the presence of 10 % Pd/C (25 mg) for 48 hr. The 
catalyst was filtered off and the filter washed well with methanol. The solvent was removed 
under reduced pressure to produce the free pyrrolizidine 293 (15 mg, 88 %) as a clear oil. 
 
Rf 0.12 (EtOAc); δH (400 MHz, D2O): 2.15-2.31 (4H, m, C6- H2 & C7-H2), 3.74-3.79 (1H, 
m, C3-H), 3.85-3.92 (1H, m, C5-H), 3.9-4.0 (4H, m, C3-H2& C5- H2), 4.07-4.09 (2H, m, C1- 
H &  C7a-H), 4.11-18 (1H, m, C2-H). δc (100 MHz): 24.77 (CH2-6), 26.34 (CH2-7), 57.14 & 
57.82 (CH2-8 & CH2-9), 64.78 (CH-3), 68.44 (CH-5), 71.22 (CH-7a), 74.59 (CH-2), 77.27 
(CH-1); IR νmax (br. OH), 3301.58, 3087.6, 3062.4, 3030.4, 2869.0, 1672.9, 1454.8, 1365.6, 
1199.1, 1098.0, 1070.3, 1026.7, 736.2, 697.9 cm-1; LRMS (ES): 204.2; HRMS (ES) 
204.1242 [M+;  C9H18NO4 requires 204.1236]. Anal. Calcd for C9H18NO4: C, 52.93; H, 8.88; 
N, 6.86. Found: C, 52.89; H, 8.91; N, 6.83. 
 
 
Appendices 
144 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 APPENDICES 
  
Appendices 
145 
 
4.1 Appendix A: X-ray data for compound 236 
 
Table 4.  Crystal data and structure refinement for ASM111A  x82103_0m. 
Identification code  x82103_0m 
Empirical formula  C19 H20 O5 
Formula weight        328.35 
Temperature               100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1) 
Unit cell dimensions a = 9.0996(14) Å = 90°. 
 b = 5.1326(9) Å = 93.602(10)°. 
 c = 17.537(3) Å  = 90°. 
Volume 817.4(2) Å3 
Z 2 
Density (calculated) 1.334 Mg/m3 
Absorption coefficient 0.096 mm-1 
F(000) 348 
Crystal size 0.81 x 0.68 x 0.08 mm3 
Theta range for data collection 2.46 to 29.21°. 
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Index ranges -12<=h<=12, -7<=k<=7, -24<=l<=23 
Reflections collected 19320 
Independent reflections 2439 [R(int) = 0.0414] 
Completeness to theta = 25.00° 99.8 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9923 and 0.8489 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2439 / 1 / 218 
Goodness-of-fit on F2 1.124 
Final R indices [I>2sigma(I)] R1 = 0.0395, wR2 = 0.0856 
R indices (all data) R1 = 0.0474, wR2 = 0.0888 
Largest diff. peak and hole 0.248 and -0.206 e.Å-3 
 
Table 5.   Bond lengths [Å] and angles [°] for x82103_0m. 
_____________________________________________________ 
O(1)-C(2)  1.342(2) 
O(1)-C(5)  1.461(2) 
C(2)-O(2)  1.204(2) 
C(2)-C(3)  1.528(2) 
C(3)-O(3)  1.4093(19) 
C(3)-C(4)  1.526(3) 
C(3)-H(3)  1.0000 
O(3)-H(3A)  0.8400 
C(4)-O(4)  1.405(2) 
C(4)-C(5)  1.539(2) 
C(4)-H(4)  1.0000 
O(4)-C(6)  1.4354(19) 
C(5)-C(13)  1.503(2) 
C(5)-H(5)  1.0000 
C(6)-C(7)  1.499(3) 
C(6)-H(6A)  0.9900 
C(6)-H(6B)  0.9900 
C(7)-C(8)  1.380(3) 
C(7)-C(12)  1.382(3) 
C(8)-C(9)  1.381(3) 
C(8)-H(8)  0.9500 
C(9)-C(10)  1.376(3) 
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C(9)-H(9)  0.9500 
C(10)-C(11)  1.376(3) 
C(10)-H(10)  0.9500 
C(11)-C(12)  1.380(3) 
C(11)-H(11)  0.9500 
C(12)-H(12)  0.9500 
C(13)-O(14)  1.417(2) 
C(13)-H(13A)  0.9900 
C(13)-H(13B)  0.9900 
O(14)-C(15)  1.435(2) 
C(15)-C(16)  1.507(3) 
C(15)-H(15A)  0.9900 
C(15)-H(15B)  0.9900 
C(16)-C(21)  1.388(3) 
C(16)-C(17)  1.393(3) 
C(17)-C(18)  1.377(3) 
C(17)-H(17)  0.9500 
C(18)-C(19)  1.383(4) 
C(18)-H(18)  0.9500 
C(19)-C(20)  1.390(4) 
C(19)-H(19)  0.9500 
C(20)-C(21)  1.387(3) 
C(20)-H(20)  0.9500 
C(21)-H(21)  0.9500 
C(2)-O(1)-C(5) 109.77(13) 
O(2)-C(2)-O(1) 120.96(15) 
O(2)-C(2)-C(3) 128.15(16) 
O(1)-C(2)-C(3) 110.89(15) 
O(3)-C(3)-C(4) 118.49(15) 
O(3)-C(3)-C(2) 112.35(14) 
C(4)-C(3)-C(2) 100.54(14) 
O(3)-C(3)-H(3) 108.3 
C(4)-C(3)-H(3) 108.3 
C(2)-C(3)-H(3) 108.3 
C(3)-O(3)-H(3A) 109.5 
O(4)-C(4)-C(3) 117.22(14) 
O(4)-C(4)-C(5) 109.58(13) 
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C(3)-C(4)-C(5) 102.00(14) 
O(4)-C(4)-H(4) 109.2 
C(3)-C(4)-H(4) 109.2 
C(5)-C(4)-H(4) 109.2 
C(4)-O(4)-C(6) 111.77(13) 
O(1)-C(5)-C(13) 110.47(14) 
O(1)-C(5)-C(4) 103.35(13) 
C(13)-C(5)-C(4) 116.09(14) 
O(1)-C(5)-H(5) 108.9 
C(13)-C(5)-H(5) 108.9 
C(4)-C(5)-H(5) 108.9 
O(4)-C(6)-C(7) 109.41(14) 
O(4)-C(6)-H(6A) 109.8 
C(7)-C(6)-H(6A) 109.8 
O(4)-C(6)-H(6B) 109.8 
C(7)-C(6)-H(6B) 109.8 
H(6A)-C(6)-H(6B) 108.2 
C(8)-C(7)-C(12) 118.49(18) 
C(8)-C(7)-C(6) 120.40(18) 
C(12)-C(7)-C(6) 121.06(19) 
C(7)-C(8)-C(9) 121.0(2) 
C(7)-C(8)-H(8) 119.5 
C(9)-C(8)-H(8) 119.5 
C(10)-C(9)-C(8) 120.1(2) 
C(10)-C(9)-H(9) 120.0 
C(8)-C(9)-H(9) 120.0 
C(9)-C(10)-C(11) 119.3(2) 
C(9)-C(10)-H(10) 120.3 
C(11)-C(10)-H(10) 120.3 
C(10)-C(11)-C(12) 120.5(2) 
C(10)-C(11)-H(11) 119.7 
C(12)-C(11)-H(11) 119.7 
C(11)-C(12)-C(7) 120.6(2) 
C(11)-C(12)-H(12) 119.7 
C(7)-C(12)-H(12) 119.7 
O(14)-C(13)-C(5) 110.67(15) 
O(14)-C(13)-H(13A) 109.5 
Appendices 
149 
 
C(5)-C(13)-H(13A) 109.5 
O(14)-C(13)-H(13B) 109.5 
C(5)-C(13)-H(13B) 109.5 
H(13A)-C(13)-H(13B) 108.1 
C(13)-O(14)-C(15) 110.60(14) 
O(14)-C(15)-C(16) 111.91(14) 
O(14)-C(15)-H(15A) 109.2 
C(16)-C(15)-H(15A) 109.2 
O(14)-C(15)-H(15B) 109.2 
C(16)-C(15)-H(15B) 109.2 
H(15A)-C(15)-H(15B) 107.9 
C(21)-C(16)-C(17) 119.16(19) 
C(21)-C(16)-C(15) 121.11(18) 
C(17)-C(16)-C(15) 119.71(19) 
C(18)-C(17)-C(16) 120.6(2) 
C(18)-C(17)-H(17) 119.7 
C(16)-C(17)-H(17) 119.7 
C(17)-C(18)-C(19) 119.8(2) 
C(17)-C(18)-H(18) 120.1 
C(19)-C(18)-H(18) 120.1 
C(18)-C(19)-C(20) 120.4(2) 
C(18)-C(19)-H(19) 119.8 
C(20)-C(19)-H(19) 119.8 
C(21)-C(20)-C(19) 119.4(2) 
C(21)-C(20)-H(20) 120.3 
C(19)-C(20)-H(20) 120.3 
C(20)-C(21)-C(16) 120.6(2) 
C(20)-C(21)-H(21) 119.7 
C(16)-C(21)-H(21) 119.7 
_____________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
 
 Table 6.  Torsion angles [°] for x82103_0m. 
________________________________________________________________ 
C(5)-O(1)-C(2)-O(2) 179.07(15) 
C(5)-O(1)-C(2)-C(3) -1.18(19) 
O(2)-C(2)-C(3)-O(3) 31.5(3) 
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O(1)-C(2)-C(3)-O(3) -148.26(15) 
O(2)-C(2)-C(3)-C(4) 158.42(17) 
O(1)-C(2)-C(3)-C(4) -21.30(17) 
O(3)-C(3)-C(4)-O(4) -84.24(18) 
C(2)-C(3)-C(4)-O(4) 153.00(13) 
O(3)-C(3)-C(4)-C(5) 156.12(14) 
C(2)-C(3)-C(4)-C(5) 33.36(15) 
C(3)-C(4)-O(4)-C(6) 76.8(2) 
C(5)-C(4)-O(4)-C(6) -167.64(17) 
C(2)-O(1)-C(5)-C(13) -101.62(16) 
C(2)-O(1)-C(5)-C(4) 23.20(18) 
O(4)-C(4)-C(5)-O(1) -160.20(14) 
C(3)-C(4)-C(5)-O(1) -35.31(16) 
O(4)-C(4)-C(5)-C(13) -39.1(2) 
C(3)-C(4)-C(5)-C(13) 85.78(18) 
C(4)-O(4)-C(6)-C(7) 172.32(16) 
O(4)-C(6)-C(7)-C(8) -130.9(2) 
O(4)-C(6)-C(7)-C(12) 51.8(3) 
C(12)-C(7)-C(8)-C(9) 0.2(3) 
C(6)-C(7)-C(8)-C(9) -177.2(2) 
C(7)-C(8)-C(9)-C(10) -0.5(4) 
C(8)-C(9)-C(10)-C(11) 0.5(4) 
C(9)-C(10)-C(11)-C(12) -0.3(4) 
C(10)-C(11)-C(12)-C(7) 0.1(4) 
C(8)-C(7)-C(12)-C(11) 0.0(3) 
C(6)-C(7)-C(12)-C(11) 177.4(2) 
O(1)-C(5)-C(13)-O(14) 51.02(19) 
C(4)-C(5)-C(13)-O(14) -66.2(2) 
C(5)-C(13)-O(14)-C(15) -178.38(13) 
C(13)-O(14)-C(15)-C(16) -73.4(2) 
O(14)-C(15)-C(16)-C(21) 109.8(2) 
O(14)-C(15)-C(16)-C(17) -68.7(2) 
C(21)-C(16)-C(17)-C(18) 0.8(3) 
C(15)-C(16)-C(17)-C(18) 179.3(2) 
C(16)-C(17)-C(18)-C(19) -0.8(4) 
C(17)-C(18)-C(19)-C(20) 0.5(4) 
C(18)-C(19)-C(20)-C(21) -0.3(4) 
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C(19)-C(20)-C(21)-C(16) 0.4(3) 
C(17)-C(16)-C(21)-C(20) -0.7(3) 
C(15)-C(16)-C(21)-C(20) -179.10(19) 
________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
  
Table 7.  Hydrogen bonds for x82103_0m [Å and °]. 
___________________________________________________________________________
_ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
___________________________________________________________________________
_ 
 O(3)-H(3A)...O(2)#1 0.84 1.93 2.7592(19) 167.6 
___________________________________________________________________________
_ 
Symmetry transformations used to generate equivalent atoms:  
#1 -x+1,y-1/2,-z      
  
 4.2 Appendix B: NOESY interactions for compound 267
 
152 
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4.3 Appendix C: X-ray data for compound 268 
 
 
 
Two molecules in the asymmetric unit, both molecules are of the same chiral hand, assigned 
on the basis of the enclosed chemical diagram  
Solution attempted in C2 several times (pseudo symmetry relationship between molecules) 
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but not successful. Very weakly diffracting crystal, two domains second rotated from first 
domain by   3.2 degrees. 
Table 1.  Crystal data and structure refinement for twin5. asm186b 
Identification code  twin5 
Empirical formula  C24 H29 N O6 
Formula weight  427.48 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P1 
Unit cell dimensions a = 4.5560(4) Å = 77.689(5)°. 
 b = 10.5338(9) Å = 84.80(3)°. 
 c = 24.362(2) Å  = 89.82(3)°. 
Volume 1137.45(17) Å3 
Z 2 
Density (calculated) 1.248 Mg/m3 
Absorption coefficient 0.089 mm-1 
F(000) 456 
Crystal size 1.00 x 0.10 x 0.04 mm3 
Theta range for data collection 0.86 to 19.60°. 
Index ranges -4<=h<=4, -8<=k<=9, 0<=l<=22 
Reflections collected 2640 
Independent reflections 2640 [R(int) = 0.0000] 
Completeness to theta = 19.60° 85.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9964 and 0.9159 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2640 / 406 / 546 
Goodness-of-fit on F2 1.023 
Final R indices [I>2sigma(I)] R1 = 0.0845, wR2 = 0.2068 
R indices (all data) R1 = 0.1464, wR2 = 0.2672 
Largest diff. peak and hole 0.322 and -0.385 e.Å-3 
 
Table 2.   Bond lengths [Å] and angles [°] for twin5. 
_____________________________________________________ 
C(1A)-O(9A)  1.45(2) 
C(1A)-C(2A)  1.47(3) 
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C(1A)-C(8A)  1.60(2) 
C(1A)-H(1A)  1.0000 
C(2A)-N(3A)  1.48(2) 
C(2A)-C(17A)  1.59(3) 
C(2A)-H(2A)  1.0000 
N(3A)-C(4A)  1.32(2) 
N(3A)-C(7A)  1.46(2) 
C(4A)-O(4A)  1.24(2) 
C(4A)-C(5A)  1.60(2) 
C(5A)-O(5A)  1.42(2) 
C(5A)-C(6A)  1.52(3) 
C(5A)-H(5A1)  1.0000 
O(5A)-H(5A)  0.8400 
C(6A)-C(7A)  1.55(3) 
C(6A)-H(6A1)  0.9900 
C(6A)-H(6A2)  0.9900 
C(7A)-C(8A)  1.51(3) 
C(7A)-H(7A)  1.0000 
C(8A)-O(26A)  1.41(2) 
C(8A)-H(8A)  1.0000 
O(9A)-C(10A)  1.469(19) 
C(10A)-C(11A)  1.55(3) 
C(10A)-H(10A)  0.9900 
C(10A)-H(10B)  0.9900 
C(11A)-C(12A)  1.39(3) 
C(11A)-C(16A)  1.44(3) 
C(12A)-C(13A)  1.42(3) 
C(12A)-H(12A)  0.9500 
C(13A)-C(14A)  1.42(3) 
C(13A)-H(13A)  0.9500 
C(14A)-C(15A)  1.36(3) 
C(14A)-H(14A)  0.9500 
C(15A)-C(16A)  1.45(3) 
C(15A)-H(15A)  0.9500 
C(16A)-H(16A)  0.9500 
C(17A)-O(18A)  1.44(2) 
C(17A)-H(17C)  0.9900 
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C(17A)-H(17D)  0.9900 
O(18A)-C(19A)  1.48(2) 
C(19A)-C(20A)  1.55(3) 
C(19A)-H(19C)  0.9900 
C(19A)-H(19D)  0.9900 
C(20A)-C(21A)  1.36(3) 
C(20A)-C(25A)  1.43(3) 
C(21A)-C(22A)  1.41(3) 
C(21A)-H(21A)  0.9500 
C(22A)-C(23A)  1.39(3) 
C(22A)-H(22A)  0.9500 
C(23A)-C(24A)  1.38(3) 
C(23A)-H(23A)  0.9500 
C(24A)-C(25A)  1.37(2) 
C(24A)-H(24A)  0.9500 
C(25A)-H(25A)  0.9500 
O(26A)-C(27A)  1.38(2) 
C(27A)-O(28A)  1.42(3) 
C(27A)-H(27C)  0.9900 
C(27A)-H(27D)  0.9900 
O(28A)-C(29A)  1.44(2) 
C(29A)-H(29D)  0.9800 
C(29A)-H(29E)  0.9800 
C(29A)-H(29F)  0.9800 
C(1B)-O(9B)  1.47(2) 
C(1B)-C(2B)  1.54(3) 
C(1B)-C(8B)  1.60(3) 
C(1B)-H(1B)  1.0000 
C(2B)-N(3B)  1.50(2) 
C(2B)-C(17B)  1.52(3) 
C(2B)-H(2B)  1.0000 
N(3B)-C(4B)  1.34(2) 
N(3B)-C(7B)  1.48(2) 
C(4B)-O(4B)  1.29(2) 
C(4B)-C(5B)  1.488(16) 
C(5B)-O(5B)  1.44(2) 
C(5B)-C(6B)  1.55(3) 
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C(5B)-H(5B)  1.0000 
O(5B)-H(5X)  0.8400 
C(6B)-C(7B)  1.56(2) 
C(6B)-H(6B1)  0.9900 
C(6B)-H(6B2)  0.9900 
C(7B)-C(8B)  1.49(3) 
C(7B)-H(7B)  1.0000 
C(8B)-O(26B)  1.43(2) 
C(8B)-H(8B)  1.0000 
O(9B)-C(10B)  1.50(2) 
C(10B)-C(11B)  1.50(3) 
C(10B)-H(10C)  0.9900 
C(10B)-H(10D)  0.9900 
C(11B)-C(12B)  1.35(3) 
C(11B)-C(16B)  1.43(3) 
C(12B)-C(13B)  1.37(3) 
C(12B)-H(12B)  0.9500 
C(13B)-C(14B)  1.43(3) 
C(13B)-H(13B)  0.9500 
C(14B)-C(15B)  1.30(3) 
C(14B)-H(14B)  0.9500 
C(15B)-C(16B)  1.39(3) 
C(15B)-H(15B)  0.9500 
C(16B)-H(16B)  0.9500 
C(17B)-O(18B)  1.40(2) 
C(17B)-H(17A)  0.9900 
C(17B)-H(17B)  0.9900 
O(18B)-C(19B)  1.44(2) 
C(19B)-C(20B)  1.512(19) 
C(19B)-H(19A)  0.9900 
C(19B)-H(19B)  0.9900 
C(20B)-C(21B)  1.3900 
C(20B)-C(25B)  1.3900 
C(21B)-C(22B)  1.3900 
C(21B)-H(21B)  0.9500 
C(22B)-C(23B)  1.3900 
C(22B)-H(22B)  0.9500 
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C(23B)-C(24B)  1.3900 
C(23B)-H(23B)  0.9500 
C(24B)-C(25B)  1.3900 
C(24B)-H(24B)  0.9500 
C(25B)-H(25B)  0.9500 
O(26B)-C(27B)  1.43(2) 
C(27B)-O(28B)  1.41(2) 
C(27B)-H(27A)  0.9900 
C(27B)-H(27B)  0.9900 
O(28B)-C(29B)  1.46(2) 
C(29B)-H(29A)  0.9800 
C(29B)-H(29B)  0.9800 
C(29B)-H(29C)  0.9800 
 
O(9A)-C(1A)-C(2A) 117.6(15) 
O(9A)-C(1A)-C(8A) 105.7(15) 
C(2A)-C(1A)-C(8A) 107.2(14) 
O(9A)-C(1A)-H(1A) 108.7 
C(2A)-C(1A)-H(1A) 108.7 
C(8A)-C(1A)-H(1A) 108.7 
C(1A)-C(2A)-N(3A) 106.2(13) 
C(1A)-C(2A)-C(17A) 121.2(16) 
N(3A)-C(2A)-C(17A) 108.0(14) 
C(1A)-C(2A)-H(2A) 106.9 
N(3A)-C(2A)-H(2A) 106.9 
C(17A)-C(2A)-H(2A) 106.9 
C(4A)-N(3A)-C(7A) 115.8(15) 
C(4A)-N(3A)-C(2A) 132.2(15) 
C(7A)-N(3A)-C(2A) 110.2(14) 
O(4A)-C(4A)-N(3A) 125.5(16) 
O(4A)-C(4A)-C(5A) 128.3(17) 
N(3A)-C(4A)-C(5A) 106.1(17) 
O(5A)-C(5A)-C(6A) 114.5(16) 
O(5A)-C(5A)-C(4A) 110.2(15) 
C(6A)-C(5A)-C(4A) 102.4(15) 
O(5A)-C(5A)-H(5A1) 109.8 
C(6A)-C(5A)-H(5A1) 109.8 
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C(4A)-C(5A)-H(5A1) 109.8 
C(5A)-O(5A)-H(5A) 109.5 
C(5A)-C(6A)-C(7A) 103.9(16) 
C(5A)-C(6A)-H(6A1) 111.0 
C(7A)-C(6A)-H(6A1) 111.0 
C(5A)-C(6A)-H(6A2) 111.0 
C(7A)-C(6A)-H(6A2) 111.0 
H(6A1)-C(6A)-H(6A2) 109.0 
N(3A)-C(7A)-C(8A) 105.5(14) 
N(3A)-C(7A)-C(6A) 103.0(15) 
C(8A)-C(7A)-C(6A) 121.2(18) 
N(3A)-C(7A)-H(7A) 108.8 
C(8A)-C(7A)-H(7A) 108.8 
C(6A)-C(7A)-H(7A) 108.8 
O(26A)-C(8A)-C(7A) 111.7(14) 
O(26A)-C(8A)-C(1A) 115.3(14) 
C(7A)-C(8A)-C(1A) 101.4(16) 
O(26A)-C(8A)-H(8A) 109.4 
C(7A)-C(8A)-H(8A) 109.4 
C(1A)-C(8A)-H(8A) 109.4 
C(1A)-O(9A)-C(10A) 113.5(13) 
O(9A)-C(10A)-C(11A) 108.8(14) 
O(9A)-C(10A)-H(10A) 109.9 
C(11A)-C(10A)-H(10A) 109.9 
O(9A)-C(10A)-H(10B) 109.9 
C(11A)-C(10A)-H(10B) 109.9 
H(10A)-C(10A)-H(10B) 108.3 
C(12A)-C(11A)-C(16A) 124.5(19) 
C(12A)-C(11A)-C(10A) 122.1(17) 
C(16A)-C(11A)-C(10A) 113.3(18) 
C(11A)-C(12A)-C(13A) 119(2) 
C(11A)-C(12A)-H(12A) 120.6 
C(13A)-C(12A)-H(12A) 120.6 
C(12A)-C(13A)-C(14A) 119(2) 
C(12A)-C(13A)-H(13A) 120.6 
C(14A)-C(13A)-H(13A) 120.6 
C(15A)-C(14A)-C(13A) 122(2) 
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C(15A)-C(14A)-H(14A) 119.0 
C(13A)-C(14A)-H(14A) 119.0 
C(14A)-C(15A)-C(16A) 122(2) 
C(14A)-C(15A)-H(15A) 118.9 
C(16A)-C(15A)-H(15A) 118.9 
C(11A)-C(16A)-C(15A) 114(2) 
C(11A)-C(16A)-H(16A) 123.2 
C(15A)-C(16A)-H(16A) 123.2 
O(18A)-C(17A)-C(2A) 104.5(15) 
O(18A)-C(17A)-H(17C) 110.8 
C(2A)-C(17A)-H(17C) 110.8 
O(18A)-C(17A)-H(17D) 110.8 
C(2A)-C(17A)-H(17D) 110.8 
H(17C)-C(17A)-H(17D) 108.9 
C(17A)-O(18A)-C(19A) 111.7(14) 
O(18A)-C(19A)-C(20A) 103.1(15) 
O(18A)-C(19A)-H(19C) 111.1 
C(20A)-C(19A)-H(19C) 111.1 
O(18A)-C(19A)-H(19D) 111.1 
C(20A)-C(19A)-H(19D) 111.1 
H(19C)-C(19A)-H(19D) 109.1 
C(21A)-C(20A)-C(25A) 117.0(18) 
C(21A)-C(20A)-C(19A) 122.6(19) 
C(25A)-C(20A)-C(19A) 120.1(19) 
C(20A)-C(21A)-C(22A) 124(2) 
C(20A)-C(21A)-H(21A) 117.8 
C(22A)-C(21A)-H(21A) 117.8 
C(23A)-C(22A)-C(21A) 115(2) 
C(23A)-C(22A)-H(22A) 122.5 
C(21A)-C(22A)-H(22A) 122.5 
C(24A)-C(23A)-C(22A) 124(2) 
C(24A)-C(23A)-H(23A) 118.2 
C(22A)-C(23A)-H(23A) 118.2 
C(25A)-C(24A)-C(23A) 119(2) 
C(25A)-C(24A)-H(24A) 120.6 
C(23A)-C(24A)-H(24A) 120.6 
C(24A)-C(25A)-C(20A) 121(2) 
Appendices 
161 
 
C(24A)-C(25A)-H(25A) 119.6 
C(20A)-C(25A)-H(25A) 119.6 
C(27A)-O(26A)-C(8A) 116.1(15) 
O(26A)-C(27A)-O(28A) 113.7(17) 
O(26A)-C(27A)-H(27C) 108.8 
O(28A)-C(27A)-H(27C) 108.8 
O(26A)-C(27A)-H(27D) 108.8 
O(28A)-C(27A)-H(27D) 108.8 
H(27C)-C(27A)-H(27D) 107.7 
C(27A)-O(28A)-C(29A) 108.1(15) 
O(28A)-C(29A)-H(29D) 109.5 
O(28A)-C(29A)-H(29E) 109.5 
H(29D)-C(29A)-H(29E) 109.5 
O(28A)-C(29A)-H(29F) 109.5 
H(29D)-C(29A)-H(29F) 109.5 
H(29E)-C(29A)-H(29F) 109.5 
O(9B)-C(1B)-C(2B) 114.3(16) 
O(9B)-C(1B)-C(8B) 105.1(16) 
C(2B)-C(1B)-C(8B) 107.4(15) 
O(9B)-C(1B)-H(1B) 109.9 
C(2B)-C(1B)-H(1B) 109.9 
C(8B)-C(1B)-H(1B) 109.9 
N(3B)-C(2B)-C(17B) 109.4(15) 
N(3B)-C(2B)-C(1B) 101.9(14) 
C(17B)-C(2B)-C(1B) 118.5(16) 
N(3B)-C(2B)-H(2B) 108.9 
C(17B)-C(2B)-H(2B) 108.9 
C(1B)-C(2B)-H(2B) 108.9 
C(4B)-N(3B)-C(7B) 113.5(15) 
C(4B)-N(3B)-C(2B) 131.6(16) 
C(7B)-N(3B)-C(2B) 112.8(15) 
O(4B)-C(4B)-N(3B) 123.7(15) 
O(4B)-C(4B)-C(5B) 127.4(17) 
N(3B)-C(4B)-C(5B) 108.7(18) 
O(5B)-C(5B)-C(4B) 113.3(15) 
O(5B)-C(5B)-C(6B) 109.6(14) 
C(4B)-C(5B)-C(6B) 104.1(15) 
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O(5B)-C(5B)-H(5B) 109.9 
C(4B)-C(5B)-H(5B) 109.9 
C(6B)-C(5B)-H(5B) 109.9 
C(5B)-O(5B)-H(5X) 109.5 
C(5B)-C(6B)-C(7B) 102.0(14) 
C(5B)-C(6B)-H(6B1) 111.4 
C(7B)-C(6B)-H(6B1) 111.4 
C(5B)-C(6B)-H(6B2) 111.4 
C(7B)-C(6B)-H(6B2) 111.4 
H(6B1)-C(6B)-H(6B2) 109.2 
N(3B)-C(7B)-C(8B) 104.8(15) 
N(3B)-C(7B)-C(6B) 102.9(15) 
C(8B)-C(7B)-C(6B) 121.4(17) 
N(3B)-C(7B)-H(7B) 109.0 
C(8B)-C(7B)-H(7B) 109.0 
C(6B)-C(7B)-H(7B) 109.0 
O(26B)-C(8B)-C(7B) 109.5(15) 
O(26B)-C(8B)-C(1B) 112.2(14) 
C(7B)-C(8B)-C(1B) 102.1(17) 
O(26B)-C(8B)-H(8B) 110.9 
C(7B)-C(8B)-H(8B) 110.9 
C(1B)-C(8B)-H(8B) 110.9 
C(1B)-O(9B)-C(10B) 113.7(14) 
C(11B)-C(10B)-O(9B) 107.1(15) 
C(11B)-C(10B)-H(10C) 110.3 
O(9B)-C(10B)-H(10C) 110.3 
C(11B)-C(10B)-H(10D) 110.3 
O(9B)-C(10B)-H(10D) 110.3 
H(10C)-C(10B)-H(10D) 108.6 
C(12B)-C(11B)-C(16B) 119(2) 
C(12B)-C(11B)-C(10B) 124.0(17) 
C(16B)-C(11B)-C(10B) 116.7(18) 
C(11B)-C(12B)-C(13B) 120(2) 
C(11B)-C(12B)-H(12B) 120.0 
C(13B)-C(12B)-H(12B) 120.0 
C(12B)-C(13B)-C(14B) 120(2) 
C(12B)-C(13B)-H(13B) 119.8 
Appendices 
163 
 
C(14B)-C(13B)-H(13B) 119.8 
C(15B)-C(14B)-C(13B) 119(2) 
C(15B)-C(14B)-H(14B) 120.3 
C(13B)-C(14B)-H(14B) 120.3 
C(14B)-C(15B)-C(16B) 122(2) 
C(14B)-C(15B)-H(15B) 119.1 
C(16B)-C(15B)-H(15B) 119.1 
C(15B)-C(16B)-C(11B) 119(2) 
C(15B)-C(16B)-H(16B) 120.5 
C(11B)-C(16B)-H(16B) 120.5 
O(18B)-C(17B)-C(2B) 107.2(16) 
O(18B)-C(17B)-H(17A) 110.3 
C(2B)-C(17B)-H(17A) 110.3 
O(18B)-C(17B)-H(17B) 110.3 
C(2B)-C(17B)-H(17B) 110.3 
H(17A)-C(17B)-H(17B) 108.5 
C(17B)-O(18B)-C(19B) 117.0(15) 
O(18B)-C(19B)-C(20B) 108.8(15) 
O(18B)-C(19B)-H(19A) 109.9 
C(20B)-C(19B)-H(19A) 109.9 
O(18B)-C(19B)-H(19B) 109.9 
C(20B)-C(19B)-H(19B) 109.9 
H(19A)-C(19B)-H(19B) 108.3 
C(21B)-C(20B)-C(25B) 120.0 
C(21B)-C(20B)-C(19B) 121.2(12) 
C(25B)-C(20B)-C(19B) 118.8(12) 
C(20B)-C(21B)-C(22B) 120.0 
C(20B)-C(21B)-H(21B) 120.0 
C(22B)-C(21B)-H(21B) 120.0 
C(23B)-C(22B)-C(21B) 120.0 
C(23B)-C(22B)-H(22B) 120.0 
C(21B)-C(22B)-H(22B) 120.0 
C(22B)-C(23B)-C(24B) 120.0 
C(22B)-C(23B)-H(23B) 120.0 
C(24B)-C(23B)-H(23B) 120.0 
C(25B)-C(24B)-C(23B) 120.0 
C(25B)-C(24B)-H(24B) 120.0 
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C(23B)-C(24B)-H(24B) 120.0 
C(24B)-C(25B)-C(20B) 120.0 
C(24B)-C(25B)-H(25B) 120.0 
C(20B)-C(25B)-H(25B) 120.0 
C(8B)-O(26B)-C(27B) 114.1(15) 
O(28B)-C(27B)-O(26B) 114.6(15) 
O(28B)-C(27B)-H(27A) 108.6 
O(26B)-C(27B)-H(27A) 108.6 
O(28B)-C(27B)-H(27B) 108.6 
O(26B)-C(27B)-H(27B) 108.6 
H(27A)-C(27B)-H(27B) 107.6 
C(27B)-O(28B)-C(29B) 108.8(15) 
O(28B)-C(29B)-H(29A) 109.5 
O(28B)-C(29B)-H(29B) 109.5 
H(29A)-C(29B)-H(29B) 109.5 
O(28B)-C(29B)-H(29C) 109.5 
H(29A)-C(29B)-H(29C) 109.5 
H(29B)-C(29B)-H(29C) 109.5 
_____________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
  
Table 3.  Torsion angles [°] for twin5. 
________________________________________________________________ 
O(9A)-C(1A)-C(2A)-N(3A) -128.5(15) 
C(8A)-C(1A)-C(2A)-N(3A) -9.7(19) 
O(9A)-C(1A)-C(2A)-C(17A) 108(2) 
C(8A)-C(1A)-C(2A)-C(17A) -133.3(16) 
C(1A)-C(2A)-N(3A)-C(4A) 154(2) 
C(17A)-C(2A)-N(3A)-C(4A) -75(2) 
C(1A)-C(2A)-N(3A)-C(7A) -10(2) 
C(17A)-C(2A)-N(3A)-C(7A) 121.4(17) 
C(7A)-N(3A)-C(4A)-O(4A) 176(2) 
C(2A)-N(3A)-C(4A)-O(4A) 13(4) 
C(7A)-N(3A)-C(4A)-C(5A) -6(2) 
C(2A)-N(3A)-C(4A)-C(5A) -169.6(17) 
O(4A)-C(4A)-C(5A)-O(5A) -38(3) 
N(3A)-C(4A)-C(5A)-O(5A) 144.9(16) 
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O(4A)-C(4A)-C(5A)-C(6A) -160(2) 
N(3A)-C(4A)-C(5A)-C(6A) 23(2) 
O(5A)-C(5A)-C(6A)-C(7A) -148.1(15) 
C(4A)-C(5A)-C(6A)-C(7A) -28.9(19) 
C(4A)-N(3A)-C(7A)-C(8A) -140.1(17) 
C(2A)-N(3A)-C(7A)-C(8A) 27(2) 
C(4A)-N(3A)-C(7A)-C(6A) -12(2) 
C(2A)-N(3A)-C(7A)-C(6A) 154.6(14) 
C(5A)-C(6A)-C(7A)-N(3A) 25.8(19) 
C(5A)-C(6A)-C(7A)-C(8A) 143.2(17) 
N(3A)-C(7A)-C(8A)-O(26A) -153.6(15) 
C(6A)-C(7A)-C(8A)-O(26A) 90(2) 
N(3A)-C(7A)-C(8A)-C(1A) -30.3(19) 
C(6A)-C(7A)-C(8A)-C(1A) -146.4(17) 
O(9A)-C(1A)-C(8A)-O(26A) -88.1(18) 
C(2A)-C(1A)-C(8A)-O(26A) 145.7(16) 
O(9A)-C(1A)-C(8A)-C(7A) 151.0(15) 
C(2A)-C(1A)-C(8A)-C(7A) 24.8(19) 
C(2A)-C(1A)-O(9A)-C(10A) -78(2) 
C(8A)-C(1A)-O(9A)-C(10A) 162.6(14) 
C(1A)-O(9A)-C(10A)-C(11A) 179.3(15) 
O(9A)-C(10A)-C(11A)-C(12A) 10(3) 
O(9A)-C(10A)-C(11A)-C(16A) -166.4(16) 
C(16A)-C(11A)-C(12A)-C(13A) 0(3) 
C(10A)-C(11A)-C(12A)-C(13A) -176.3(19) 
C(11A)-C(12A)-C(13A)-C(14A) -2(3) 
C(12A)-C(13A)-C(14A)-C(15A) 0(3) 
C(13A)-C(14A)-C(15A)-C(16A) 3(4) 
C(12A)-C(11A)-C(16A)-C(15A) 4(3) 
C(10A)-C(11A)-C(16A)-C(15A) 180.0(17) 
C(14A)-C(15A)-C(16A)-C(11A) -5(3) 
C(1A)-C(2A)-C(17A)-O(18A) -60(2) 
N(3A)-C(2A)-C(17A)-O(18A) 177.0(14) 
C(2A)-C(17A)-O(18A)-C(19A) 170.9(15) 
C(17A)-O(18A)-C(19A)-C(20A) 173.8(15) 
O(18A)-C(19A)-C(20A)-C(21A) 77(3) 
O(18A)-C(19A)-C(20A)-C(25A) -108(2) 
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C(25A)-C(20A)-C(21A)-C(22A) 7(3) 
C(19A)-C(20A)-C(21A)-C(22A) -178(2) 
C(20A)-C(21A)-C(22A)-C(23A) -7(3) 
C(21A)-C(22A)-C(23A)-C(24A) 5(4) 
C(22A)-C(23A)-C(24A)-C(25A) -3(4) 
C(23A)-C(24A)-C(25A)-C(20A) 3(3) 
C(21A)-C(20A)-C(25A)-C(24A) -4(3) 
C(19A)-C(20A)-C(25A)-C(24A) 180.0(18) 
C(7A)-C(8A)-O(26A)-C(27A) -154.7(16) 
C(1A)-C(8A)-O(26A)-C(27A) 90(2) 
C(8A)-O(26A)-C(27A)-O(28A) 65(2) 
O(26A)-C(27A)-O(28A)-C(29A) 69(2) 
O(9B)-C(1B)-C(2B)-N(3B) -129.7(15) 
C(8B)-C(1B)-C(2B)-N(3B) -13.5(18) 
O(9B)-C(1B)-C(2B)-C(17B) 110.3(19) 
C(8B)-C(1B)-C(2B)-C(17B) -133.5(18) 
C(17B)-C(2B)-N(3B)-C(4B) -79(3) 
C(1B)-C(2B)-N(3B)-C(4B) 155.1(19) 
C(17B)-C(2B)-N(3B)-C(7B) 118.9(18) 
C(1B)-C(2B)-N(3B)-C(7B) -7.3(19) 
C(7B)-N(3B)-C(4B)-O(4B) 175.7(18) 
C(2B)-N(3B)-C(4B)-O(4B) 13(3) 
C(7B)-N(3B)-C(4B)-C(5B) -8(2) 
C(2B)-N(3B)-C(4B)-C(5B) -170.2(17) 
O(4B)-C(4B)-C(5B)-O(5B) -41(3) 
N(3B)-C(4B)-C(5B)-O(5B) 142.9(16) 
O(4B)-C(4B)-C(5B)-C(6B) -160(2) 
N(3B)-C(4B)-C(5B)-C(6B) 24(2) 
O(5B)-C(5B)-C(6B)-C(7B) -150.8(14) 
C(4B)-C(5B)-C(6B)-C(7B) -29.3(18) 
C(4B)-N(3B)-C(7B)-C(8B) -139.2(16) 
C(2B)-N(3B)-C(7B)-C(8B) 26(2) 
C(4B)-N(3B)-C(7B)-C(6B) -11(2) 
C(2B)-N(3B)-C(7B)-C(6B) 154.3(15) 
C(5B)-C(6B)-C(7B)-N(3B) 24.6(18) 
C(5B)-C(6B)-C(7B)-C(8B) 141.1(18) 
N(3B)-C(7B)-C(8B)-O(26B) -151.3(14) 
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C(6B)-C(7B)-C(8B)-O(26B) 93(2) 
N(3B)-C(7B)-C(8B)-C(1B) -32.3(18) 
C(6B)-C(7B)-C(8B)-C(1B) -147.8(17) 
O(9B)-C(1B)-C(8B)-O(26B) -91.7(18) 
C(2B)-C(1B)-C(8B)-O(26B) 146.1(16) 
O(9B)-C(1B)-C(8B)-C(7B) 151.1(15) 
C(2B)-C(1B)-C(8B)-C(7B) 29.0(19) 
C(2B)-C(1B)-O(9B)-C(10B) -77.3(19) 
C(8B)-C(1B)-O(9B)-C(10B) 165.1(14) 
C(1B)-O(9B)-C(10B)-C(11B) -179.9(16) 
O(9B)-C(10B)-C(11B)-C(12B) 9(3) 
O(9B)-C(10B)-C(11B)-C(16B) -169.7(15) 
C(16B)-C(11B)-C(12B)-C(13B) 0(3) 
C(10B)-C(11B)-C(12B)-C(13B) -179.4(19) 
C(11B)-C(12B)-C(13B)-C(14B) 4(3) 
C(12B)-C(13B)-C(14B)-C(15B) -6(3) 
C(13B)-C(14B)-C(15B)-C(16B) 4(3) 
C(14B)-C(15B)-C(16B)-C(11B) -1(3) 
C(12B)-C(11B)-C(16B)-C(15B) -1(3) 
C(10B)-C(11B)-C(16B)-C(15B) 177.7(19) 
N(3B)-C(2B)-C(17B)-O(18B) 177.7(14) 
C(1B)-C(2B)-C(17B)-O(18B) -66(2) 
C(2B)-C(17B)-O(18B)-C(19B) 175.1(18) 
C(17B)-O(18B)-C(19B)-C(20B) 177.2(15) 
O(18B)-C(19B)-C(20B)-C(21B) 69.9(18) 
O(18B)-C(19B)-C(20B)-C(25B) -107.7(15) 
C(25B)-C(20B)-C(21B)-C(22B) 0.0 
C(19B)-C(20B)-C(21B)-C(22B) -177.5(13) 
C(20B)-C(21B)-C(22B)-C(23B) 0.0 
C(21B)-C(22B)-C(23B)-C(24B) 0.0 
C(22B)-C(23B)-C(24B)-C(25B) 0.0 
C(23B)-C(24B)-C(25B)-C(20B) 0.0 
C(21B)-C(20B)-C(25B)-C(24B) 0.0 
C(19B)-C(20B)-C(25B)-C(24B) 177.6(13) 
C(7B)-C(8B)-O(26B)-C(27B) -155.4(15) 
C(1B)-C(8B)-O(26B)-C(27B) 92.0(19) 
C(8B)-O(26B)-C(27B)-O(28B) 65.6(19) 
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O(26B)-C(27B)-O(28B)-C(29B) 67(2) 
________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
  
Table 4.  Hydrogen bonds for twin5 [Å and °]. 
___________________________________________________________________________
_ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
___________________________________________________________________________
_ 
 O(5A)-H(5A)...O(4B)#1 0.84 1.94 2.73(2) 157.1 
 O(5B)-H(5X)...O(4A)#2 0.84 1.95 2.786(19) 170.3 
___________________________________________________________________________
_ 
Symmetry transformations used to generate equivalent atoms:  
#1 x+1,y,z    #2 x-1,y,z      
  
 4.4 Appendix D: NOESY interactions for compound 310
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4.5 Appendix E:  Training record 
Conferences attended 
 
Scottish regional meeting of the RSC organic division –poster presentation 2009, 2008, 2007, 
2006. 
 
SCI postgraduate snposium –Speaker March 2009. 
 
ACS National Meeting and Exposition – Speaker and poster presentation August 2009. 
 
Courses Attended 
 
Vitae UK Grad School –Bournmouth 2009 
 
Educational Development Courses 
 
Research writing 
Communication skills for researchers 
Introduction to presenting research 
Project management for research students 
How to be an effective researcher 
Presenting your thesis 
Viva preparation 1 and 2 
LEADS 1 
 
Undergraduate lecture courses 
 
Advanced synthesis with pharmaceutical applications 
 
Postgraduate courses 
 
Advanced organic synthesis 
Optics for chemists 
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